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1. Summary
As every individual is a product of his/her genes and environment, which can be 
regarded as a paraphrase of an individual’s phenotypic characteristic, it becomes 
apparent as to why the concept of personalised medicine, i.e. tailoring a treatment 
regimen to an individual’s needs, remains an ever-prevalent topic in the medical 
community. Human cytochrome P450 enzymes (CYPs) are accountable for the 
oxidative metabolism of approximately 50% of commonly used drugs as well as 
endogenous compounds. However, CYP activity is exceedingly variable amongst 
individuals.  
Over the course of my PhD project, I worked on five different projects that implicated 
the utility of two valuable tools in personalised medicine: namely, phenotyping and 
therapeutic drug monitoring. The determination of a person’s enzymatic activity 
through phenotyping can help guide a GP’s effort to personalise drug therapy by 
administering the applicable dose, thereby improving efficacy and reducing side 
effects at the start of therapy. Therapeutic drug monitoring (TDM) on the other hand, 
enables the continued observation of a patient’s drug concentration, predominantly in 
plasma, thus allowing patients that are at risk of either over-/ or underdosing to be 
identified.  
In the past two decades, many different in vivo phenotyping cocktails, enabling the 
simultaneous assessment of multiple CYP isoforms, e.g. Cooperstown- [1], Inje- [2], 
Quebec- [3], Karolinska- [4], and the Pittsburgh-cocktail [5], as well as a great 
number of in vitro cocktails [6-14] were developed. Metabolism studies performed in 
vitro are useful to the extent of acquiring anticipatory information of in vivo 
predictions of CYP- inhibition/ -induction in an efficient time and cost saving manner. 
It is, however, uncommon to use established in vivo cocktails for in vitro studies [7]. 
Nevertheless, using probe substrates previously unaccustomed to in vitro cocktail 
studies, e.g. efavirenz (CYP2B6), losartan (CYP2C9), and metoprolol (CYP2D6), we 
were able to show the potential of the Basel cocktail [15, 16] to characterise a variety 
of different liver cell models. Of particular interest to our study was the 
characterisation of 3D primary human hepatocytes (PHH), co-cultured with 3T3-
mouse fibroblasts [17]. By using the same batch of PHH in 2D and 3D-culture, we 
were able to show the functional benefits of a co-culture system, enabling 
hepatocytes to reside in a 3D environment, and leading to improved CYP activity and 
mRNA expression. In subsequent studies, we were able to provide explanations for 
5
pending in vivo observations [15], through combining knowledge of freshly acquired 
in vitro and in vivo characterisation data of the Basel cocktail.  
In the second study, we demonstrated that the α-hydroxymetoprolol formation is not 
mediated solely by CYP2D6, since under induced conditions and through 
experiments in isoform specific supersomes, the involvement of CYP3A4 also 
became apparent. This does not, however, impede the continued applicability of 
metoprolol as probe substrate of CYP2D6 since the involvement of CYP3A4 only 
becomes apparent when induction is evaluated, which is commonly not done for 
CYP2D6. 
In the third study, we were able to show, through an in vitro interactions study, that 
flurbiprofen can be used to replace losartan as a phenotyping drug for CYP2C9. 
Subsequently, a pilot study (n=2) showed the prospect of simplifying the cocktail 
administration through the use of a combi-capsule containing all six probe drugs of 
the modified Basel cocktail.  
After having previously tested the phenotyping capacities of the Basel cocktail in two 
studies involving young, healthy, male volunteers [15, 16], the fourth study of this 
thesis demonstrates that we successfully used caffeine (CYP1A2) and midazolam 
(CYP3A4) to phenotype elderly, patients of both sexes that were being treated for 
non-small cell lung cancer (NSCLC) with erlotinib (Tarceva®). In so doing, we were 
able to show that subjects with a slow CYP3A4 metabolism had a higher likelihood of 
developing cutaneous toxicity than patients with an extensive metabolism.  
While the fourth study touched upon the possible usefulness of collecting DBS with 
which to perform TDM, as opposed to conventional plasma samples, the fifth and 
final study was devoted entirely to this topic. Here, we demonstrate the development, 
validation, and application of an automated DBS extraction method, while 
incorporating an evaluation of an antiretroviral adherence/ therapeutic drug 
monitoring study. Our study was able to show that concentrations of two antiretroviral 
drugs, nevirapine and efavirenz, could reliably be determined by automated 
extraction in DBS samples that had been obtained in a challenging setting in rural 
Tanzania.
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2. Abbreviations 
3-MC 3-methylcholanthrene 
ABCB1 ATP binding cassette subfamily B member 1; P-
glycoprotein (P-gp); multidrug resistance protein 1 
(MDR1)  
ABCG2 ATP-binding cassette sub-family G member 2; breast 
cancer resistance protein (BCRP) 
AE Adverse event 
AhR Aryl hydrocarbon receptor 
ALAT Alanine aminotransferase 
ASAT Aspartate aminotransferase 
ATP    Adenosine triphosphate 
AUC    Area under the curve 
bp    base pair 
CAR    Constitutive androstane receptor 
cART    combined antiretroviral treatment 
CYP450   Cytochrome p450 
Cmax     Peak plasma concentration 
CPS    Counts per second 
Css    Steady-state plasma concentration 
Css/dose    Dose normalised steady-state plasma concentration 
Ctrough    Trough plasma concentration 
CTCAE   Common Terminology Criteria for Adverse Events 
CV%    coefficient of variation 
DBS    Dried Blood Spot 
DMEM    Dulbecco’s modified Eagle’s medium 
DMSO    Dimethyl sulfoxide 
E-3174   Losartan carboxylic acid, main metabolite of losartan 
EDTA    Ethylenediaminetetraacetic acid 
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EFA    Efavirenz 
EGFR    Epidermal growth factor receptor 
EM    Extensive metaboliser 
ESI    Electrospray inonisation 
FCS    Foetal calf serum 
FDA    Food and Drug Administration 
G6PDH   Glucose-6-phosphate dehydrogenase 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GIST    Gastrointestinal stromal tumour  
GP    General practitioner  
HBV    Hepatitis B virus 
HIV    Human immunodeficiency virus 
HPLC    High Performance Liquid Chromatography 
HPRT1   Hypoxanthine phosphoribosyltransferase 1 
HCT    Haematocrit 
IM    Intermediate metaboliser 
IS    Internal standard 
i.v.    Intravenous 
LC-MS/MS Liquid Chromatography-Triple quadrupole Mass 
Spectrometry 
LLOQ Lowest limit of quantification 
LPV Lopinavir 
mAbs Monoclonal antibodies 
MeOH Methanol 
MR    Metabolic ratio 
MRM    Multiple reaction monitoring 
m/z    mass-to-charge ratio 
NONMEM   Nonlinear-mixed-effects modelling 
NSCLC   Non-small cell lung cancer 
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NVP    Nevirapine 
OSI-420   Desmethyl erlotinib, main active metabolite of erlotinib 
PDGFR   Platelet derived growth factor receptor 
PHH    Primary human hepatocytes 
PPI    Proton pump inhibitor 
PK    Pharmacokinetic 
PM    poor metaboliser 
pmol    picomol 
PXR    Pregnane X receptor 
RCC    Renal-cell cancer 
SCFR    Stem cell factor receptor 
SD    Standard deviation 
SEM    Standard error of the mean 
Su-12662   N-desethyl sunitinib, main active metabolite of sunitinib 
Tmax    Time corresponding to peak plasma concentration 
t ½    Half-time 
TDM    Therapeutic Drug Monitoring 
TK    Tyrosine Kinase 
TKI    Tyrosine Kinase Inhibitor 
TSH    Thyroid stimulating hormone 
ULN    Upper limit of normal     
VEGFR   Vascular endothelial growth factor receptor 
v/v    percentage volume of a substance of the total volume 
WHO    World Health Organisation 
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3. General Introduction  
The concept of addressing each patient according to his or her individuality was 
introduced as early as Ancient Greece, through Hippocrates, the ‘father of western 
medicine’ [18]. He is reputed to have said, “It is far more important to know what sort 
of person has a disease, than to know what sort of disease a person has,” long 
before the concept of personalised medicine was coined [19]. Personalised medicine 
challenges the age-old “one dose fits all” therapy strategy, favouring instead a 
treatment tailored to the individual (Figure 1). Following the rule of the 5Rs – to be 
able to give “the right dose of the right drug for the right indication for the right 
patient at the right time” – personalised medicine is intent on maximising the 
likelihood of therapeutic efficacy, whilst minimising the risk of toxicity for an individual 
patient [20].  
 
Figure 1. Differences in prescribing the same drug (e.g. nortryptilline, metabolised by CYP2D6) with the ‘one-dose-
fits-all’ approach (left panel) and through personalised medicine (right panel). In the right panel, fully functional alleles 
of the CYP2D6 gene are illustrated by orange boxes, functional but impaired alleles by purple boxes, non-functional 
alleles by white boxes, and deletion of the whole CYP2D6 gene by a dashed line. The phenotype is predicted for 
each individual patient. To achieve the same plasma drug level dose adjustments are required. Adapted from [20, 
21]. 
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Further long-term benefits of personalised medicine, a term that has been used 
interchangeably with precision medicine, stratified medicine, and p4 (predictive, 
preventive, personalised, participatory) medicine, include personalised prescriptions, 
improved patient compliance, and a reduction in the costs of disease management 
[22]. 
The extent to which a person responds to any given drug is determined by the set of 
an individual’s genes (genotype) and the influence of a variety of different 
environmental and non-genetic factors that make up the expression of an individual’s 
characteristic phenotype (Figure 2). Through phenotype-guided dosing, an 
individual’s ability to metabolise drugs according to the activity of their respective 
cytochrome P450 (CYP450) enzymes (or ABC-transporters) can be investigated. 
Phenotyping of CYP450 is performed by administering a selective substrate for a 
specific CYP enzyme, e.g. midazolam for the CYP450 isoform 3A4.  
 
Figure 2. The phenotype, i.e. the variability of drug disposition and drug response, is determined by an interplay of 
the genotype and a variety of non-genetic factors, adapted from [23]. 
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Subsequently either pharmacokinetic parameters or the measurement of single 
concentration ratios at selected time points of the parent drug (e.g. midazolam) and 
its respective metabolite (e.g. 1’-hydroxymidazolam) can be used to assess the 
metabolic activity of the CYP450 enzyme in question [23]. The cocktail approach 
makes use of a number of selective probe substrates that do not interact amongst 
themselves and can be applied when two or more CYP450 isoforms are to be 
assessed simultaneously [24]. 
Pharmacogenomics, the study of how genes affect a person’s response to drugs, 
has progressed in leaps and bounds since the completion of the human genome 
project [25, 26], opening up new possibilities for personalised medicine. For instance, 
a number of drugs, such as the tyrosine kinase inhibitor Tarceva® (erlotinib) or the 
monoclonal antibody Herceptin® (trastuzumab), are only effective in sub-populations. 
Early identification of responders through screening for pharmacogenomic 
biomarkers, e.g. EGFR activating mutations or Her2/neu overexpression 
respectively, enables the effective treatment of that sub-population. On the other 
hand, non-responders are not being subjected to the unnecessary risk of adverse 
events through a drug treatment with no benefit. 
Another form of personalised treatment is therapeutic drug monitoring (TDM), 
through which plasma concentrations are most commonly measured at designated 
intervals in order to achieve and uphold target blood concentration. It can 
furthermore be used to design individualised dosage regimens. Quantitation of 
plasma levels is routinely performed through liquid-chromatography tandem mass 
spectrometry (LC-MS/MS) analysis. A rationale to perform TDM includes the 
assessment of AEs, the diagnosis of dietary or drug-drug interactions, dose 
adjustments, the monitoring of high-risk patients (children, elderly, patients with 
impaired organ function), minimising underdosing of patients, and the monitoring of 
adherence [27]. TDM is most commonly used during treatments in which a drug has 
a narrow therapeutic range, marked pharmacokinetic variability, and where a direct 
relationship between drug concentration and efficacy/ toxicity has been established. 
TDM is widely applied to antibiotic, anticonvulsant, antipsychotic, and antineoplastic 
treatment [28].  
 
The overall goal of this doctoral thesis was to investigate phenotyping and TDM as 
two important tools of personalised medicine. In the first three projects, the recently 
developed in vivo Basel phenotyping cocktail was investigated in vitro using different 
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liver cell models. In the fourth study, patients that were being treated with tyrosine 
kinase inhibitors were phenotyped using two probe drugs of the Basel cocktail. In the 
fifth and final project, the use of dried blood spots for the TDM of antiretroviral drugs 
from a clinical study conducted in a resource-limited setting was investigated. For the 
reliable analysis of samples from all sub-projects, liquid chromatography tandem 
mass-spectrometry (LC-MS/MS) was utilised as a key bioanalytical method.   
Previously, the Basel cocktail – an in vivo phenotyping tool that contains caffeine 
(CYP1A2), efavirenz (CYP2B6), losartan (CYP2C9), omeprazole (CYP2C19), 
metoprolol (CYP2D6), and midazolam (CYP3A4) – was characterised in healthy 
male volunteers after being treated with a combination of different CYP450 inhibitors 
and a broad CYP inducer [15, 16]. After this detailed in vivo characterisation, it was 
relevant to also evaluate the utilised probe drugs in vitro. In the first study, we, 
therefore, assessed the performance and usability of the Basel cocktail in vitro by 
comparing in vitro and in vivo results. Furthermore, we wanted to evaluate the 
suitability of a variety of different liver cell models, i.e. the hepatoma cell lines HepG2 
and HepaRG, and primary hepatocytes in 2-Dimensional (2D) culture and in 3D co-
culture as hepatocyte-spheroids [17], to investigate drug metabolism and CYP 
induction.  
The metabolism of metoprolol, a cardio-selective beta-blocker currently used mainly 
in the treatment of heart failure [29], myocardial infarction [30], and arterial 
hypertension [31], to its α-hydroxy-metabolite is considered to be exclusively 
mediated by CYP2D6 [32, 33]. On that account, it has been used as a probe 
substrate for CYP2D6 [3, 34-36], including in the Basel phenotyping cocktail [15, 16]. 
After induction treatment with rifampicin, we surprisingly observed a change not only 
in the metabolic ratios for CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, but 
also for CYP2D6 [15]. Since CYP2D6 is considered to be a non-inducible CYP 
isoform [37-42], these results were difficult to interpret. We thus decided to first 
confirm these findings in vitro using two different hepatocyte systems, and 
subsequently to find out the mechanism leading to this observation. 
Another in vivo observation that warranted closer inspection was the inclusion of 
losartan as a probe substrate of CYP2C9. Unlike other cytochrome P450 isoforms 
readily inducible by rifampicin, i.e. CYP2B6, CYP2C19, and CYP3A4, the use of 
losartan metabolic ratios did not reflect induction of CYP2C9 [15, 16]. Thus, in the 
third study, we assessed whether flurbiprofen, a non-steroidal anti-inflammatory drug 
(NSAIDs) [43, 44] previously used in cocktail studies [5, 45], could replace losartan 
14
as a selective substrate for CYP2C9 in the Basel cocktail. Instead of performing 
another time-consuming and cost-intensive clinical trial, this was evaluated in vitro 
using the previously characterised primary human hepatocytes in 3D-co culture. 
Furthermore, to streamline the administration of the phenotyping cocktail, we 
evaluated a newly developed combination-capsule, containing all six low dosed 
drugs in place of separate commercially available formulations, in a pilot study, which 
was necessary to design the formal evaluation process in a future clinical trial.  
Tyrosine kinase inhibitors (TKIs) are antineoplastic agents given orally at a fixed 
dose, despite their large pharmacokinetic variability. Due to the relationship between 
drug exposure and treatment outcome, the “one-dose-fits-all” approach can 
unintentionally lead either to under- or overexposure [46]. After having previously 
characterised the Basel phenotyping cocktail in healthy, male subjects [15, 16], this 
fourth study represents the first time we used two of its substrates, namely 
midazolam and caffeine, to gather phenotyping information in elderly patients of both 
sexes, being treated with erlotinib (Tarceva®) for non-small cell lung cancer 
(NSCLC). The primary aim of the study was to evaluate the relationship between 
individual CYP3A4 and CYP1A2 phenotype with erlotinib exposure. A secondary aim 
was to assess the correlation of individual CYP-phenotype with treatment-related 
toxicity. Furthermore, we were also interested in determining the feasibility of using 
dried blood spots (DBS), a microsampling technique whereby capillary blood is 
spotted onto a filter paper after a simple fingerprick, to perform bio-analysis of 
erlotinib. 
The aim of the last study was to develop and validate an automated extraction 
method for the analysis of three antiretroviral agents in TDM DBS samples. On the 
one hand, adherence to antiretroviral therapy has been strongly correlated with viral 
suppression, an increase in survival, and improved quality of life [47, 48]. On the 
other hand, patients with suboptimal adherence are at risk of HIV progression and 
the development of drug resistance, which consequently narrows options for future 
treatment [47, 49, 50]. However, adherence assessment by health care providers, 
particularly in developing countries, is performed infrequently [47, 49, 51]. Within the 
framework of an adherence assessment study in rural Tanzania (Ifakara) DBS and 
plasma samples of patients treated with combined antiretroviral therapy (cART) were 
collected [52]. For TDM in remote settings, obtaining dried blood spots (DBS) is 
particularly advantageous, as DBS samples do not yield a further biohazardous risk 
and are generally stable at room temperature, making the maintenance of cold 
chains unnecessary [53, 54]. Treatments with two non-nucleoside reverse 
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transcriptase inhibitors, efavirenz and nevirapine, and a protease inhibitor, lopinavir, 
were monitored in this study. Unlike previous studies dealing with the measurement 
and validation of the respective cART compounds through manual DBS extraction 
[55-59], in this study, DBS were extracted in a fully automated manner using a 
CAMAG DBS-MS-500 autosampler [60]. Here, the objective was to test whether 
automated extraction would help to overcome drawbacks of conventional DBS 
methodology. Additionally, to show the utility of DBS collection in rural settings, we 
compared concentrations measured in plasma with corresponding concentrations 
found in DBS. 
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Below, the five sub-projects of this thesis are listed and will be presented in detail in 
the following chapters: 
 
• Comparison of liver cell models using the Basel phenotyping cocktail 
(Chapter 4)  
• Assessment of cytochrome p450 2D6 activity with metoprolol α-
hydroxylation in vivo and in vitro (Chapter 5)  
• In vitro evaluation of replacing losartan by flurbiprofen as a probe 
substrate for cytochrome p450 2C9 in the Basel phenotyping cocktail 
(Chapter 6) 
• Cytochrome p450 3A4 and 1A2 phenotyping for the individualisation of 
treatment with erlotinib (or sunitinib) in cancer patients (Chapter 7)  
• Therapeutic drug monitoring of antiretroviral drugs using a fully automated 
dried blood spot extraction method to measure samples from a clinical 
study in rural Tanzania (Chapter 8) 
 
 
 
Figure 3. Interplay of the five sub-projects making up this thesis. Numbers match the respective chapter mentioned 
above. 
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Abstract 
Currently used hepatocyte cell systems for in vitro assessment of drug metabolism 
include hepatoma cell lines and primary human hepatocyte (PHH) cultures.  We in-
vestigated the suitability of the validated in vivo Basel phenotyping cocktail (caffeine 
[CYP1A2], efavirenz [CYP2B6], losartan [CYP2C9], omeprazole [CYP2C19], 
metoprolol [CYP2D6], midazolam [CYP3A4]) in vitro and characterised four hepato-
cyte cell systems (HepG2 cells, HepaRG cells, and primary cryopreserved human 
hepatocytes in 2-dimensional [2D] culture or in 3D-spheroid co-culture) regarding ba-
sal metabolism and CYP inducibility. Under non-induced conditions, all CYP activities 
could be determined in 3D-PHH, CYP2B6, CYP2C19, CYP2D6 and CYP3A4 in 2D-
PHH and HepaRG, and CYP2C19 and CYP3A4 in HepG2 cells. The highest non-
induced CYP activities were observed in 3D-PHH and HepaRG cells. mRNA expres-
sion was at least 4-fold higher for all CYPs in 3D-PHH compared to the other cell 
systems. After treatment with 20µM rifampicin, mRNA increased 3 to 50-fold for all 
CYPs except CYP1A2 and 2D6 for HepaRG and 3D-PHH, 4-fold (CYP2B6) and 17-
fold (CYP3A4) for 2D-PHH and 4-fold (CYP3A4) for HepG2. In 3D-PHH at least a 2-
fold increase in CYP activity was observed for all inducible CYP isoforms while 
CYP1A2 and CYP2C9 activity did not increase in 2D-PHH and HepaRG. CYP in-
ducibility assessed in vivo using the same phenotyping probes was also best reflect-
ed by the 3D-PHH model. 
Our studies show that 3D-PHH and (with some limitations) HepaRG are suitable cell 
systems for assessing drug metabolism and CYP induction in vitro. HepG2 cells are 
less suited to assess CYP induction of the 2C and 3A family. The Basel phenotyping 
cocktail is suitable for the assessment of CYP activity and induction also in vitro. 
Key words: cytochrome P450 (CYP), Basel cocktail, 3-dimensional spheroid primary 
human hepatocyte culture, CYP induction, liquid chromatography tandem mass 
spectrometry 
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1. Introduction
Cytochrome P450 enzymes (CYPs) are involved in the oxidative metabolism of the 
majority of the commonly used low molecular weight drugs, thereby influencing the 
pharmacokinetics of these drugs and having an important role in drug-drug interac-
tions [1]. Genetic variants and exogenous factors such as diet, smoking habits, and 
concomitant medication can affect the activity of CYPs. All of these factors are re-
sponsible for wide interindividual variations in CYP activity and drug plasma concen-
trations, which can be associated with either increased toxicity or an insufficient 
pharmacological effect. 
Simultaneous determination of the activity of different CYPs in an individual patient 
can be performed by administering a combination (“cocktail”) of specific probe drugs 
[2]. Several cocktails have been characterised in clinical studies and are used in indi-
vidual patients, including the Karolinska cocktail [3], the Cooperstown 5+1 cocktail 
[4], the Geneva cocktail [5] and the Basel Cocktail [6]. These cocktails have also 
been shown to be valuable tools to assess the capacity of drugs to induce or inhibit 
CYPs [5, 7]. Drug cocktails have also been used to perform in vitro studies, in par-
ticular when assessing the CYP inhibition and induction potential of chemical com-
pounds [8-10].  
Suitable in vitro systems to assess drug metabolism are mainly liver microsomes, 
hepatocarcinoma cell cultures (e.g. HepG2 and HepaRG cells) and primary human 
hepatocytes. Monolayer-grown primary human hepatocytes or hepatocarcinoma cell-
lines are currently the gold standard for in vitro drug-drug interaction and hepatotoxi-
city studies. However, monolayer hepatocyte culture systems have major drawbacks. 
Primary human hepatocyte cultures suffer from a rapid loss of cell polarity and of 
specific hepatic functions, which limits their applicability for drug metabolism experi-
ments to a few days. Furthermore, they exhibit a large variation in cell functions, es-
pecially in CYP activities, as well as a variable response to CYP inducers [11, 12]. In 
comparison, hepatocarcinoma cell line cultures can be used over extended periods 
of time, but their metabolic activity and response to CYP inducers are generally lim-
ited [13]. As an alternative to 2D cultures of primary human hepatocytes or hepato-
carcinoma cell lines, a variety of different 3D liver models are being explored, as they 
are thought to approximate the in vivo tissue structure and cell behaviour more close-
ly [12, 14]. 
Limited availability of phenotyping probe drugs is a frequent limitation of published in 
vivo phenotyping cocktails. To facilitate clinical application of phenotyping, we there-
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fore developed a new low-dose cocktail, which is based on probe drugs that are 
widely used in clinical practice [6]. In a subsequent study, we characterised this cock-
tail in healthy male subjects treated with a combination of different CYP inhibitors and 
a CYP inducer [7]. Since we now have a detailed in vivo characterisation of this cock-
tail, it was of interest to also test the cocktail in vitro. The two principle aims of our 
investigation were therefore i) to assess the performance and usability of the Basel 
cocktail in vitro by comparing in vitro with in vivo results and ii) to assess the suitabil-
ity of different hepatocyte cell models for the investigation of drug metabolism and 
CYP induction. 
In order to accomplish these aims, we tested the metabolism of the Basel cocktail 
(containing caffeine, metoprolol, omeprazole, losartan, efavirenz and midazolam) in 
HepG2 cells, HepaRG cells, and primary cryopreserved human hepatocytes grown in 
2D and in 3D culture under basal conditions and after CYP induction with rifampicin. 
CYP induction achieved by rifampicin in vitro could then be compared with the extent 
of in vivo CYP induction. 
2. Materials and methods
2.1. Chemicals and reagents 
8’-hydroxyefavirenz, efavirenz-d4, losartan, losartan-carboxylic acid (E3174), losar-
tan-d4, omeprazole, 5’-hydroxyomeprazole, omeprazole-d3, metoprolol, α-
hydroxymetoprolol, and metoprolol-d7 were purchased from TRC (Toronto, Canada). 
1’-hydroxymidazolam and midazolam-d6 were acquired from Lipomed (Arlesheim, 
Switzerland), whereas rifampicin and β-glucuronidase (type HP-2 from Helix 
pomatia) were obtained from Sigma-Aldrich (Sigma- Aldrich Chemie GmbH, Buchs, 
Switzerland). Midazolam (F. Hoffmann-La Roche, Basel, Switzerland) and efavirenz 
(Merck, NJ, USA) were kindly provided by the respective manufacturers. The chemi-
cal structures of the probe drugs and their phase I metabolites are provided in Sup-
plementary Figure 2. Formic acid, HPLC grade methanol, and HPLC grade water 
were purchased from Merck (Darmstadt, Germany). Media used were purchased 
from GIBCO (Lucerne, Switzerland). 
Stock solutions, calibration and quality control spiking solutions were prepared in 
DMSO. Calibration standards and quality controls were prepared by enriching the 
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respective medium with the corresponding spiking solutions. Internal standard solu-
tions containing the deuterated cocktail probe drugs were prepared in methanol. 
2.2. Cell cultures 
The human hepatoma cell line HepG2 was obtained from  ATCC (Manassas, VA, 
USA). HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
with 2 mM GlutaMAX®, 1.0 g/l glucose and sodium bicarbonate) supplemented with 
10% (v/v) heat-inactivated foetal calf serum (FCS), and 10 mM HEPES buffer, pH 
7.2. In general, all cells were kept at 37°C in a humidified 5% CO2 cell culture incu-
bator and passaged using trypsin, while the cell number was determined using a 
Neubauer hemacytometer. Viability was checked using the tryptan blue exclusion 
method. For the experiments, HepG2 cells were seeded at 10’000 cells/ well in 96-
well plates or 150’000 cells/ well in 12-well plates. 
HepaRG cells were purchased from Biopredic International (Rennes, France) as un-
differentiated cryopreserved cells with the associated medium. Freshly split HepaRG 
cells were seeded at 9000 cells/ well in 96-well plates and treated over the course of 
the next four weeks as previously described (Aninat et al., 2006). 
Primary cryopreserved human hepatocytes (Life Technologies, Lot Hu8119, female 
donor) were plated at 50’000 cells/ well in collagen type-1 precoated 96 well plates in 
William’s E medium supplemented with 10% FBS (v/v), 1% L-Glutamine 200 mM 
(v/v), 1% Pen Strep (v/v), 0.1% dexamethasone 100 µM (v/v), and 0.1% insulin 100 
µM (v/v) and left to incubate at 37°C, 95% humidity, 5% CO2. 
For the 3D-hepatocyte co-culture model originally described by Ohkura et al. [15], 
3T3 fibroblast cells from Swiss albino mouse embryo tissue (3T3 Balb/clone A31, 
ATCC product number CCL 163) were seeded at a density of 8000 cells/well in 96-
well plates or at 40’000 cells/ well in 24-well plates into micro-patterned plates (Cell-
able™, Cosmo Bio USA Inc., CA, USA) in Dulbecco's Modified Eagle's medium 
(DMEM; with 2mM GlutaMAX®,) supplemented with 10% FBS. The cells were cul-
tured in a 5% CO2, 95% air humidified environment at 37°C.  After 2 days, cryo-
preserved human hepatocytes (Life Technologies Lot Hu8119) were seeded at a 
density of 25’000 cells/well in the same 96 well plates containing the 3T3 cells (or 
125’000 cells/ well in 24-well plates). The 3T3-cryopreserved human hepatocyte co-
culture was maintained for a minimum of two days to allow for spheroid formation, 
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using the same medium as for the conventional two-dimensional (2D) cryopreserved 
hepatocyte culture. 
Cryopreserved human hepatocyte preparations were only used for experiments if 
their morphological characteristics and viability (>85%) were acceptable. 
2.3. Markers of CYP450 activity 
CYP activity was assessed by the addition of a CYP probe drug cocktail consisting of 
caffeine (CYP1A2, 80 µM), efavirenz (CYP2B6, 10 µM), losartan (CYP2C9, 14 µM), 
omeprazole (CYP2C19, 17 µM), metoprolol (CYP2D6, 23 µM), and midazolam 
(CYP3A4, 5 µM). The substrates were used at concentrations close to their Km val-
ues previously published. 
A previously developed liquid chromatography tandem mass spectrometry (LC-
MS/MS) method [6] was used to analyse the phase I metabolites of the probe drugs. 
Chromatographic separation was performed on a Shimadzu HPLC system (Shimad-
zu AG, Reinach, Switzerland) coupled to a triple quadrupole tandem mass spectrom-
eter (API4000, AB/MDS Sciex, Concord, Canada) operating in positive electrospray 
ionisation mode, except for 8’-hydroxyefavirenz, which was detected in negative 
mode. Total run time was 2.9 minutes. Inter-assay accuracy (determined as the % 
bias) ranged from -10.7 to 9.8 and inter-assay precision (determined as the CV%) 
was lower than 11.3 for all analytes. The lower limit of quantification (LLOQ) was 
0.25 ng/ml for hydroxymetoprolol, 8-hydroxyefavirenz, 1’-hydroxymidazolam, 5-
hydroxyomeprazole, E-3174, and 0.5 ng/ml for paraxanthine. 
2.4. CYP450 induction experiments 
2.4.1. Evaluation of mRNA expression 
HepG2 cells, HepaRG cells, 2D-cultured human hepatocytes and 3D-cultured human 
hepatocytes were seeded in 24 well plates and treated for 48 h with rifampicin 20 
µM. 350 µL of RLT buffer (Qiagen, Hombrechtikon, Switzerland) was used to lyse the 
respective hepatocytes, after which the lysate was transferred to Qiashredder col-
umns and centrifuged for 2 min at 13’000 rpm. From the eluate, total RNA was ex-
tracted and purified according to the manufacturer’s instructions (Qiagen, RNeasy 
mini extraction kit). The concentration of the extracted RNA was measured spectro-
photometrically at 260 nm on a NanoDrop 2000 (Thermo Fisher Scientific, Wohlen, 
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Switzerland). cDNA was reverse-transcribed from the isolated RNA using the Qiagen 
omniscript system. For quantitative RT-PCR 10 ng cDNA was used. Forward and re-
verse primers for all CYPs tested and endogenous references, hypoxanthine phos-
phoribosyltransferase 1 (HPRT1) and Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), were purchased from Microsynth (Balgach, Switzerland; listed in Table 1). 
rt-PCR was performed using SYBR green (Roche Diagnostics, Rotkreuz, Switzer-
land) on an ABI PRISM 7700 sequence detector (PE Biosystems, Rotkreuz, Switzer-
land). Quantification of mRNA expression levels was performed using the compara-
tive-threshold cycle method [16]. 
Table 1. Gene-specific primers used for rt-PCR. 
Target 
Gene 
Organism 
 
Primer Sequence (5’- 3’) 
Length 
(bp) 
CYP1A2 human 
Fw GGACAGCACTTCCCTGAGAG 20 
Rev GCTCCTGGACTGTTTTCTGC 20 
CYP2B6 human 
Fw CAGTGAATTCAGCCACCAGA 20 
Rev ATTTTGGCTCGGTCATGAAG 20 
CYP2C9 human 
Fw AGGAAAACGGATTTGTGTGG 20 
Rev GGCCATCTGCTCTTCTTCAG 20 
CYP2C19 human 
Fw GGATTGTAAGCACCCCCTG 19 
Rev TAAAGTCCCGAGGGTTGTTG 20 
CYP2D6 human 
Fw TGTGCCCATCACCCAGAT 18 
Rev AAGGTGGAGACGGAGAAGC 19 
CYP3A4 human 
Fw TACACAAAAGCACCGAGTGG 20 
Rev TGCAGTTTCTGCTGGACATC 20 
HPRT1 human 
Fw GGTCCTTTTCACCAGCAAGCT 21 
Rev TGACACTGGCAAAACAATGCA 21 
GAPDH human 
Fw AGCCACATCGCTCAGACAC 19 
Rev GCCCAATACGACCAAATCC 19 
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2.4.2. Functional assessment of CYP induction 
HepG2 cells, HepaRG cells, cryopreserved human hepatocytes, as well as three-
dimensionally seeded co-cultured cryopreserved human hepatocyte spheroids, were 
cultured in a 5% CO2 and 95% air humidified atmosphere at 37°C. Induction treat-
ment (rifampicin 20 µM) lasted for 72 h, with the medium being changed every 24 h. 
Rifampicin stock solution was prepared in DMSO and further diluted in the appropri-
ate culture medium to achieve a final DMSO concentration of 0.1% (v/v). Experi-
mental control culture wells were treated with solvent (DMSO, 0.1% (v/v)) alone. Fol-
lowing induction treatment, CYP activity was assessed by the addition of fresh medi-
um containing the cocktail probe drugs to the control and pre-treated cells. Sub-
strates were dissolved and serially diluted in DMSO to the required concentrations. 
The final concentration of DMSO during the cocktail incubation was 0.2% (v/v). At 
selected time points (0, 15, 30, 45, 60, 90, and 120 min) the incubation was stopped 
by the addition of a threefold volume of ice-cold methanol containing the respective 
internal standards. The bottom of the wells was scraped using a pipette tip, after 
which the contents were transferred to an autosampler vial. After vigorous shaking 
(10 minutes) and centrifugation (3220 g, 30 min, 10°C) the supernatants were stored 
at -20°C until quantification by LC-MS/MS. 
To determine the velocity of midazolam 1’-hydroxylation and efavirenz 8’-
hydroxylation, the entire content of the autosampler vials were evaporated using a 
minivap microplate evaporator (Porvair Sciences Ltd., King’s Lynn, Norfolk, UK). The 
analytes were then resuspended in 45 µl of the respective culture medium to which 5 
µl (500 units) of β-glucuronidase was added. Following a 12 h incubation at 37°C, the 
reaction was terminated by the addition of methanol, after which the samples were 
treated as described above. 
2.5. In vivo assessment of CYP induction 
The in vivo characterisation of the Basel cocktail has been described in previous pub-
lications [6, 7]. Fifteen healthy volunteers were treated with 600 mg rifampicin per 
day for 7 days to induce CYP activity [7]. Genotyping identified one subject as a 
CYP2D6 intermediate metaboliser (CYP2D6*4/*41) and another subject as a 
CYP2C19 poor metaboliser (CYP2C19*2/*2). Data from these two subjects were not 
included in the analysis for CYP2C19 (n=14) and CYP2D6 (n=14), respectively. 
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Clearance ratios of the probe drugs (induced vs non-induced) were used to assess 
the extent of CYP induction.  
2.6. Data analysis 
CYP activities were determined as the respective metabolite formation rates corre-
sponding to the slope in the metabolite concentration versus time graphs. Metabolite 
concentrations were quantified using standard curves of pure compounds as previ-
ously described [6]. 
For induction experiments, formation rates were determined and the fold change ver-
sus the basal conditions was calculated as the ratio of the metabolite formation rate 
in wells exposed to an inducer and control wells. 
Means were compared with the two-tailed Student’s t-test using GraphPad Prism 6.0 
(GraphPad Software, San Diego, CA, USA). Data are presented as mean ± SEM un-
less stated otherwise.  
3. Results
CYP mRNA expression and CYP activities were investigated using four different liver 
cell cultures: HepG2 cells, HepaRG cells, primary human hepatocytes seeded two-
dimensionally (2D) and primary hepatocytes from the same donor in three-
dimensional (3D) spheroid co-culture. 
3.1. Basal mRNA expression of CYPs in the different liver cell models 
Basal CYP mRNA expression relative to GAPDH was detectable in all cell systems 
investigated and was highest in 3D-cultured primary human hepatocytes (Figure 1). 
For HepG2 cells, the CYP mRNA expression was lower than for every other cell sys-
tem investigated. In comparison to 3D-cultured primary human hepatocytes, HepaRG 
cells showed a 4 times lower mRNA expression of CYP3A4 and 2C19, whereas the 
mRNA expression of the other CYPs investigated was more than 10 times lower. In 
2D-cultured primary human hepatocytes, CYP2C19 mRNA expression was approxi-
mately 4 times lower than in 3D-cultured hepatocytes, whereas the mRNA expres-
sion of the other CYPs was more than 10 times lower. 
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Figure 1. Basal mRNA expression of CYP1A2 (a), 2B6 (b), 2C9 (c), 2C19 (d), 2D6 (e), and 3A4 (f) in HepG2, Hep-
aRG, 2D-, and 3D-cultured primary cryopreserved human hepatocytes. mRNA expression was determined by rt-PCR 
as described in the methods section. Results are expressed as mean ± SEM relative to GAPDH of at least 3 inde-
pendent experiments. PHH = primary human hepatocytes. 
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3.2. Basal metabolic activity of the liver cell models used 
Experiments using single substrates instead of the entire cocktail showed no mutual 
interactions between the probe drugs, except for 10 µM efavirenz, which was associ-
ated with a 30% decrease in CYP2C9 and a 20% decrease in CYP2C19 activity (re-
sults not shown). For HepaRG and conventional hepatocyte incubations, the use of 
10 µM efavirenz was necessary, as lower efavirenz concentrations did not yield 
quantifiable concentrations of 8’-hydroxyefavirenz. All experiments were performed 
with the entire cocktail, hence the slight inhibitory effect of efavirenz was present in 
both conditions (basal and induced). In the in vivo cocktail, this interaction had been 
avoided by using efavirenz at a very low dose [7].  
Basal activities for all substrates investigated could be determined in HepaRG cells, 
2D- and 3D-cultured primary human hepatocytes, but not in HepG2 cells (Table 2).  
Table 2. Basal CYP activity in HepG2, HepaRG, 2D-, and 3D-cultured primary cryopreserved human hepatocytes 
(PHH). Primary human hepatocytes used for 2D- and 3D-cultures were from the same batch of cryopreserved cells. 
Values presented are the metabolite formation rates (see Figure 2) and the corresponding regression coefficients (r2) 
of the metabolite-time curves. Metabolite concentrations were determined by LC-MS/ MS. Data are presented as 
mean ± SEM of at least 3 independent experiments. Values in brackets are based on measurements of the last ex-
perimental time-point only, concentrations of all earlier time-points were below LLOQ. nd = not determinable (i.e. 
lacking basal activity).
Basal CYP activities 
(pmol/ h / 50’000 cells) 
HepG2 
cells 
HepaRG 
cells 
2D-cultured 
PHH 
3D-cultured 
PHH 
CYP1A2 
nd (0.46 ± 0.02) (0.09 ± 0.01) 0.22 ± 0.02 
0.932 
CYP2B6 
nd 0.33 ± 0.02 0.54 ± 0.04 2.11 ± 0.07 
0.999 0.905 0.985 
CYP2C9 
nd (0.11 ± 0.01) (0.016 ± 0.002) 0.16 ± 0.01 
0.854 
CYP2C19 
0.16 ± 0.01 18.5 ± 1.0 0.47 ± 0.04 3.7 ± 0.1 
0.976 0.939 0.815 0.978 
CYP2D6 
nd 0.69 ± 0.06 0.25 ± 0.01 6.2 ± 0.3 
0.823 0.950 0.935 
CYP3A4 
0.64 ± 0.04 85.6 ± 4.5 27.4 ± 1.5 60.4 ± 1.5 
0.645 0.991 0.903 0.993 
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The highest activities were observed for CYP3A4, CYP2C19 and CYP2D6 in 3D-
cultured primary human hepatocytes and in HepaRG cells. In HepG2 cells, only ac-
tivities of CYP3A4 and CYP2C19 could reliably be determined; metabolite formation 
remained below the limit of detection for the other CYPs. 
Figure 2 shows the metabolite formation rates for the two CYP isoforms (CYP2C19 
and CYP3A4) with activity in all four cell models using omeprazole and midazolam as 
probe drugs. Metabolite accumulation was linear with time up to 45 minutes for 
CYP3A4 and up to 1 hour for CYP2C19, respectively. The metabolite formation rates 
were highest for HepaRG cells and lowest for HepG2 cells. Formation rates in 3D-
cultured primary hepatocytes were higher than in 2D-cultures, illustrating a benefit of 
the 3D spheroid co-culture. 
Figure 2. Basal activity of CYP2C19 and CYP3A4 assessed using formation rates of 5-hydroxyomeprazole (a) and 
1’-hydroxymidazolam (b) in HepG2, HepaRG, 2D-, and 3D-cultured primary cryopreserved human hepatocytes. Pri-
mary hepatocytes were from the same batch of cryopreserved cells. Metabolite concentrations were determined by 
LC-MS/MS. The corresponding velocities and regressions are given in Table 2. Data are presented as mean ± SEM 
of at least 3 independent experiments. PHH = primary human hepatocytes. 
3.3. Induced mRNA expression of CYPs in liver cell models exposed to rifam-
picin 
Liver cell models were exposed to 20 µM rifampicin for 48 h and mRNA expression 
of the 6 CYPs isoforms was determined. In HepG2 cells, mRNA expression in-
creased only for CYP3A4 (Figure 3). In HepaRG cells, mRNA expression increased 
for CYP2B6, 2C9, 2C19 and 3A4, but not for CYP1A2 and 2D6. A similar pattern of 
CYP induction was obtained for 3D-cultured primary human hepatocytes, showing 
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induction for CYP2B6, 2C9, 2C19 and 3A4, but not for CYP2D6 and 1A2. In compar-
ison, when primary hepatocytes from the same batch were cultured conventionally 
(2D), induced mRNA expression could only be found for CYP3A4 and CYP2B6. 
Figure 3. mRNA expression of CYP1A2, 2B6, 2C9, 2C19, 2D6, and 3A4  in HepG2 (a), HepaRG (b), 2D- (c), and 
3D-cultured primary cryopreserved human hepatocytes (d) after treatment with 20 µM rifampicin for 48 h. mRNA 
expression was determined by rt-PCR as described in the methods section. Values were normalized to GAPDH ex-
pression. Results are expressed as the mean ± SEM fold increase after treatment with rifampicin relative to levels 
observed in control cultures. PHH = primary human hepatocytes. *p<0.05 vs. control culture. 
Since rifampicin is only a weak inducer of CYP1A2, we exposed 3D-cultured primary 
human hepatocytes also to 3-methylcholanthrene, which is a well-established in vitro 
CYP1A2 inducer [17, 18]. As shown in Supplementary Figure 1 (S1), in 3D-cultured 
primary human hepatocytes CYP1A2 mRNA was induced approximately 13 times by 
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3-methylcholathrene, which was also reflected in an approximately six times higher 
production of paraxanthine from caffeine. 
3.4. CYP activity after treatment of liver cell models with rifampicin 
Metabolite formation was assessed after treatment of liver cells with 20 µM rifampicin 
for 72 h. As shown in Figure 4, treatment of 3D-cultured primary human hepatocytes 
was associated with increased metabolite formation by all tested CYP isoforms. The 
metabolite production rates were linear for at least 45 min (midazolam) and up to 120 
min (caffeine and efavirenz). 
In agreement with the mRNA expression data after induction with rifampicin and ba-
sal CYP activity, metabolite formation could be determined for all substrates in Hep-
aRG cells, and in 2D- and 3D-cultured primary human hepatocytes, but not in HepG2 
cells (Table 3). The highest activities were detected for CYP3A4 and CYP2C19 in 
3D-cultured primary human hepatocytes and in HepaRG cells. In HepG2 cells, only 
activities of CYP3A4 and 2C19 could be detected. 
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Figure 4. Formation of paraxanthine (a), 8’-OH-efavirenz (b), E-3174 (c), 5-OH-omeprazole (d), α-OH-metoprolol (e), 
and 1’-hydroxymidazolam (f) by 3D-cultured primary human hepatocytes after treatment with 20 µM rifampicin for 72 
h (open symbols) compared to control cultures (closed symbols). Metabolite concentrations were determined by LC-
MS/MS. The corresponding formation rates and regression coefficients in control cultures and after treatment with 20 
µM rifampicin are given in Tables 2 and 3. Data are presented as mean ± SEM of at least 3 independent experi-
ments.  
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Table 3. CYP activity in HepG2, HepaRG, 2D-, and 3D-cultured primary cryopreserved human hepatocytes (PHH) 
after treatment with 20 µM rifampicin for 72 h. Primary human hepatocytes used for 2D- and 3D-cultures were from 
the same batch of cryopreserved cells. Values presented are the metabolite formation rates and the regression coef-
ficients (r2) of the metabolite-time curves after pre-treatment with rifampicin. Metabolite concentrations were deter-
mined by LC/MS. Data are presented as mean ± SEM of at least 3 independent experiments. Values in brackets are 
based on measurements of the last experimental time-point only, concentrations of all earlier time-points were below 
LLOQ. nd = not determinable (lacking basal activity). 
Induced CYP activities [20µM rifampicin] 
(pmol/ h / 50’000 cells) 
HepG2 
cells 
HepaRG 
cells 
2D-cultured 
PHH 
3D-cultured 
PHH 
CYP1A2 
nd (0.51 ± 0.04) (0.09 ± 0.01) 0.46 ± 0.02 
  
0.956 
CYP2B6 
nd 1.31 ± 0.04 1.7 ± 0.1 5.7 ± 0.1 
0.998 0.975 0.994 
CYP2C9 
nd (0.12 ± 0.02) (0.022 ± 0.002) 0.41 ± 0.01 
  
0.985 
CYP2C19 
0.21 ± 0.01 75.9 ± 1.8 1.96 ± 0.11 30.7 ± 1.7 
0.979 0.996 0.978 0.980 
CYP2D6 
nd 3.9 ± 0.2 0.35 ± 0.01 8.6 ± 0.4 
0.992 0.928 0.952 
CYP3A4 
1.1 ± 0.1 675 ± 20 129 ± 8 432 ± 17 
0.999 0.999 0.943 0.952 
3.5. Comparison rifampicin-induced CYP activity in vitro and in vivo 
Compared to baseline, CYP2C9 and CYP3A4 activities were increased 1.5 to 2 times 
in HepG2 cells without reaching statistical significance (Figure 5). In HepaRG cells, 
activities of CYP3A4, CYP2D6, 2C19 and 2B6 were increased significantly, with the 
exception of CYP2D6 matching well with the mRNA induction data. An almost identi-
cal result was obtained for 2D-cultured primary human hepatocytes. In 3D-cultured 
primary human hepatocytes, CYP activities of all inducible CYP isoforms were in-
creased at least 2-fold after rifampicin induction. 
Treatment of healthy volunteers with rifampicin [7] was associated with an approxi-
mately 7-fold induction of CYP3A4, a 14-fold induction of CYP2C19, a doubling of 
34
CYP2C9 activity and an approximately 1.7-fold increase in CYP2B6 activity. When 
compared to the liver cell models investigated, this pattern was reflected best by the 
3D-cultured primary human hepatocytes. 
Figure 5. Fold increase (relative to non-induced control) of CYP activity in vitro in HepG2 (A), HepaRG (B), 2D-, and 
3D-cultured primary human hepatocytes (C and D), and in vivo in healthy male subjects (E, n=14 for CYP2C19 and 
CYP2D6; n=15 for all other CYP isoforms) after treatment with rifampicin. Hepatocyte cell lines were treated with 20 
µM rifampicin for 72 h and healthy volunteers with 600 mg rifampicin per day for 7 days as described in the methods 
section. Metabolite and parent drug concentrations were determined by LC-MS/MS. Results are expressed as mean 
± SEM. PHH = primary human hepatocytes. *p<0.05 vs. control. 
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4. Discussion
This study confirms that basal mRNA expression and CYP activity as well as CYP 
inducibility show large differences between in vitro used hepatocyte cell models and, 
depending on the hepatocyte model used, that the in vivo characterised Basel phe-
notyping cocktail is suitable for CYP induction experiments in vitro. 
HepG2 cells represent a hepatoma cell line, which is used extensively for toxicologi-
cal studies but less frequently for studies of drug metabolism [19-21]. Drug metabo-
lism is difficult to assess with this cell line since CYPs show weak mRNA expression 
and activity [13, 22, 23]. In this point, the results of the current investigation are in 
agreement with these previous studies. In the basal state, mRNA expression was 
clearly lower than in the other cell types for every CYP investigated and the activity 
could reliably be determined only for CYP3A4 and CYP2C19. CYP induction with ri-
fampicin resulted in a significant 4-fold increase in the CYP3A4 mRNA, which was 
only partially reflected in a corresponding increase in CYP3A4 activity. A limited in-
ducibility of the CYP3A and CYP2C families in HepG2 cells has also been shown in 
other studies [13, 22] and has been attributed to a low expression of the nuclear re-
ceptors CAR and PXR [24, 25], which are mediating the induction of the CYP2C and 
3A families [26]. In contrast, inducibility of CYP1A2 (which we did not determine in 
our studies) has been shown to be maintained in HepG2 cells [27]. CYP1A2 induc-
tion is mediated by the aryl hydrocarbon receptor [26], which is highly expressed in 
HepG2 cells [24]. In contrast to phase I enzyme activities, conjugation reactions ap-
pear to be maintained quite well in HepG2 cells [28]. HepG2 cells can therefore only 
be used to answer very specific questions regarding drug metabolism. 
HepaRG cells represent a hepatoma cell line, which has first been described in 2002 
as a cell model suitable for HBV infection and propagation [29]. Soon after their first 
description, HepaRG cells were characterised and proposed for their use as a model 
for drug metabolism studies [24]. The gene expression profile shows profound differ-
ences compared to HepG2 cells, explaining the observed differences in their drug 
metabolism phenotype [30]. HepaRG cells have also been used in drug toxicity stud-
ies, particularly, when active metabolites are suspected [22, 25]. Considering the cur-
rent study, HepaRG cells were clearly a more suitable hepatocyte model for studying 
drug metabolism than HepG2 cells. mRNA expression could be detected for all CYPs 
investigated and was inducible except for CYP1A2 and 2D6. Lack of CYP1A2 induc-
tion is not a problem of the cell line, but of rifampicin, which was used as a CYP in-
ducer. As shown in vitro [22, 27] and in vivo [7], rifampicin is a good inducer for the 
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CYP2C and 3A families, but not for CYP1A2. With specific CYP1A2 inducers such as 
3-methylcholanthrene CYP1A2 can be induced in HepaRG cells on both the mRNA 
and the activity level [24, 25]. CYP2D6 has a low activity in HepaRG cells, possibly 
because the cell line originates from a slow CYP2D6 metaboliser [25], and it cannot 
be induced with rifampicin [22]. 
Interestingly, the activity for CYP3A4 and 2C19 were higher in HepaRG cells as 
compared to 3D-cultured primary human hepatocytes, whereas the corresponding 
mRNA expressions (relative to GAPDH) were lower. This could be a problem of 
standardisation to GAPDH (different GAPDH expression in HepaRG cells and prima-
ry hepatocytes) or a bad correlation between mRNA levels and protein expression 
and/or activity. In the study of Choi et al. [27], GAPDH mRNA expression was quite 
stable among different hepatocyte cell lines, arguing against the first possibility. On 
the other hand, it is well established that posttranslational modifications such as 
acetylation, glycosylation and phosphorylation can have a large impact on protein 
activity [31], favouring the second possibility. In our study, the CYP activity profile 
and inducibility of HepaRG cells were more closely related to primary hepatocytes 
than to HepG2 cells. 
Primary hepatocytes are currently considered to be the gold standard for drug me-
tabolism studies. By using the same batch of human cryopreserved hepatocytes in 
the 2D- and 3D-cultures, we were able to estimate whether the 3D environment 
would lead to differences in CYP activity and/or expression compared to the 2D-
cultures. Indeed, in comparison to 2D-cultures, 3D-cultured primary human hepato-
cytes exhibited a higher CYP mRNA expression, a higher basal CYP activity and a 
better inducibility. In comparison to the in vivo results regarding CYP induction, 3D-
cultured primary human hepatocytes showed a better agreement than the other cell 
lines tested, suggesting that they could be usable to predict the induction potential of 
new drugs. Hepatocyte 3D-cultures are currently being developed and characterise 
as an alternative to 2D-cultures in order to overcome well-known drawbacks of 2D-
cultures such as varying expression of CYP activities, varying CYP inducibility and 
loss of differentiation over time [24, 32]. Assuming that 3D-cultures of primary human 
hepatocytes may offer advantages compared to the corresponding 2D-cultures, 
many 3D-hepatocyte models have been and are currently being explored for drug 
metabolism and drug toxicity studies [12, 14, 33, 34]. 
We performed our studies with a co-culture system using 3T3-Swiss albino mouse 
fibroblasts as feeder cells for human cryopreserved primary hepatocytes. This sys-
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tem has originally been described in detail by Ohkura et al. [15] who characterised it 
regarding the mRNA expression of phase I and phase II drug metabolism enzymes 
and demonstrated its capacity to produce metabolites from different drugs. The mod-
el uses special plates coated with a block co-polymer that allows the fibroblasts and 
hepatocytes to only adhere to certain areas of the wells. In time, the mouse fibro-
blasts and human cryopreserved hepatocytes are able to form 3D structures de-
scribed as spheroids. Spheroids can be regarded as a cell aggregation with an ener-
gy- and surface-minimised structure that, according to van Zijl et al. [35] mimic the in 
vivo situation quite efficiently regarding cell shape and cellular environment. The re-
sults of our study support this assumption. 
After having been characterised in vivo [6, 7], the substrate cocktail showed a satis-
factory performance also in vitro. Critical substrates were losartan (CYP2C9) and caf-
feine (CYP1A2), which were metabolised at a low rate even in 3D-cultured primary 
human hepatocytes and showed no significant metabolism in HepG2 cells. On the 
other hand, they correctly reflected CYP2C9 induction by rifampicin and CYP1A2 in-
duction by 3-methylcholanthrene. Depending on the question to be answered and on 
the cell system used, they could be replaced by phenacetin (CYP1A2) and diclofenac 
(CYP2C9), which have been shown to be suitable substrates in vitro [8, 10, 32]. 
In conclusion, our studies demonstrate that the 3D-primary human hepatocyte sphe-
roid culture system is suitable for the assessment of drug metabolism and CYP in-
duction in vitro. Among the four tested cell systems, 3D-cultured primary human 
hepatocytes best reflect CYP inducibility in vivo. HepaRG cells are close to 3D-
cultured primary human hepatocytes but induced CYP activities correlate less well 
with CYP induction in vivo. HepG2 cells are known to predict CYP1A2 induction but 
are less suitable for CYPs of the 2C and 3A family. The substrates of the Basel phe-
notyping cocktail only show minimal interactions in vitro and the cocktail is thus usa-
ble for the assessment of CYP induction in vitro. 
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Supplementary Files 
Figure S1. (a) Fold increase (relative to non-induced control) of CYP1A2 mRNA levels after treatment of 3D-cultured 
primary human hepatocytes with 3-methylcholanthrene [2 µM] for 72 h. mRNA levels were determined using rt-PCR 
as described in the methods section. mRNA expression in control cultures and after treatment with 3-
methylcholanthrene was first normalized to the respective GAPDH expression. Data are given as mean ± SEM of at 
least 3 independent experiments (b) Activity of CYP1A2 assessed using caffeine-N3-demethylation in 3D-cultured 
primary cryopreserved human hepatocytes after treatment with 3-methylcholanthrene [2 µM] (open symbols) for 72 h 
compared to control cultures (closed symbols). * = p<0.05 vs. corresponding basal value. 
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Abstract 
Metoprolol α-hydroxylation has been described as exclusively catalysed by CYP2D6, 
a CYP450 isoform that is considered to be not inducible through the use of typical 
inducers of the CYP2C and CYP3A families, such as rifampicin, phenobarbital, and 
hypericum extract. While assessing CYP2D6 activity under basal conditions and after 
pretreatment with rifampicin in vivo, we observed a surprising, slight change in 
metoprolol AUC ratio as well as in the metabolic ratio. We investigated these findings 
in vitro using HepaRG cells and primary human hepatocytes, studied before and after 
treatment with 20µM rifampicin. While mRNA expression levels of CYP3A4 showed a 
15- to 30-fold increase in both cell models, mRNA of CYP2D6 was not affected by 
rifampicin. 1’-hydroxymidazolam formation (a marker of CYP3A4 activity) increased 
by a factor of 5 to 8 in both cell models, while the formation of α-hydroxymetoprolol 
increased by a factor of 6 in HepaRG cells and by a factor of 1.4 in primary cryo-
preserved human hepatocytes. In order to test whether CYP3A4 was contributing to 
metoprolol α-hydroxylation, we studied midazolam and metoprolol metabolism in su-
persomes expressing CYP3A4. Midazolam was rapidly converted to 1’-
hydroxymidazolam in CYP3A4 supersomes, a reaction strongly inhibited by the 
CYP3A4 inhibitor ketoconazole. However, metoprolol was also α-hydroxylated by 
CYP3A4 supersomes. This reaction was inhibited with ketoconazole, but not with the 
CYP2D6-specific inhibitor quinidine. Therefore, we can conclude that α-hydroxylation 
of metoprolol is not exclusively metabolised by CYP2D6 and that CYP3A4 is also 
involved to some extent. This contribution is larger when CYP3A4 is induced but is 
too small to compromise the usability of metoprolol α-hydroxylation for phenotyping. 
 
 
 
Keywords: CYP2D6, α-hydroxymetoprolol, metoprolol, phenotyping, CYP induction, 
rifampicin
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1. Introduction 
Metoprolol is a cardioselective beta blocker, that is currently mainly used in the 
treatment of heart failure [1], myocardial infarction [2], and arterial hypertension [3]. 
Intestinal absorption of metoprolol is rapid and almost complete; however, due to an 
extensive first pass metabolism [4], the bioavailability of metoprolol is approximately 
50%. The half-life is in the range of 3 to 4 hours in young adults and between 7 to 9 
hours in elderly patients [5]. Due to its short half-life, sustained release preparations 
have been developed and are currently prescribed for patients with heart failure 
and/or hypertension. Metoprolol is thoroughly biotransformed with less than 5% of an 
oral dose being excreted in non-metabolised form by the kidneys [4-7]. Approximate-
ly 70% of orally administered metoprolol is metabolized by CYP2D6 [8]. Major oxida-
tive pathways are: O-demethylation to O-desmethylmetoprolol and its further oxida-
tion to the corresponding metoprolol acid (65% of the oral dose recovered in urine); 
N-dealkylation to form N-desisopropylmetoprolol (10%); and α-hydroxylation to form 
α-hydroxymetoprolol (10%) [9] (Figure 1).  
 
	 
Figure 1. Major metabolic pathway of metoprolol in man. Metoprolol (I), α-hydroxymetoprolol (II), O-
desmethylmetoprolol (III), metoprolol acid (IV), and N-desisopropylmetoprolol (V), adapted from [6, 7]. 
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Whereas the carboxylic acid metabolites have no pharmacological activity, the α-
hydroxymetabolite on the other hand is active, but only contributes to approximately 
10% of the total beta-blocking activity of metoprolol [10]. Crucially, in contrast to the 
formation of the carboxylic acid metabolites, the α-hydroxylation of metoprolol only 
involves one enzymatic step, which is considered to be exclusively mediated by 
CYP2D6 [6, 11]. Furthermore, the metabolism of metoprolol is stereoselective; in ex-
tensive CYP2D6 metabolisers (CYP2D6 EM), R-metoprolol has a 40% higher clear-
ance than S-metoprolol [12]. 
Due to the exclusive nature by which CYP2D6 is responsible for the metabolism of 
metoprolol, this step in the metabolic pathway of metoprolol has previously been 
used for the assessment of CYP2D6 activity in vivo [13-17] and in vitro [18]. We have 
recently published a clinical study in healthy volunteers investigating the effect of 
CYP inhibitors and inducers on the Basel phenotyping cocktail, which contains six 
low-dosed commercially available drugs (caffeine, efavirenz, losartan, omeprazole, 
metoprolol, and midazolam) [13]. After CYP induction with rifampicin, we not only ob-
served a change in the phenotyping metric for CYP1A2, CYP2B6, CYP2C9, 
CYP2C19, and CYP3A4, but also surprisingly for CYP2D6, which was evaluated 
through use of the metabolic ratio of metoprolol and its α-hydroxy-metabolite, as well 
as the corresponding AUC0-24h ratio. As CYP2D6 is considered to be non-inducible 
[19-24], this result was difficult to interpret. 
Since it has been shown in a clinical study that the metabolism of metoprolol cannot 
be completely inhibited by quinidine [8], an efficient and specific CYP2D6 inhibitor 
[25, 26], it is likely that apart from CYP2D6, other CYP isoforms are also involved in 
the oxidative degradation of this drug, possibly even in its α-hydroxylation. Taking the 
results obtained from our in vivo study into account [13], we set out to confirm these 
findings in vitro using two different hepatocyte systems. We then attempted to figure 
out the mechanism behind this observation. 
 
 
2. Materials and methods 
2.1. Chemicals and reagents 
Metoprolol, α-hydroxymetoprolol, O-desmethylmetoprolol, metoprolol acid, and 
metoprolol-d7 were purchased from TRC (Toronto, Canada). 1’-hydroxymidazolam 
and midazolam-d6 were acquired from Lipomed (Arlesheim, Switzerland), while ri-
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fampicin, ketoconazole, quinidine, and β-glucuronidase (type HP-2 from Helix 
pomatia) were obtained from Sigma-Aldrich (Sigma-Aldrich Chemie GmbH, Buchs, 
Switzerland). Midazolam was provided by Roche (Hoffmann-La Roche, Basel, Swit-
zerland). Formic acid, HPLC grade methanol, and HPLC grade water were pur-
chased from Merck (Darmstadt, Germany). The media used were purchased from 
GIBCO (Lucerne, Switzerland). 
Stock solutions, calibration spiking solutions, and quality controls were prepared in 
DMSO. Calibration standards and quality controls were prepared by enriching the 
respective medium with the corresponding spiking solutions. Internal standard solu-
tions containing the deuterated cocktail probe drugs were prepared in methanol. 
 
2.2. Cell culture 
Recombinant human CYP3A4 supersomes (rhCYP3A4, + P450 reductase + cyto-
chrome b5, Lot #4070007) and NADPH regenerating solutions A and B (A, contains 
NADP+, glucose-6-phophate, and MgCl2; B, contains glucose-6-phosphate dehydro-
genase) were purchased from Corning Life science (Woburn, MA, USA). HLM sam-
ples were stored at -80°C until used. 
HepaRG cells were purchased from Biopredic International (Rennes, France) as un-
differentiated cryopreserved cells with the associated medium. Freshly split HepaRG 
cells were seeded at 9000 cells/well in 96-well plates (or 0.05x106 cells/well in 24-well 
plates) and treated over the course of the next four weeks as previously described 
[27]. 
Primary cryopreserved human hepatocytes (Life Technologies, Lot #Hu8119 and Lot 
#Hu8124) were plated at 0.05x106 cells/well in collagen type-1 precoated 96-well 
plates (or 0.25x106 cells/well in 24-well plates) in William’s E medium supplemented 
with 10% FCS (v/v), 1% L-Glutamine 200 mM (v/v), 1% Pen Strep (v/v), 0.1% dexa-
methasone 100 µM (v/v), and 0.1% insulin 100µM (v/v), and then left to incubate at 
37°C, 95% humidity, 5% CO2. 
 
2.3. Markers of CYP450 activity 
CYP activity was assessed by the addition of metoprolol (CYP2D6, 23 µM) and mid-
azolam (CYP3A4, 5 µM). The substrates were used at concentrations close to their 
previously published Km values. 
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A previously developed liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method [14] was used to analyse the phase I metabolites of the probe sub-
strates. Chromatographic separation was performed on a Shimadzu HPLC system 
(Shimadzu AG, Reinach, Switzerland), coupled to a triple quadrupole tandem mass 
spectrometer (API4000 or API5500, AB/MDS Sciex, Concord, Canada), operating in 
positive electrospray ionisation mode. The total run time was 2.9 minutes. Inter-assay 
accuracy (determined as the % bias) ranged from -8.6 to 8.9 and inter-assay preci-
sion (determined as the CV%) was lower than 8.3 for all analytes. The lower limit of 
quantification (LLOQ) utilising the API 4000 was 0.25 ng/mL for α-hydroxymetoprolol 
and 1’-hydroxymidazolam, whereas on the API5500 the LLOQ for α-
hydroxymetoprolol, O-desmethylmetoprolol, and metoprolol acid was 0.025 ng/mL.  
 
2.4. In vivo assessment of CYP induction 
The in vivo characterisation of the Basel cocktail has been described in prior publica-
tions [13, 14]. Here, CYP induction had been achieved by treating 15 healthy volun-
teers with 600 mg rifampicin per day for 7 days [13]. Genotyping identified one sub-
ject as a CYP2D6 intermediate metabolizer (IM, CYP2D6*4/ *41). As such, data from 
this subject was included in the analysis for CYP2D6. We used the ratio between the 
induced and the basal state of the clearance of the parent drug as a marker of CYP 
induction.  
 
2.5. CYP2D6 and CYP3A4 induction experiments 
2.5.1. Gene expression evaluation 
HepaRG cells and primary cryopreserved human hepatocytes were seeded in 24 
well plates and treated for 48h with rifampicin 20 µM. 350 µL of RLT buffer (Qiagen, 
Hombrechtikon, Switzerland) was used to lyse the respective liver cell models, after 
which the lysate was transferred to Qiashredder columns and centrifuged for 2 
minutes at 13’000 rpm. From the eluate, total RNA was extracted and purified ac-
cording to the manufacturer’s instructions (Qiagen, RNeasy mini extraction kit). The 
concentration of the extracted RNA was measured spectrophotometrically at 260 nm 
on a NanoDrop 2000 (Thermos Scientific, Wohlen, Switzerland). cDNA was reverse 
transcribed from the isolated RNA using the Qiagen omniscript system. For quantita-
tive rt-PCR, 10 ng cDNA was used. Forward and reverse primers for all CYPs tested, 
and endogenous references, Hypoxanthine phosphoribosyltransferase 1 (HPRT1) 
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and GAPDH, were purchased from Microsynth (Balgach, Switzerland; listed in Table 
1). rt-PCR was performed using SYBR green (Roche Diagnostics, Rotkreuz, Switzer-
land) on an ABI PRISM 7700 sequence detector (PE Biosystems, Rotkreuz, Switzer-
land). Quantification of mRNA expression levels was performed using the compara-
tive-threshold cycle method [28].  
 
Table 1. Gene-specific primers for rt-PCR. 
	 	 	 	 	Target 
Gene Organism Primer Sequence (5’à3’) 
Length 
(bp) 
CYP2D6 human Fw TGTGCCCATCACCCAGAT 
18 
Rev AAGGTGGAGACGGAGAAGC 19 
CYP3A4 human Fw 
TACACAAAAGCACCGAGTGG 20 
Rev TGCAGTTTCTGCTGGACATC 20 
HPRT1 human Fw 
GGTCCTTTTCACCAGCAAGCT 21 
Rev TGACACTGGCAAAACAATGCA 21 
GAPDH human Fw 
AGCCACATCGCTCAGACAC 19 
Rev GCCCAATACGACCAAATCC 19 
 
 
2.5.2. Functional assessment of CYP induction 
HepaRG cells and primary cryopreserved human hepatocytes were cultured in a 5% 
CO2 and 95% air-humidified atmosphere at 37°C. Induction treatment (rifampicin 
20µM) lasted for 72h, with the medium being changed every 24h. Rifampicin stock 
solution was prepared in DMSO and further diluted in the appropriate culture medi-
um, to achieve a final DMSO concentration of 0.1% (v/v). Experimental control cul-
ture wells were treated with solvent (DMSO, 0.1% (v/v)) alone. Following induction 
treatment, CYP activity was assessed by the addition of fresh medium, containing the 
probe drugs, to the control and pre-treated cells. Substrates were dissolved and seri-
ally diluted to the required concentrations with DMSO. The final concentration of 
DMSO during the incubation was 0.2% (v/v). At selected time points (0, 15, 30, 45, 
60, 90, 105, and 120 min), the incubation was stopped by the addition of a threefold 
volume of ice-cold methanol containing the respective internal standards. The bot-
toms of the wells were scraped using a pipette tip, after which the contents were 
transferred to an autosampler vial. After vigorous shaking (10 min) and centrifugation 
(3220 g; 30 min; 10°C), the supernatants were stored at -20°C until analysis by LC-
MS/MS. 
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To determine 1’-hydroxymidazolam, the entire content of the autosampler vials were 
evaporated using a minivap microplate evaporator (Porvair Sciences Ltd., King’s 
Lynn, Norfolk, UK). The analytes were then re-suspended in 45 µl of the respective 
culture medium, to which 5 µl (500 units) of β-glucuronidase was added. Following a 
12 h incubation at 37°C, the reaction was terminated by the addition of methanol, af-
ter which the samples were treated in the same manner as above. 
 
2.6. Metabolism of metoprolol and midazolam by rHCYP3A4 supersomes 
The reaction mixture (final volume of 500 µL) contained test compounds, incubation 
buffer (0.1 M potassium phosphate buffered saline, pH 7.4), rhCYP3A4 (20 pmol 
P450/mL) and an NADPH-generating system. For inhibition studies, the reaction mix-
ture was pre-incubated with either 0.5 µM ketoconazole or 1 µM quinidine for 10 
minutes prior to addition of test compounds and NADPH. The suspensions were in-
cubated at 37°C in a thermomixer (compact 5350, Eppendorf, Hamburg, Germany). 
Following the incubation in the absence (control) and presence of inhibitors at select-
ed time-points (0, 1, 2, 4, 8, 15, 30, and 60 min), the reactions were terminated by 
transferring 50 µL of the incubation mixture into a matrix autosampler vial, to which a 
threefold volume of ice-cold methanol, containing the internal standards, was added. 
After vigorous shaking (10 min) and centrifugation (3220 g; 30 min; 10°C) the sam-
ples were stored at -20°C until analysis by LC-MS/MS. The remaining percentage 
formation rate (pmol/ min/ pmol P450) after inhibition relative to control (without inhib-
itors) was calculated. 
 
2.7. Data analysis 
CYP activities were determined as the respective metabolite formation rates corre-
sponding to the slope in the metabolite concentration versus time graphs. Metabolite 
concentrations were quantified using standard curves of pure compounds as previ-
ously described [14].  
For induction experiments, formation rates were determined, and the fold change 
versus the basal conditions was calculated as the ratio of the metabolite formation 
rate in wells exposed to an inducer and control wells. 
Means were compared with the two-tailed Student’s t-test using GraphPad Prism 6.0 
(GraphPad Software, San Diego, CA, USA). Data are presented as mean ± SD un-
less otherwise stated. Induction levels above 2-fold with statistically significant differ-
ences (p < 0.05) were considered relevant. Areas under the curve (AUC), from times 
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0 to 24h after dosing (AUC0-24h), were estimated with non-compartmental methods 
using Phoenix WinNonlin software (Certara, Princeton, NJ, USA).  
 
3. Results 
3.1. In vivo clearance of metoprolol before and after treatment with rifampicin 
We have performed a clinical study using 15 healthy volunteers, where we investi-
gated the effect of pretreatment with rifampicin on the Basel phenotyping cocktail, 
which contains caffeine, efavirenz, losartan, omeprazole, metoprolol and midazolam 
as probe drugs [13]. As expected, we observed an increase in midazolam clearance 
(Figure 2a) and a decrease in midazolam AUC0-24h (supplemental material, Figure 
S1a) in all subjects tested, which is used as a marker of CYP3A4 activity. Surprising-
ly, we also observed a considerable change in metoprolol concentrations between 
basal and induced conditions, leading to a significant increase in metoprolol clear-
ance (Figure 2b) and a decrease in metoprolol AUC0-24h (supplemental material, Fig-
ure S1b) through rifampicin treatment. A slight change in the formation of α-
hydroxymetoprolol was also observed after treatment with rifampicin. However, un-
like with metoprolol, the difference between basal and induced concentrations did not 
lead to a significant change in AUC0-24h of α-hydroxymetoprolol (supplemental materi-
al, Figure S1c). In order to study this question in more detail, we performed in vitro 
investigations in primary human hepatocytes and in HepaRG cells. 
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Figure 2.  Effect of rifampicin on (a) midazolam and (b) metoprolol clearance in human subjects. Subjects were 
treated orally with 12.5 mg metoprolol and 2 mg midazolam before (basal, grey circles) and after pre-treatment with 
rifampicin, 600 mg once daily for 7 days (induced, grey squares). Metoprolol and Midazolam was determined using 
LC/MS-MS. Clearance was calculated by dividing the dose by the respective AUCs (trapezoidal rule) of the subjects. 
Closed symbols represent CYP2D6 EMs; open symbol represents the CYP2D6 IM. The black horizontal lines signify 
the median. The p-value (* = p<0.05) for midazolam clearance (a) is from a paired t-test, while for metoprolol clear-
ance (b), it is from a Wilcoxon matched-pairs signed ranks test.  
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3.2. mRNA expression of CYP2D6 and CYP3A4, metoprolol and midazolam me-
tabolism before and after rifampicin in HepaRG cells 
HepaRG cells represent a hepatoma cell line with inducible CYPs [20, 27, 29]. In 
HepaRG cells, mRNA of CYP3A4 (determined as a control) increased approximately 
30-fold after treatment with rifampicin (20 µM for 48h) compared to basal conditions 
(Figure 3a). In contrast, mRNA of CYP2D6 was not induced by pre-treatment with 
rifampicin (Figure 3a). 
In agreement with the mRNA data, pre-treatment with rifampicin was associated with 
a significant increase in the formation of 1’-hydroxymidazolam (Figure 3b), reflecting 
induction of CYP3A4 by rifampicin. In contrast to the results obtained for CYP2D6 
mRNA, pre-treatment with rifampicin was associated with a significant increase in α-
hydroxymetoprolol formation (Figure 3c). Since α-hydroxylation of metoprolol is con-
sidered to be specific for CYP2D6 [6, 11], this would, at first sight, suggest induction 
of CYP2D6 in HepaRG cells. 
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Figure 3. Effect of rifampicin pretreatment on  mRNA expression (a), and CYP activity of CYP3A4 (b), and CYP2D6 
(c) in HepaRG cells. HeparRG cells were studied for either 48h or 72h  under basal activity (0.1% DMSO, v/v; either 
white box plot [a] or white bars [b, c]) and compared to treatment with rifampicin (20 µM; either dark grey box plot [a] 
or dark grey bars [b, c]). mRNA was quantified using rt-PCR, while metabolite formation was determined using 
LC/MS-MS, both as described in Methods section. Data are presented as mean ± SEM of at least 3 independent 
experiments.  The p-values (* = p<0.05) for 1’-hydroxymidazolam and α-hydroxymetoprolol formation are from paired 
t-tests.  
 
 
3.3. mRNA expression of CYP2D6 and CYP3A4, metoprolol and midazolam me-
tabolism before and after rifampicin in 2D primary hepatocytes 
In order to confirm the results obtained in HepaRG cells, we performed the same ex-
periments using primary human hepatocytes. Identical to our findings in HepaRG 
cells, pre-treatment with rifampicin was associated with a 16-fold increase in CYP3A4 
mRNA expression, whereas no increase in mRNA expression levels could be ob-
served for CYP2D6 (Figure 4a). 
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Pre-treatment with rifampicin led to a five-fold increase in production of 1’-
hydroxymidazolam (Figure 4b). Similar to the findings in HepaRG cells, rifampicin 
increased α-hydroxylation of metoprolol in primary human hepatocytes (Figure 4c), 
but to a much lesser extent than in HepaRG cells. These findings confirmed the re-
sults obtained with HepaRG cells, while at the same time excluding an artifact due to 
modified regulation of CYP expression in the HepaRG hepatoma cell line. 
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Figure 4. Effect of rifampicin pretreatment on (a) mRNA expression, and CYP activity of (b) CYP3A4, and (c) 
CYP2D6, in primary human hepatocytes cultured in 2D. Primary human cryopreserved hepatocytes (Lot #8119) were 
studied for either 48h or 72h  under basal activity (0.1% DMSO, v/v; either white box plot [a] or white bars [b, c]) and 
compared to treatment with rifampicin (20 µM; either dark grey box plot [a] or dark grey bars [b, c]). mRNA was quan-
tified using rt-PCR,  while metabolite formation was determined using LC/MS-MS, both as described in methods. 
Data are presented as mean ± SEM of at least 3 independent experiments. The p-values (* = p<0.05) for 1’-
hydroxymidazolam and α-hydroxymetoprolol formation are from paired t-tests. 
 
Using a different batch of primary cryopreserved human hepatocytes we additionally 
investigated whether O-desmethylmetoprolol and metoprolol acid, which make up the 
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main metabolic pathway of metoprolol, would also be susceptible to induction by ri-
fampicin. Our findings show, that similar to the increase of α-hydroxymetoprolol (Fig-
ure 5b), the O-demethylation of metoprolol (Figure 5c) and its subsequent oxidation 
to metoprolol acid (Figure 5d) increased 1.4-fold through treatment with rifampicin.  
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Figure 5. Effect of rifampicin pretreatment on the formation of 1’-hydroxymidazolam (a), α-hydroxymetoprolol (b), O-
desmethylmetoprolol (c), and metoprolol acid (d) in primary cryopreserved human hepatocytes. Primary human cryo-
preserved hepatocytes (Lot #8124) were studied for either 48h or 72h  under basal activity (0.1% DMSO, v/v; either 
white box plot [a] or white bars [b, c, d]) and compared to treatment with rifampicin (20 µM; either dark grey box plot 
[a] or dark grey bars [b, c]). Data are presented as mean ± SEM of at least 3 independent experiments.  The p-values 
(* = p<0.05) for the respective metabolites of metoprolol and midazolam are from paired t-tests. 
 
3.4. Experiments with rHCYP3A4 supersomes 
Other than CYP2D6 induction, an alternative explanation for the observed increase in 
α-hydroxymetoprolol formation through rifampicin treatment could be the involvement 
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through induction of an altogether different CYP isoform. Since CYP3A4 can perform 
hydroxylation reactions and is the CYP involved in most phase I reactions [30], we 
investigated the possible involvement of CYP3A4 in the metabolism of metoprolol by 
using recombinant human CYP3A4 supersomes (rHCYP3A4). To ensure that these 
supersomes do not contain CYP2D6 activity, we exposed the supersomes to dex-
tromethorphan, a typical CYP2D6 substrate [15]. The conversion to dextrorphan was 
not quantifiable, excluding a significant CYP2D6 activity (data not shown). 
As shown in Figure 6a, the formation of 1’-hydroxymidazolam from midazolam was 
rapid, showing non-linearity after 4 minutes of incubation due to substrate depletion. 
Midazolam 1’-hydroxylation could be almost completely inhibited by ketoconazole, a 
CYP3A4 inhibitor. Crucially, metoprolol was also α-hydroxylated by CYP3A4 super-
somes, but at a much slower rate, compared to midazolam. 
As shown in Figure 6b, α-hydroxylation of metoprolol could be inhibited by ketocona-
zole, but not by quinidine, which is a specific CYP2D6 inhibitor [8, 11]. This proves 
that α-hydroxylation of metoprolol cannot only be catalysed by CYP2D6, but also by 
CYP3A4. 
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Figure 6. Formation of 1’-hydroxymidazolam and α-OH-metoprolol by CYP3A4 expressing supersomes (a) 1’-
hydroxymidazolam formation before (open triangles) and after (open upside down triangles) treatment with inhibitors 
(0.5 µM ketoconazole); and (b) α-OH-metoprolol formation before (closed circles) and after treatment with inhibitors, 
1 µM quinidine (open circles) and 0.5 µM ketoconazole (closed upside down triangles). Metabolite concentrations 
were determined by LC-MS/MS. Data are presented as mean ± SEM of at least 3 independent experiments. 
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4. Discussion 
In two hepatocyte models, we could show that treatment with rifampicin induced 
CYP3A4, but not CYP2D6 mRNA expression. In comparison, in the same hepatocyte 
models, treatment with rifampicin was associated with increased activity of midazo-
lam 1’-hydroxylation (reflecting CYP3A4 activity) and also of metoprolol α-
hydroxylation, which is considered to reflect CYP2D6 activity [6, 11]. Our in vitro data 
are in agreement with in vivo data showing that rifampicin treatment lead to a consid-
erable increase of midazolam clearance (decrease in midazolam AUC0-24h, Figure 2a 
in the current publication; also [13]) compared to basal activity, while also indicating 
that CYP2D6 can be either induced to a small extent by rifampicin or that another 
inducible CYP isoform contributes to metoprolol degradation. 
In our studies, we found metoprolol clearance significantly increased (AUC0-24h de-
creased) in patients being treated with rifampicin for 1 week. This is consistent with 
previous findings, which showed a decrease of metoprolol AUC after induction treat-
ment [31, 32]. However, the slightly higher concentrations of α-hydroxymetoprolol 
under induced condition did not yield a relevant change in clearance. This would 
support the hypothesis that treatment with rifampicin leads to an increased metabolic 
activity of an alternative CYP isoforms involved in the degradation of metoprolol. By 
demonstrating that rifampicin treatment leads to an increase in the formation of O-
desmethylmetoprolol (and metoprolol acid) in vitro, which make up the main metabol-
ic pathway of metoprolol [9], we would consider this to be the most likely explanation 
for the significant increase in metoprolol clearance found in vivo. Alternatively, the 
lack of a significant increase in α-hydroxymetoprolol found in plasma could be due to 
induced excretion into the urine. Increased phase II metabolism of α-
hydroxymetoprolol, i.e. glucuronidation, would be another possibility [33]; however, 
this was ruled out by treating samples with β-glucuronidase, which did not result in a 
significant change of α-hydroxymetoprolol concentrations (results not shown). A pre-
vious study supported this finding by showing that the glucuronide of α-
hydroxymetoprolol is only formed in significant amounts in horses, not, however, in 
humans (nor in rats and dogs), therefore, making the aforementioned assumption all 
the more unlikely [34]. 
The mRNA expression data of CYP2D6, which showed no increase after pretreat-
ment with rifampicin, agree with other studies in primary human hepatocytes [20, 23]. 
An increase in mRNA transcription of CYP2D6 appears therefore not to be the cause 
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of our observations. In human subjects treated with 600 mg rifampicin for 10 days, 
the CYP2D6 protein content in enterocytes increased by a factor of 1.6, but with a 
large variability without reaching statistical significance [21]. Post-transcriptional 
mechanisms can therefore not be ruled out with complete certainty. Sparteine meta-
bolic clearance, an in vivo marker of CYP2D6 activity [6], increased by a factor of 1.3 
in subjects treated with rifampicin compared to the basal state, without reaching sta-
tistical significance [19]. Similarly, in primary human hepatocytes, the activity of dex-
tromethorphan O-demethylation increased by a factor of 1.3, without reaching statis-
tical significance [22]. In the same publication, phenobarbital had an almost identical 
effect on dextromethorphan O-demethylation as rifampicin [22]. Similarly, hypericum 
extract did not significantly affect the metabolic ratio of dextrorphan/ dextrome-
thorphan, suggesting that CYP2D6 is not induced by this treatment [24]. 
These data show that CYP2D6 is not induced by the classical inducers of the CYP2C 
and CYP3A family. Our findings in HepaRG cells and primary hepatocytes were, 
therefore, surprising and suggested that α-hydroxylation of metoprolol is not mediat-
ed exclusively by CYP2D6, but also by at least one other inducible CYP-isoform. 
Since CYP3A4 was strongly induced by rifampicin in both evaluated cell systems, 
and as CYP3A4 is the most important CYP involved in oxidative reactions, such as 
hydroxylation reactions [30], we decided to study metoprolol α-hydroxylation in su-
persomes exclusively expressing CYP3A4. Using this system, we could demonstrate 
that metoprolol can be α-hydroxylated by CYP3A4, since the supersomes used had 
no CYP2D6 activity, and ketoconazole (but not quinidine) could block this reaction 
almost completely. Based on our experiments, we cannot, however, exclude with cer-
tainty that other CYPs are also involved in this reaction. 
The study of McGourty et al. [6] showed that debrisoquine EM excreted 7.4% of an 
oral dose of metoprolol as α-hydroxy metabolite in the urine, whereas this was only 
0.06% in debrisoquine PM. Furthermore, urinary excretion of α-hydroxymetoprolol 
showed a bimodal distribution and correlated with the debrisoquine phenotype, indi-
cating that metoprolol α-hydroxylation is a function of CYP2D6. Similarly, Otton et al. 
[11] demonstrated that liver microsomes from a liver of a debrisoquine poor metabo-
liser (PM) did not produce α-hydroxymetoprolol and that α-hydroxymetoprolol produc-
tion by microsomes from debrisoquine EM could be inhibited completely by quinidine. 
These studies suggest that α-hydroxylation of metoprolol is mediated only by 
CYP2D6, but a small contribution from other CYPs in both investigations could not be 
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excluded. In the case of CYP induction, this contribution can increase, since, as dis-
cussed above, CYP2D6 cannot be induced, while CYP3A4 is highly inducible. 
The question now arises whether metoprolol can be recommended as a substrate for 
CYP2D6 phenotyping, taking into account the contribution of CYP3A4 to metoprolol 
α-hydroxylation. The problem could be that CYP2D6 PM might not be recognised 
due to the contribution of CYP3A4, which is not affected by this polymorphism. In the 
study of McGourty et al. [6] there was a clear separation in renal excretion of α-
hydroxymetoprolol into debrisoquine EM and PM. Also in the study of Tamminga et 
al. [17] and of Derungs et al. [13], CYP2D6 EM and PM could clearly be distin-
guished using α-hydroxymetoprolol plasma concentrations. A further potential prob-
lem could be the distinction between CYP2D6 EM and PM in patients with CYP3A4 
induction. However, also in this situation, it was possible to classify patients using 
their respective α-hydroxymetoprolol plasma concentrations [13]. 
In conclusion, CYP3A4 contributes to metoprolol α-hydroxylation. This contribution 
explains a very slight increase in α-hydroxymetoprolol formation in vivo and the more 
pronounced increase in vitro through induction of CYP3A4. However, the contribution 
of CYP3A4 is low and does not impair the usability of α-hydroxymetoprolol formation 
for CYP2D6 phenotyping, especially as the involvement of CYP3A4 only becomes 
apparent when induction is evaluated, which is not commonly done for CYP2D6 [19-
24]. 
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Figure S1. Effect of rifampicin on (a) metoprolol, (b) α-hydroxymetoprolol, (c) midazolam, and (d) 1’-
hydroxymidazolam AUC0-24h in human subjects. Subjects were treated orally with 12.5 mg metoprolol and 2 mg mid-
azolam before (basal, grey circles) and after pre-treatment with rifampicin, 600 mg once daily for 7 days (induced, 
grey squares). Metoprolol, α-hydroxymetoprolol, midazolam, and 1’-hydroxymidazolam were determined using 
LC/MS-MS. AUCs were through the trapezoidal rule. Closed symbols represent CYP2D6 EMs, open symbols repre-
sent the CYP2D6 IM. The black horizontal lines signify the median. The p-value for midazolam and its metabolite (a, 
b) are from paired t-tests, while for metoprolol and its metabolite (c, d) they are from Wilcoxon matched-pairs signed 
ranks tests.  
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 Abstract 
In an earlier in vivo study using the Basel in vivo phenotyping cocktail, losartan was 
used as a CYP2C9 probe drug. However, in plasma, the losartan/ losartan-carboxylic 
acid (E-3174) ratio did not reflect induction after pre-treatment with the inducer rifam-
picin (600 mg per day for 7 days). Therefore, losartan has to be replaced by a differ-
ent CYP2C9 probe-drug to improve the performance of this cocktail. Flurbiprofen is 
primarily metabolised via the cytochrome P450 2C9 isoform to the 4’-hydroxy metab-
olite and has previously been evaluated as a phenotyping probe drug for CYP2C9 in 
urine, plasma, and DBS samples in two phenotyping cocktails. By incubating the five 
remaining probe substrates (caffeine [CYP1A2], efavirenz [CYP2B6], omeprazole 
[CYP2C19], metoprolol [CYP2D6], midazolam [CYP3A4]) of the Basel cocktail with 
and without flurbiprofen in vitro, using primary human hepatocytes in 3D co-culture, 
we were able to show that flurbiprofen did not cause a significant change in enzyme 
activity of any of the other five CYP450 isoforms, therefore enabling its inclusion into 
the cocktail.  
Previously, the six probe drugs of the Basel cocktail were administered as individual 
commercially available formulations. However, for phenotyping to become more 
widely accepted as a routine tool in clinical practice, simplified administration of the 
probe drugs is of great importance. Therefore, as a secondary goal of this study, we 
were able to show in a pilot study (n=2), that the administration of a combination-
capsule (combi-capsule) containing all six probe drugs of the modified Basel cocktail 
(including flurbiprofen instead of losartan) is feasible, which will consequently facili-
tate the intake of probe substrates.  
 
 
 
Keywords: Cytochrome P450 (CYP), CYP2C9, Basel cocktail, Flurbiprofen, 3-
dimensional spheroid primary human hepatocyte culture, phenotyping, LC-MS/MS 
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 1. Introduction 
In 2013 we first described and validated the Basel Cocktail which simultaneously 
measures the in vivo activity six specific cytochrome P450 (CYP450) enzymes using 
commercially available probe drugs, including caffeine [CYP1A2], efavirenz 
[CYP2B6], losartan [CYP2C9], omeprazole [CYP2C19], metoprolol [CYP2D6], and 
midazolam [CYP3A4]. Whilst further characterising the cocktail using known inhibi-
tors and the inducer rifampicin in plasma, it became apparent that using the losartan/ 
losartan carboxylic acid (E-3174) ratio did not reflect induction after pre-treatment 
with the inducer rifampicin (600 mg per day for 7 days). Therefore, losartan has to be 
replaced by a different CYP2C9 probe-drug to improve the performance of the cock-
tail. Flurbiprofen, a phenyl alkanoic acid derivative, is a non-steroidal anti-
inflammatory drug (NSAID) used to treat rheumatoid arthritis or osteoarthritis, as well 
as serving as a pre-operative antimiotic ophthalmic solution [1, 2]. It is primarily me-
tabolised via the cytochrome P450 2C9 isoform to the 4’-hydroxy metabolite [3, 4] 
and has previously been evaluated as a phenotyping probe drug for CYP2C9 in 
urine, plasma, and DBS samples [5, 6] in two phenotyping cocktails [7-9].  
As we have previously found that certain in vitro cell systems, such as cryopreserved 
human hepatocytes in three-dimensional (3D) co-cultures (3D-PHH), provide compa-
rable results to in vivo phenotyping [10], we decided to use this system to test wheth-
er losartan could be replaced by flurbiprofen without causing interference with the 
other probe drugs. This was implemented by incubating the five remaining probe 
substrates (caffeine, efavirenz, omeprazole, metoprolol, midazolam) with and without 
flurbiprofen in vitro using 3D-PHH.  
A second aim of this study was to evaluate a newly developed combination-capsule 
(combi-capsule), containing all six probe drugs of the modified Basel phenotyping 
cocktail in the form of miniature tablets. As new drug formulations and lower doses of 
certain probe substrates are used in the combi-capsule, we assessed whether quan-
tifiable concentrations of the probe drugs and their phase-I metabolites could be 
reached in plasma. Results of an in vivo pilot study involving three healthy volunteers 
are reported upon below.   
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 2. Material and methods 
2.1. Chemicals and reagents 
The chemicals and reagents used for this project have previously been described 
[10]. Additionally, flurbiprofen, 4’-hydroxyflurbiprofen, and flurbiprofen-d3 (used as an 
internal standard) were purchased from TRC (Toronto, Canada).  
 
2.2. Cell Culture  
Preliminary in vitro experiments were performed using human liver microsomes, 
while the potential of flurbiprofen to impede metabolite production of Basel cocktail 
substrates was investigated using 3D-PHH.  
Characterised human liver microsomes (HLM, pooled, n=35, Lot 4133007) and 
NADPH regenerating solutions A and B (A containing NADP+, glucose-6-phophate, 
and MgCl2; B containing glucose-6-phosphate dehydrogenase (G6PDH)) were pur-
chased from Corning Life science (Woborn, MA, USA). HLM samples were stored at 
-80°C until used.  
For microsomal experiments, the reaction mixture (final volume of 500 µL) contained 
either Losartan [14 µM] or flurbiprofen [5 µM], incubation buffer (0.1 M potassium 
phosphate buffered saline, pH 7.4), human liver microsomes (0.5 mg prot./mL), and a 
NADPH generating system. The suspensions were incubated at 37°C in a thermo-
mixer (compact 5350, Eppendorf, Hamburg, Germany) for 5 minutes, after which the 
reaction was initiated through the addition of the NADPH generating system.  
Experiments under basal conditions with primary human hepatocytes in 3D co-
culture were performed as previously described in chapter 4. CYP activity was as-
sessed by the addition of fresh medium, containing the cocktail with either n=5 (caf-
feine [80 µM], efavirenz [10 µM], omeprazole [17 µM], metoprolol [23 µM], and mid-
azolam [5 µM]) or n=6 probe drugs (same composition as n=5, but with the addition 
of flurbiprofen).  
Substrates were dissolved and serially diluted with DMSO to the required concentra-
tions. Final concentration of DMSO during incubations was 0.2% (v/v). At selected 
time points - 0, 1, 2, 4, 8, 15, 30, 60 min in HLM, and 0, 15, 30, 45, 60, 75, 90, 105, 
120 min in 3D-PHH - reactions were terminated by transferring 50 µL of the incuba-
tion mixture into a autosampler vial, to which a threefold volume of ice-cold methanol 
containing the internal standards was added. After vigorous shaking (10 min) and 
centrifugation (3220g; 30 min; 10°C), the samples were stored at -20°C until analysis 
by LC-MS/MS.  
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 By comparing the metabolic production rate over time (pmol/ h/ 0.025x106 cells), with 
(n=6) or without (n=5) the inclusion of flurbiprofen, we could evaluate whether flurbi-
profen influenced the CYP isoforms responsible for the production of the respective 
metabolites. 
 
2.3. In vivo pilot study 
To simplify simultaneous application of the cocktail probe drugs, a capsule containing 
the probe drugs of the modified Basel phenotyping cocktail in the form of miniature 
tablets (Figure 1), was developed by the Division of Pharmaceutical Technology, 
University of Basel (Prof. J. Huwyler). The novel composition of the combi-capsule 
content is given below (Table 1). Compared to the previous Basel cocktail [11, 12], 
the dose of caffeine was reduced from 100 mg to 7.5 mg (20 mini-tabs) to fit a size 0 
capsule. Moreover, due to technical reasons, efavirenz was no longer used in a 
nano-milled form, but rather in a non-treated pure powder form, with an unknown im-
pact on bioavailability of the active ingredient. Omeprazole was used as the race-
mate, containing both the (S)- and (R)-isomer of omeprazole (as found in Antra-
mups®). 
 
 
Figure 1. Mini-tabs (left) and mini-tabs in size 0 capsule (right). 
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 Table 1. Composition of the combi-capsule (size 0). 
	 	Probe drug Dose 
Caffeine 7.5 mg 
Efavirenz 49 mg 
Flurbiprofen 11.7 mg 
Omeprazole 10 mg 
Metoprolol 9.3 mg 
Midazolam 2 mg 
	 	 
The combi-pill was tested on three healthy male subjects in an in vivo pilot-study. 
Subjects were asked to adhere to a methylxanthine-free diet for 48 hours prior to the 
commencement of the pilot study. After an overnight fast, the combi-capsule was 
administered. Blood from an antecubital vein was collected into ethylenediaminetet-
raacetic acid (EDTA), containing vials before and 1, 2, 4, 6, and 8 hours after drug 
administration, according to the limited sampling strategy previously described [13]. 
Blood samples were centrifuged (1500 g; 10min; 4°C), and the ensuing plasma was 
stored at -20°C until analysis. 
 
2.4. Bioanalytical analysis 
A previously developed liquid chromatography tandem mass spectrometry (LC-
MS/MS) method was used to analyse in vitro and plasma samples [11]. Flurbiprofen, 
4’-hydroxyflurbiprofen, and the internal standard flurbiprofen-d3 were added to the 
existing method. Flurbiprofen (and its metabolite and IS) was detected using negative 
ESI (ion spray voltage -4500 eV). 
Below, Table 2 outlines the additionally monitored MRM transitions, whereas Figure 
2 shows a representative chromatogram of a calibration sample containing 250 
ng/mL of each analyte in plasma. 
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Table 2. Additional multiple reaction monitoring (MRM) transitions monitored in the analytical method used to quantify 
the modified Basel cocktail.  
    
Analyte Precursor Ion (m/z) Product Ion (m/z) Ionisation mode 
Flurbiprofen 243.0 199.0 ESI- 
4’-OH-Flurbiprofen 259.1 212.9 / 214.9 ESI- 
Flurbiprofen-d3 246.0 202.0 ESI- 
     
 
 
 
Figure 2. Chromatogram of the modified Basel cocktail LC-MS/MS method used in this study. The dotted line indi-
cates the point at which the switch from positive ESI mode to negative ESI mode took place. 
 
The total run time was 2.9 minutes. Inter-assay accuracy (determined as the % bias) 
ranged from  -8.5 to 6.8 and inter-assay precision (determined as the CV,%) was 
lower than 13.9 for all analytes.  
 
 
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0
1×105
2×105
3×105
4×105
5×105
6×105
7×105
Time [min]
In
te
ns
ity
 [c
ou
nt
s 
pe
r s
ec
on
d]
Flurbiprofen-d3 (IS)
+ - Flurbiprofen
1'-OH-Flurbiprofen
73
  
3. Results and discussion  
Flurbiprofen was metabolised to 4’-hydroxyflurbiprofen in human liver microsomes, 
similar to the extent that losartan was metabolised to E-3174 (Figure 3). 
 
 
Figure 3. Metabolite formation of E-3174 (closed circles) and 4’-OH-Flurbiprofen (open circles) in HLM (0.5mg 
prot./mL) after a 1h incubation with either losartan [14µM] or flurbiprofen [5µM]. 
 
 
Previously, through incubations using cDNA-expressed microsomes for P450 
CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C19, 2D6, 2E1, and 3A4, two studies showed that 
flurbiprofen can be considered to be a highly specific probe substrate of CYP2C9, as 
none of the tested CYPs were involved in flurbiprofen hydroxylation at physiological 
concentrations [4, 14].  
Furthermore, the Pittsburgh cocktail [9] and the Geneva cocktail [7, 8] have used 
some of the phenotyping drugs that are also contained in the Basel cocktail – i.e. caf-
feine (CYP1A2), omeprazole (CYP2C19), and midazolam (CYP3A4) – providing evi-
dence that flurbiprofen does not interfere or inhibit the respective CYP isoforms. The 
other CYP isoforms characterised in the Basel cocktail were also evaluated by either 
the Pittsburgh or Geneva cocktail, making use of different probe substrates: i.e. bu-
propion (CYP2B6), debrisoquine, or dextromethorphan (CYP2D6). Thus, as could be 
expected, incubating the remaining five probe substrates of the Basel cocktail, with or 
without flurbiprofen, in cryopreserved human hepatocytes in 3D co-culture, did not 
lead to a significant change in the formation rates of their respective metabolites, as 
can be seen in Figure 4. Because linear curve fitting for paraxanthine formation (Fig-
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 ure 4a) was not ideal when using the time-point at 0.75h (saturation), it was excluded 
to be able to give a rough estimate of the slope.  
 
 
Figure 4. Metabolite formation of Phase-I metabolites of Basel cocktail probe substrates, (a) paraxanthine - CYP1A2, 
(b) 8’-hydroxyefavirenz - CYP2B6, (c) 5’-hydroxyomeprazole - CYP2C19, (d) α-hydroxymetoprolol - CYP2D6, and (e) 
1’-hydroxymidazolam - CYP3A4, after incubation in primary human hepatocytes cultured in 3D, either cultured in the 
presence of flurbiprofen (hexagon, n=6 substrates incubated) or without flurbiprofen (5-pointed star, n=5 substrates 
incubated). PHH = primary human hepatocytes. 
 
 
Although not directly comparable, due to shortened sampling time and aforemen-
tioned different dosages and formulations of probe substrates, the pharmacokinetic 
profiles and PK parameters measured after intake of the combi-capsule (Figure 4) 
seem to be in agreement with Basel cocktail studies [11, 12], and to a previous com-
bi-pill prototype study. Metabolic single time-point ratios of parent/ metabolite (except 
for CYP1A2 and CYP2C9, metabolite/ parent ratio) calculated in this pilot-study were 
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 all in the previously determined range [12], except for metoprolol (Table 3). This 
slight deviation encountered for metoprolol/ α-hydroxymetoprolol ratio is explained by 
the fact that, unlike in the combi-capsule, an extended release formulation 
(BelocZOK®) had been used in the initial Basel phenotyping cocktail.  
In comparison to flurbiprofen ratios (4’-hydroxyflurbiprofen/ flurbiprofen) calculated 
through use of the Geneva cocktail in DBS [7], ratios found in the present study were 
around 50% lower.  
Through use of the modified bioanalytical method used to determine parent and me-
tabolites of the Basel cocktail, we were able to quantify all analytes. However, par-
axanthine and 8’-hydroxyefavirenz concentrations were close to the respective 
LLOQs of the analytical method. For paraxanthine, this was due to the supposedly 
caffeine-free plasma used to create calibrators and QCs containing not entirely ne-
glectable concentrations of paraxanthine.  
 
Table 3. Comparison of probe drug metabolic ratios (MRs, i.e. concentration of metabolite/concentration of parent 
probe drug) determined in plasma after intake of either the combi-capsule or six separate commercially available 
formulations during the Basel cocktail study II [12] for (a) CYP1A2 - paraxanthine/ caffeine, (b) CYP2B6 - efavirenz/ 
8’-hydroxyefavirenz, (c) CYP2C9 - 4’-hydroxyflurbiprofen/ flurbiprofen (compared to Geneva cocktail, concentrations 
measured in DBS [7]), (d) CYP2C19 - omeprazole/ 5’-hydroxyomeprazole, (e) CYP2D6 - metoprolol/ α-
hydroxymetoprolol, and  (f) CYP3A4 - midazolam/1’-hydoxymidazolam. 
 
a 
 
metabolic 
ratio 
Paraxanthine / Caffeine Basel Cocktail II  
metabolic ratio     
(range - low to high)  Subject 1  Subject 2  Subject 3  
2h 0.34 0.59 0.73 0.16 - 0.54 
4h 0.45 0.81 0.73 0.24 - 0.92 
6h 0.54 0.94 0.75 0.29 - 1.4 
8h 0.58 0.98 0.74 0.38 - 1.64 
 
 
b 
metabolic 
ratio 
Efavirenz / 8'-OH-Efavirenz Basel Cocktail II  
metabolic ratio     
(range - low to high)  Subject 1  Subject 2  Subject 3  
2h n/a 21.4 51.5 13 - 46 
4h 34.0 34.3 42.7 14 - 73 
6h 49.6 46.4 68.8 29 - 78 
8h 57.5 56.4 95.6 31 - 105 
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c 
metabolic 
ratio 
4'-OH-Flurbiprofen / Flurbiprofen Geneva Cocktail     
(range - low to high)  
Subject 1  Subject 2  Subject 3  
2h 0.03 0.03 0.04 0.05 - 0.06 
4h 0.04 0.04 0.05 0.05 - 0.07 
6h 0.04 0.04 0.05 0.06 - 0.08 
8h 0.04 0.03 0.04 0.05 - 0.08 
 
d 
metabolic 
ratio 
Omeprazole / 5'-OH-Omeprazole Basel Cocktail II  
metabolic ratio     
(range - low to high)  Subject 1  Subject 2  Subject 3  
2h 1.08 0.71 n/a 0.6 - 3.1 
4h 1.33 0.44 0.29 0.2 - 2 
6h 0.72 0.35 0.11 0.16 - 1.16 
8h 0.41 0.19 0.04 n/a 
 
e 
metabolic 
ratio 
Metoprolol / α-OH-Metoprolol Basel Cocktail II  
metabolic ratio     
(range - low to high)  Subject 1  Subject 2  Subject 3  
2h 2.7 3.86 3.2 ≈ 2 (not enough values) 
4h 2.6 3.23 3.2 1.5 - 3.4 
6h 1.8 2.75 2.5 1.4 - 3.7 
8h 1.5 1.89 1.6 1.2 - 3.3 
 
f 
metabolic 
ratio 
Midazolam / 1'-OH-Midazolam Basel Cocktail II  
metabolic ratio     
(range - low to high)  Subject 1  Subject 2  Subject 3  
2h 1.44 3.05 3.05 0.5 - 3.4 
4h 1.97 3.26 3.34 0.5 - 3.9 
6h n/a n/a n/a 0.9 - 4.3 
8h n/a n/a n/a n/a  
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Figure 5. Plasma concentration time-profiles of the cocktail probe drugs (circle) and their metabolites (diamond) ob-
tained after administration of the combi-capsule in three healthy subjects: black symbols correspond to subject 1, 
while white symbols correspond to subject 2, for (a) caffeine and paraxanthine (CYP1A2), (b) efavirenz and 8’-
hydroxyefavirenz (CYP2B6), (c) flurbiprofen and 4’-hydroxyflurbiprofen (CYP2C9), (d) omeprazole and 5’-
hydroxyomeprazole (CYP2C19), (e) metoprolol and α-hydroxymetoprolol (CYP2D6), and (f) midazolam and 1’-
hydroxymidazolam (CYP3A4). 
 
To facilitate and improve compliance, a number of drugs containing more than one 
active ingredient are already used in clinical practice, as is the case for certain anti-
diabetic, anti-infective, and anti-hypertensive medications, as well as for a variety of 
different cold and flu remedies. Previously, the Basel cocktail was administered 
through five different tablets and a liquid formulation, which enabled the phenotyping 
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 of six CYP isoforms responsible for the majority of phase I drug metabolism [11, 12, 
15]. However, for phenotyping to become more widely accepted as a routine pre-
dosing tool in clinical practice, simplified administration of probe substrates is para-
mount. The combi-capsule is therefore able to facilitate the intake of probe sub-
strates, while doses of the respective probe drugs can more easily be modified, as 
the dose of the phenotyping agent is no longer reliant on commercially available drug 
formulations. 
In summary, flurbiprofen did not interact with any probe substrates of the Basel cock-
tail in primary human hepatocytes in 3D-culture. Hence, in future studies, flurbiprofen 
can replace losartan as probe substrate for CYP2C9. Furthermore, results of the pi-
lot-study showed that the use of a combi-capsule, containing probe substrates of the 
modified Basel cocktail in the form of miniature tablets, is feasible. Comparable met-
abolic ratios were observed when the formulation was compared to earlier studies 
with the Basel cocktail and to a pilot-study using a prototype combi-pill [11, 12]. 
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Abstract 
Bioavailability after oral intake of erlotinib and sunitinib is highly variable due to their 
dependence on gastrointestinal absorption and first-pass metabolism in the liver. 
Thus, the uniform dosing strategy currently in place for TKIs is not adequate, as it 
can result in unacceptable side effects in some patients and under treatment with 
diminished therapeutic activity in others. Although a number of covariates have been 
proposed, a substantial interpatient variability in erlotinib  (sunitinib) exposure re-
mains unexplained. Since erlotinib and sunitinib are mainly metabolised by CYP3A4 
(and erlotinib to a lesser extent also by CYP1A2), differences in the activities of these 
enzymes might be able to explain a sizeable amount of the observed interpatient var-
iability in the pharmacokinetics of the respective TKIs. In contrast to genotyping, 
which can only assess genetic polymorphisms, patient phenotyping with probe drugs 
measures the overall activity of CYP isoforms and is the most promising approach for 
treatment individualisation of TKI, as has previously been shown with other anti-
cancer drugs such as tamoxifen, gefitinib, and imatinib. We were able to demonstrate 
that low dose orally administered midazolam and caffeine could successfully be uti-
lised in a clinical setting to perform phenotyping of CYP3A4 and CYP1A2. A correla-
tion between CYP3A4/ CYP1A2 phenotype and erlotinib exposure could however not 
be determined due to lack of reliable exposure markers (i.e. AUC0-24h or Ctrough). In-
terestingly, the assessment of treatment-dependent toxicity showed, that patients 
with slow CYP3A4 metabolism were more likely to develop skin rash than patients 
with higher CYP3A4 activity. We also investigated the feasibility of drug bioanalysis 
from dried blood spots (DBS). However, after having measured erlotinib using the 
current set of DBS samples, we are at present not able to advocate the interchange-
ability of DBS and conventional plasma measurement.  
Before final conclusions can be drawn, a population-PK model which is currently be-
ing developed using nonlinear-mixed-effects modelling (NONMEM), which is pre-
dominantly used in studies of this manner, has to be evaluated, as it is expected to 
support meaningful analysis of the gathered data.                           
 
 
 
Keywords: Erlotinib, Tyrosine-kinase inhibitors (TKI), CYP1A2, CYP3A4, phenotyp-
ing, DBS, LC-MS/MS 
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1. Introduction 
Erlotinib (Tarceva®; F. Hoffmann-La Roche; Basel, Switzerland) and Sunitinib 
(Sutent®; Pfizer; NY, USA) are among the most frequently used orally active multitar-
geted tyrosine kinases inhibitors (TKIs). Erlotinib is currently approved for treatment 
of pancreatic cancer and locally advanced or metastatic non-small cell lung cancer 
(NSCLC) in patients with activating EGFR mutations, while sunitinib is used to treat 
metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumours (GIST), and 
pancreatic neuroendocrine tumours [1, 2]. Erlotinib reversibly and selectively inhibits 
the intracellular autophosphorylation of tyrosine kinases (TK) in association with the 
epidermal growth factor receptor (EGFR). On the intracellular domain of the TK, erlo-
tinib is in competition with ATP for binding sites and is thus able to inhibit down-
stream signalling pathways that can lead to oncogenesis [3-6]. Sunitinib, on the other 
hand, has been shown to target the inhibition of a number of TKs including the vas-
cular endothelial growth factor receptors (VEGFR - 1,2, and 3), the platelet derived 
growth factor receptor (PDGFR - α,β), and mast/stem cell growth factor receptor 
(SCFR/ c-Kit) [7-9].   
Although conventional chemotherapy attempts to pinpoint certain macromolecules or 
enzymes, they do not typically discriminate efficiently between rapidly dividing normal 
cells – e.g. bone marrow, gastrointestinal tract, or hair follicles – and the tumour cells 
they are intended to eliminate. They are consequently prone to causing severely tox-
ic adverse events. On the other hand, targeted or cytostatic therapies such as TKIs, 
which, instead of extinguishing tumour cells, lead to the blocking of tumour cell 
growth and progression by interfering with a multitude of molecular targets, lead to 
considerably less toxicity [10-12]. For erlotinib and sunitinib, the most prevalent forms 
of toxicity are of a cutaneous, hematologic, and gastrointestinal nature [13]. Howev-
er, potentially life-threatening toxicities, such as interstitial lung disease (erlotinib) 
and cardiac dysfunction (sunitinib), are becoming increasingly important, as these 
drugs are being introduced into long-term treatment [14-16].  
Erlotinib is metabolised in the liver, mainly by cytochrome P450 3A4 (CYP3A4) and, 
to a lesser degree, by CYP1A2 to its active metabolite OSI-420, with metabolites 
primarily excreted in the bile. OSI-420 accounts for approximately 10% of the parent 
drug while being equipotent in inhibiting EGFR TK activity [17]. Erlotinib is known to 
be transported via the active efflux pumps P-glycoprotein (MDR1/ ABCB1) and 
breast cancer resistance protein (BCRP/ ABCG2) [18-20]. Sunitinib is metabolised by 
CYP3A4 to its equally potent N-desethyl metabolite Su-12662 [7]. 
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The daily-recommended oral dose of erlotinib is 150mg in NSCLC patients and 
100mg in pancreatic cancer patients, whereas 50mg of sunitinib is recommended in 
RCC or GIST patients (for 4 weeks followed by a 2-week hiatus). However, bioavail-
ability after oral intake is highly variable due to its dependence on gastrointestinal 
absorption and first-pass metabolism in the liver, two processes that show consider-
able inter-individual differences [21, 22]. Variability in erlotinib pharmacokinetics (PK) 
can, therefore, have a critical impact on previously reported rates of adverse effects 
[13, 23-28]. Although a number of covariates have been proposed, i.e. hepatic func-
tion, smoking habit, and ABCG2 polymorphisms [25], a substantial inter-patient vari-
ability in erlotinib exposure remain unexplained. Thus, the uniform dosing strategy 
currently in place is inadequate, as it can result in unacceptable side effects in some 
patients and under treatment with diminished therapeutic activity in others. Since er-
lotinib and sunitinib are mainly metabolised by CYP3A4 (and, in the case of erlotinib, 
to a lesser extent also by CYP1A2), differences in the activities of these enzymes 
might provide an explanation for a sizeable amount of the unexplained observed in-
terpatient variability in the pharmacokinetics of the respective TKIs. In contrast to 
genotyping, which can only assess genetic polymorphisms, patient phenotyping with 
probe drugs measures the overall activity of CYP isoforms and is the most promising 
approach for treatment individualisation of TKI, as has previously been shown with 
other anticancer drugs such as tamoxifen [29].  
The primary aim of this study was to evaluate the relationship between individual 
CYP3A4 and CYP1A2 phenotype, assessed using oral midazolam and caffeine as 
phenotyping probes, with erlotinib and sunitinib exposure. Secondary aims were to 
assess the correlation of individual CYP-phenotype with treatment-related toxicity, as 
well as to assess the feasibility of using dried blood spots to perform the bioanalysis 
of erlotinib. 
 
 
2. Methods 
2.1. Clinical study 
Patients diagnosed with early or advanced renal cell cancer (RCC), gastrointestinal 
stromal tumour (GIST) or non-small cell lung cancer (NSCLC), were eligible for entry 
into the study and were treated according to their indication with either sunitinib or 
erlotinib (Table 2). All patients taking part in this prospective, nonrandomised, phar-
macological cohort study were > 18 years of age, and had adequate laboratory pa-
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rameters, as defined by serum creatinine and serum bilirubin ≤ 1.5 x ULN (upper limit 
of normal), serum ALT and AST ≤ 2.5 x ULN (or ≤ 5 in case of liver metastases), and 
serum calcium ≤ 11,6 mg/ dl (2.9 mmol/ L). Concurrent radiotherapy or systemic an-
ticancer treatment (with the exception of bisphosphonates and bevacizumab in pa-
tients with NSCLC), as well as previous treatment with erlotinib, were regarded as 
exclusion criteria. Concomitant use of substances known or likely to interfere with 
either CYP3A4 or CYP1A2 (unless there was no therapeutic alternative available) 
was not allowed. Patients with a known hypersensitivity to either trial drug or any 
compounds of the drugs were excluded from the study.  
A clinical assessment, including physical examination (blood pressure, WHO perfor-
mance status, weight), haematological tests (haemoglobin, neutrophils, thrombocyte 
counts), and blood chemistry tests (ALAT, bilirubin, serum albumin, serum creati-
nine), was performed on each visit to the clinic, i.e. on day 1 and at 2, 4, 8, and 10-
week intervals thereafter. 
Adverse events (AE) were coded according to the NCI Common Terminology Criteria 
for Adverse Events, version 4.0 (CTCAE, National Institutes of Health, Bethesda, 
MD). AE were treated symptomatically or managed according to appropriate erlo-
tinib/ sunitinib prescribing information; in the case of CTCAE grade 3 toxicity, dosage 
was lowered and/or completely discontinued in the case of CTCAE grade 4 toxicity.  
This study was carried out as part of routine patient care and was conducted in ac-
cordance with the Declaration of Helsinki and its amendments. The study was ap-
proved by the local ethics committee (Canton St. Gallen, Switzerland) and the na-
tional regulatory authority (Swiss agency for the authorisation and supervision of 
therapeutic products, Swissmedic, ClinicalTrials.gov Identifier: NCT01402089). All 
patients gave informed written consent before entering the study and agreed to un-
dergo PK-sampling. 
 
2.2. Sample Collection and Phenotyping 
After an overnight fast, 2 mg of oral midazolam (in-house formulation; Pharmacy of 
the cantonal hospital St. Gallen, Switzerland) was administered in tap water as the 
CYP3A4 probe drug [30]. Blood collected from an antecubital vein was collected into 
ethylenediaminetetraacetic acid (EDTA) containing vials before and 1, 2, 3, 4, and 6 
hours after drug administration, according to the limited sampling strategy previously 
described [31]. Additionally, CYP1A2 phenotyping was performed after a methylxan-
thine-free diet over 36h using 100 mg oral caffeine (Mylan Dura GmbH, Darmstadt, 
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Germany). Blood samples for caffeine and paraxanthine determinations were col-
lected before dosing and 6 hours after the administration of caffeine.  
An aliquot of each blood sample was transferred to a different vial and centrifuged (at 
1500 g; 10 min; 4°C), after which the residual plasma and the remaining whole blood 
aliquots were stored at -80°C until analysis. 
Patients were treated with either commercially available erlotinib tablets (Tarceva®; 
Roche Pharma; Basel, Switzerland) with a once daily oral dose of 150 mg or sunitinib 
maleate hard capsules (Sutent®; Pfizer; NY, USA) with a once daily dose of 50mg for 
4 out of 6 weeks, barring disease progression, unacceptable toxicity, or withdrawal of 
informed consent. On day 1, both sunitinib and erlotinib were sampled at the same 
time-points as the phenotyping drugs. Subsequently, steady-state plasma concentra-
tions were sampled in weeks 2, 4, 8, and 10. Additionally, DBS were taken by the 
patient’s general practitioner (GP), preferably in week 6 and 10 (for patients still re-
maining on the study drug). DBS samples were collected through the puncture of a 
fingertip, using a single-use, disposable lancet device (Accu-Check Softclix Pro; 
Roche Pharma, Basel, Switzerland). After collecting four droplets of blood per collec-
tion card, it was left to dry for at least 2h at room temperature, after which the card 
was stored at -80°C in a sealable plastic bag containing a desiccant packet until 
ready for analysis.  
 
 
Figure 1. Study Design (adapted from study protocol - clinicaltrials.gov ID: NCT01402089). 
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2.3. Materials and Reagents 
Erlotinib hydrochloride, O-desmethyl erlotinib (OSI-420), sunitinib maleate, N-
desethyl sunitinib (Su-12662), as well as the internal standards (erlotinib-d6, 
sunitinib-d10, caffeine-d9), were purchased from TRC (Toronto, Canada). 1’-
hydroxymidazolam and midazolam-d6 were acquired from Lipomed (Arlesheim, 
Switzerland), whereas midazolam was kindly provided to us by Hoffmann-La Roche, 
Basel, Switzerland. Caffeine and paraxanthine were obtained from Sigma-Aldrich 
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). Formic acid, DMSO, high-
performance liquid chromatography (HPLC)-grade methanol, and HPLC-grade water 
were purchased from Merck (Darmstadt, Germany). DBS cards (FTA DMPK-C 
cards), manual hole-punchers (3 mm diameter) and cutting mats were obtained from 
Whatman (Sanford, ME, USA). 
 
2.4. Bioanalysis 
Concentrations of TKIs and phenotyping agents, as well as their main metabolites in 
plasma, whole blood, and DBS, were determined by LC-MS/MS.  
In brief, 50 µL aliquots of plasma or whole blood were mixed with 150 µL of an inter-
nal standard solution containing deuterated analogues of the respective drugs and 
phenotyping agents, (at a concentration of 50 ng/mL for midazolam-d6, and 100 
ng/mL for erlotinib-d6, sunitinib-d10, and caffeine-d9), was vortex mixed for 30 se-
conds, and then centrifuged (3200 g; 30 min; 10°C). For DBS analysis, a disc with a 
diameter of 3 mm was cut out of the centre of the DBS and added to a vial containing 
200 µL of the internal standard solution (methanol/water (1/1, v/v). The vials were 
then vortex mixed for 10 minutes and centrifuged (3200 g; 30 min; 10°C). Chromato-
graphic separation was performed on a Shimadzu HPLC system (Shimadzu AG, 
Reinach, Switzerland), coupled to a triple quadrupole tandem mass spectrometer 
(API3200 or API4000, AB/MDS Sciex, Concord, ON, Canada) operating in positive 
electrospray ionisation mode. The selected mass to charge (m/z) ratio transitions of 
the analytes and internal standards used in selective reaction monitoring mode can 
be found in Table 1. Analyst software 1.6.2 (AB Sciex, MA, USA) was used to oper-
ate the LC-MS/MS system. 
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Table 1. Multiple Reaction Monitoring (MRM) transitions monitored. 
	 	 	 	
Analyte Precursor Ion [m/z] 
Product Ion 
[(m/z] 
Ionisation 
mode 
Caffeine 195 138 ESI + 
Paraxanthine 181 124 ESI + 
Caffeine-d9 204 144 ESI + 
Midazolam 326 291 ESI + 
OH-Midazolam 342 324 ESI + 
Midazolam-d6 332 297 ESI + 
Sunitinib 399 326 ESI + 
Su-16226 371 283 /238 ESI + 
Sunitinib-d10 409 283 ESI + 
Erlotinib 394 278 ESI + 
OSI-420 380 278 / 276 ESI + 
Erlotinib-d6 400 278 ESI + 
	 	 	 	 
 
A representative chromatogram showing the retention time and separation of the re-
spective analytes can be seen in Figure 2. The total run time was 3.0 minutes. 
 
 
Figure 2. Chromatogram of the analytical method used to analyse erlotinib, sunitinib, midazolam, caffeine, and their 
metabolites, as well as their respective internal standards (IS). 
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The linear calibration curve for every measured analyte showed a coefficient of de-
termination greater than 0.99, generated over the respective calibration range. Inter-
assay accuracy (determined as the % bias) ranged from -6.5 to 6.5% and inter-assay 
precision (determined as the CV%) was lower than 12.4% for all analytes. The lower 
limit of quantification (LLOQ) was 0.25 ng/ml for OSI-420, Su-12662, midazolam, and 
1’-hydroxymidazolam; 1.25 ng/ml for erlotinib and sunitinib; and 12.5 ng/ml for par-
axanthine and caffeine in plasma and whole blood. LLOQ was 1 ng/mL for midazo-
lam and OSI-420; 5 ng/mL for erlotinib, sunitinib, Su-12662, 1’-hydroxymidazolam, 
caffeine, and paraxanthine. Stock solutions, calibration spiking solutions, and quality 
controls were prepared in DMSO. Calibration standards and quality controls were 
prepared by enriching the respective caffeine-free blank human plasma or whole 
blood, using the corresponding spiking solutions. Internal standard solutions contain-
ing the deuterated compounds were prepared in methanol. For analysis of DBS, the 
same concentrations of deuterated compounds were dissolved in methanol/water 
(1/1, v/v).  
 
2.5. Data Analysis 
All graphs, figures, and tables make use of erlotinib, OSI-420, sunitinib, Su-12662, 
midazolam, 1’-hydroxymidazolam, caffeine, and paraxanthine concentrations meas-
ured in plasma. The partial area under the concentration-time curve, from time 0 to 6 
hours (AUC0-6h) after dosing on day 1, was estimated using the linear trapezoidal 
method and calculated using Microsoft® Excel 2010 add-on PKsolver [32]. Maximal 
concentrations (Cmax) and time to reach Cmax (Tmax) were taken directly from observed 
data. Correlations between single time-point concentration ratios and AUC ratios 
were tested using linear regression analysis. The relationship between midazolam 
exposure and erlotinib exposure was examined by Pearson correlation analysis. The 
unpaired Student’s t-test was used to assess the impact of smoking and the intake of 
PPIs on various pharmacokinetic parameters (Css, Cmax, AUC0-6h, etc.), while the 
paired t-test was used to determine the impact of sustained treatment on erlotinib 
MR. One-way ANOVA was performed to evaluate the impact of midazolam MR on 
the severity of skin rash. Bland-Altman analysis was used to compare measurements 
of erlotinib and osi-420 between plasma, DBS, and whole blood. All Statistical analy-
sis was performed using GraphPad Prism Software (Version 6.0g, La Jolla, CA, 
USA). The level of significance was set at p < 0.05 for all performed tests.  
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3. Results 
3.1. Patients and Treatment 
In total, fifty-two patients took part in the study. Thirty-seven of these patients were 
treated for NSCLC with erlotinib at the Cantonal Hospital of St. Gallen between Feb-
ruary 2012 and May 2015 (Table 2): their median age was 65.5 years (range 52.0-
77.8) and 26 patients (70%) were male.  
Ten patients included in the study were treated with sunitinib for either gastrointesti-
nal stromal tumour (GIST) or renal cell cancer (RCC) between January 2012 and 
August 2015. One of the patients being treated with sunitinib abandoned the trial 
shortly after enlisting and is therefore no longer taken into consideration. However, 
due to a large number of missing samples in the patient group being treated with 
sunitinib, meaningful analysis requires a population PK approach, which will be per-
formed at a later point in time.  
A further five patients were treated with pazopanib (Votrient®; GlaxoSmithKline; 
Brentford, United Kingdom). These patients were not included in this body of work 
and shall be analysed at a later point. 
Therefore only results of the patients treated with erlotinib will be discussed in this 
chapter.  
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Table 2. Patient demographics and clinical characteristics. 
  
Baseline Screening 
Median (range) or     
Number of patients 
Drug Erlotinib 
Number of females 11 
Number of males 26 
Age (years) 66.5 (52.0 - 77.8) 
Weight (kg) 71.0 (37.1 - 96.7) 
Tumor Type  
   NSCLC 37 
  Stage of tumour disease (WHO) 
    1 2 
    2  
    3 10 
    4 25 
Pretreatment clinical chemistry  
   ASAT (IU/L) 20.0 (8.0 - 57.0) 
   ALAT (IU/L) 14.0 (5.0 - 119) 
   Total bilirubin (µM/L) 9.0 (4.0 - 27.0) 
   Serum creatinine (µM/L) 86.0 (38.0 - 267) 
   Haematocrit (%) 37.0 (26.0 - 46.0) 
   Serum albumine (g/L) 34.8 (18.7 - 45.9) 
   TSH (mU/L) 1.5 (0.3 - 23.3) 
Patient History  
   Prior surgery 7 
   Prior radiotherapy 15 
   Prior anticancer drug treatment 36 
   Smoking Status  
     never  4 
     former 23 
     current 10 
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Baseline Screening 
Median (range) or    Number 
of patients 
Drug Sunitinib 
Number of females 1 
Number of males 8 
Age (years) 64.4 (54.7 - 70.0) 
Weight (kg) 89.2 (57.1 - 105.2) 
Tumor Type  
   GIST 7 
   RCC 2 
Stage of tumour disease (WHO)  
    1  
    2 1 
    3 5 
    4 3 
Pretreatment clinical chemistry  
   ASAT (IU/L) 32.0 (6.0 - 61.0) 
   ALAT (IU/L) 24.0 (55.0 - 78.0) 
   Total bilirubin (µM/L) 13.0 (6.0 - 34.0) 
   Serum creatinine (µM/L) 105 (64.0 - 157.0) 
   Haematocrit (%) 40.0 (33.0 - 45.0) 
   Serum albumine (g/L) 38.8 (24.2 - 44.9) 
   TSH (mU/L) 1.6 (0.7 - 4.6) 
Patient History  
   Prior surgery 9 
   Prior radiotherapy 2 
   Prior anticancer drug treatment 2 
	
	
	 
Twenty-one (57%) of the 37 patients treated with erlotinib were monitored for the en-
tire 10 weeks and 16 (43%) were prematurely discontinued from the study, primarily 
due to adverse events. One patient died from disease progression during the study. 
Skin rash, anorexia, and diarrhoea were the principal drug-related toxicities, and the-
se were reported in 70%, 60%, and 46% of the patients, respectively. Other ob-
served toxicities included nausea, hypertension, vomiting, and oral mucositis, all of 
which were generally of mild to moderate intensity (Table 3).  
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Table 3. List of reported adverse events (CTCAE grade). 
    
                                       Occurrence of AE Grade     1 / 2 
Grade     
3 / 4 
Nausea Day 1 4 / - - / - 
Week 2 3 / - 2 / -  
Hypertension Day 1 - / - - / - 
Week 2 - / - - / - 
Anorexia Day 1 9 / 5 - / - 
Week 2 6 / 4 1 / - 
Skin rash Day 1 - / - - / - 
Week 2 11 / 7 4 / - 
Vomiting Day 1 - / - - / - 
Week 2 2 / - - / - 
Diarrhoea Day 1 1 / 2 - / - 
Week 2 5 / 1  - / - 
Oral mucositis Day 1 2 / 2 - / - 
Week 2 - / - - / - 
    
   
Occurrence of AE  (at anytime in study) Grade      1 / 2 
Grade     
 3 / 4 
Nausea 7 /2 3 / 4 
Hypertension - / 1 - / - 
Anorexia 11 / 10 1 / - 
Skin rash 12 / 10 4 / - 
Vomiting 3 / 2 - / - 
Diarrhoea 11 / 5  1 / - 
Oral mucositis 3 / 3 - / - 
   
Ten patients (27%) were smokers, 23 (62%) were former smokers, while 17 (46%) 
patients took an acid-inhibiting drug (proton-pump inhibitor (PPI): either omeprazole, 
esomeprazole, lansoprazole, or pantoprazole) during the course of the study. Ac-
cording to patient diaries and hospital charts, no other medication was taken 
throughout the study that could have had an impact on erlotinib metabolism. Twenty-
eight patients (76%) stayed on the initial dosage regimen of 150 mg erlotinib per day 
throughout the entire study.  Five patients required a dose reduction, and four pa-
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tients started treatment with a reduced daily dose (three patients on 100 mg/day; one 
patient on 75 mg/day). There were no dose escalations. 
At baseline, seven study participants already had detectable erlotinib concentrations, 
and, in one patient, high midazolam concentrations were found at baseline (t=0h). 
These eight patients were excluded from pharmacokinetic analysis on day 1.  
 
3.2. Erlotinib, midazolam, and caffeine pharmacokinetics 
Observed maximal erlotinib concentrations on day 1 (Cmax) were 1340 ± 975 ng/mL 
(median 1100 ng/mL; range 184 - 4290 ng/mL), with a high inter-patient variability 
(co-efficient of variation 74%). Cmax of the main metabolite of erlotinib, OSI-420, was 
approximately 10-fold lower compared to the parent compound, with Cmax averaging 
151 ± 164 ng/mL (median 96 ng/mL; range 20 - 848 ng/mL). Average Tmax was 3.3 ± 
1.6h	(median 3.0h) for erlotinib and 3.7 ± 1.6h (median 4.0h) for OSI-420. The partial 
area under the plasma concentration-time curve from time 0 to 6 hours after drug in-
take on day 1 (AUC0-6h) was 5.7 ± 4.6 µg/ml*h (median 4.8 µg/ml*h; range 0.8 - 21.2 
µg/ml*h) for erlotinib and 0.6 ± 0.5 µg/ml*h (median 0.4 µg/ml*h; range 0.1 - 2.9 
µg/ml*h) for OSI-420. During the 10-week course of erlotinib treatment, Css values 
averaged 2069 ± 1101 ng/mL (median 1852; range 671 - 6540 ng/mL; Figure 3). 
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Figure 3. Individual plasma concentration time profiles (grey lines) and mean ± SD (black line) of (a) erlotinib on day 
1 (n=30), (b) OSI-420 on day 1 (n=30), (c) erlotinib after weeks 2, 4, 8, and 10 (n=37), and (d) OSI-420 after weeks 
2, 4, 8, and 10 (n=37). 
 
Among all eligible patients, AUC0-6h of midazolam on day one was 20.8 ± 13.9 
ng/ml*h (median 19.7 ng/ml*h; range 3.2 - 64.7 ng/ml*h) and 6.8 ± 3.9 ng/ml*h (me-
dian 6.2 ng/ml*h; range 1.8 - 19.1 ng/ml*h) for 1’-hydroxymidazolam. Cmax for mid-
azolam and 1’-hydroxymidazolam was 9.1 ± 5.4 ng/mL (median 8.8 ng/mL; range 2.3 
- 24.7 ng/mL) and 3.4 ± 1.8 ng/mL (median 3.07 ng/mL; range 1.2 - 8.4 ng/mL), re-
spectively, while Tmax was 1.04 ± 0.2 h.  
AUC0-6h of caffeine on day one was 12.8 ± 6.3 µg/ml*h (median 7.3 µg/ml*h; range 
7.3 - 37.4 µg/ml*h) and 3.8 ± 2.9 µg/ml*h (median 3.2 µg/ml*h; range 0.7 - 8.6 
µg/ml*h) for paraxanthine. Cmax for caffeine and paraxanthine was 3034 ± 1293 
ng/mL (median 2580 ng/mL; range 1598 - 7168 ng/mL) and 808 ± 577 ng/mL (medi-
an 637 ng/mL; range 171 - 2394 ng/mL), whilst Tmax was 1.6 ± 1.4 h (median 1h) and 
4.8 ± 1.8 h (median 6h), respectively (Figure 4).  
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Figure 4. Individual plasma concentration time profiles (grey lines) and mean ± SD (black line) of (a) midazolam 
(n=29), (b) 1'-hydroxymidazolam (n=29), (c) caffeine (n=30), and (d) paraxanthine (n=30) on day one.  
 
Co-administration of proton pump inhibitors (PPIs) was associated with a statistically 
significant decrease in erlotinib partial AUC0-6h (Figure 5a) and erlotinib Cmax (Figure 
5b).  
 
 
Figure 5. Influence of proton pump inhibitors (PPIs) on (a) erlotinib partial AUC0-6h, and (b) erlotinib Cmax. Values are 
mean ± SD. The p-values are from unpaired t-tests. 
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3.2. Correlation between single point ratios and AUC ratios 
The single time point parent to metabolite MR, 2h after administration of midazolam, 
was strongly correlated with the AUCparent (0-6h) / AUCmetabolite (0-6h) ratio (partial AUC0-6h 
ratio) (Figure 6a).  The same was found for the single time-point concentration of 
midazolam (2h) and midazolam AUC(0-6h) (Figure 7a). The metabolic ratio (MR) of 
midazolam showed an 8-fold variation in the study population with a median of 2.9 
(range 0.9 to 7.4). As there is no uniformly accepted measure to enable the classifi-
cation of CYP3A4 slow metabolisers (or extensive metabolisers), we used the 25th 
and 75th percentile of the 28 patients for whom we were able to calculate the meta-
bolic ratio at 2h. Thus, the seven patients with MR > 4.1 were classified to have a 
slow phenotype, while seven patients with MR < 2.3 were accordingly classified to be 
portraying an extensive phenotype for CYP3A4. 
 
 
Figure 6. Correlation of MR ratio and AUC0-6h ratio of (a) midazolam, and (b) caffeine. Red dots signify slow metabo-
lisers; black dots signify intermediate metabolisers; grey dots signify fast metabolisers. 
 
The MR of paraxanthine to caffeine at 6h and following a 36h caffeine abstinence, 
correlated well with the partial AUC0-6h ratio (Figure 6b), while merely using the single 
time-point concentration of caffeine (6h) and caffeine AUC0-6h also led to a statistical-
ly significant correlation (Figure 7b).  
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 Figure 7. Correlations between AUC0-6h and single time-point measurements for (a) midazolam- concentration 2h 
post-dose, and (b) caffeine - concentration 6h post-dose. 
 
The plasma paraxanthine / caffeine ratio showed a 13-fold variation in the study pop-
ulation with a median of 0.41 (range 0.1 to 0.9). The six patients with an MR below 
0.3 (25th percentile) were classed as slow metabolisers of CYP1A2, while the six pa-
tients with a paraxanthine to caffeine ratio above 0.6 (75th percentile) were assigned 
to having a fast CYP1A2 phenotype.  
 
 
Figure 8. Correlations between (a) erlotinib - concentration 2h post-dose and erlotinib AUC0-6h, and (b) erlotinib MR 
and erlotinib partial AUC0-6h ratio. 
 
The single time-point concentration of erlotinib (2h) was strongly correlated with erlo-
tinib partial AUC0-6h (Figure 8a) while using the MR of erlotinib at 2h of erlotinib and 
erlotinib partial AUC0-6h ratio also led to a statistically significant correlation (Figure 
8b).  
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3.3. Association between CYP3A4 / CYP1A2 phenotype and erlotinib pharma-
cokinetics 
No correlation could be observed between CYP3A4 metabolic ratio (i.e. midazolam 
to 1’-hydroxymidazolam concentration after 2h), AUC ratio, or midazolam partial 
AUC0-6h and erlotinib exposure described through erlotinib partial AUC0-6h, erlotinib 
concentration after 2h (C2h), Cmax, steady-state concentration after 2 weeks (Css,2W)    
(Figure 9a-e).  Also, there was no detectable correlation between CYP1A2 metabolic 
ratio and erlotinib exposure (Figure 9f). 
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Figure 9. Correlations between (a) midazolam MR and erlotinib partial AUC(0-6h, (b) midazolam AUC(0-6h) and erlotinib 
partial AUC(0-6h), (c) midazolam AUC(0-6h) ratio and erlotinib partial AUC(0-6h), (d) midazolam MR and erlotinib Cmax, (e) 
midazolam MR and erlotinib concentrations 2h post-dose on day 1, and (f) caffeine MR and erlotinib partial AUC(0-6h).  
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A borderline significant correlation between the metabolic ratio of midazolam and er-
lotinib was observed (Figure 10a). This result was also shown between the partial 
AUC(0-6h) ratio of midazolam/1’-OH-midazolam and partial AUC(0-6h) ratio of erlotinib/ 
osi-420 (Figure 10b).  
 
 
Figure 10. Correlations between MR and AUC(0-6h) ratios for a. midazolam MR and erlotinib MR; and b. midazolam 
AUC ratio(0-6h) and erlotinib AUC(0-6h) ratio. 
 
However, after 2 weeks of sustained antineoplastic treatment, the erlotinib/osi-420 
metabolic ratio decreased drastically (Figure 11), and the correlation between the 
MRs of midazolam and erlotinib could not be replicated (Figure 12). 
 
 
Figure 11. Changes in the MR of erlotinib (a) between Day 1 and Week 2, and (b) between Day 1 and Week 2, 4, 8, 
and 10. Results are shown as individual data (grey lines) with mean ± SD (black line). The p-value is from a paired t-
test. 
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Figure 12. Correlations between (a) midazolam MR and erlotinib MR (after 2 weeks), and (b) midazolam MR and 
erlotinib Css,dose. 
 
No correlations between erlotinib MR and CYP1A2 phenotype could be observed on 
day one or after sustained antineoplastic treatment (data not shown). 
Although the association between CYP1A2 MR and smoking status bordered on a 
significant value (p = 0.062, Figure 13f), no statistically significant correlation be-
tween other evaluated PK parameters or CYP3A4 MR and smoking status could be 
observed (Figure 13a-e).  
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 Figure 13. Evaluation of the influence of smoking on (a) erlotinib partial AUC(0-6h)x, (b) erlotinib partial AUC(0-6h) ratio, 
(c) erlotinib Cmax, (d) erlotinib dose corrected Css,dose, (e) erlotinib MR, and (f) caffeine MR. Values are mean ± SD. 
The p-values are from unpaired t-tests.  
 
3.4. Exposure toxicity relationships 
The MR of midazolam at 2h shows patients in the 25th percentile (extensive CYP3A4 
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the population in the 75th percentile (slow CYP3A4 metabolisers). A similar trend was 
also observed when comparing the occurrence of skin rash in the 25th and 75th per-
centile range of the erlotinib/osi-420 ratio on day one (Figure 14a and b).  
 
 
Figure 14. Occurrence of skin rash in 25th percentile (fast CYP3A4 metabolisers), interquartile, and the 75th percen-
tile (slow CYP3A4 metabolisers) in relation to MR of (a) midazolam, and (b) erlotinib. 
 
Therefore, patients with a high MR, being classified as slow metabolisers of CYP3A4 
had a statistically significant likelihood of developing CTCAE grade 3 toxicity (Figure 
15a). After 2 weeks, patients that developed grade 3 skin toxicity did not show a sig-
nificant trend towards having higher dose-normalised Css than patients having devel-
oped either grade 1, 2, or no skin toxicity altogether (Figure 15b). Dose-normalised 
steady-state concentrations of patients that developed skin toxicity after 2 weeks 
(median 13.9, range 5.5 - 38.3) did not significantly differ from those without skin tox-
icity (median 12.5, range 5.7-43.6, p = 0.67; Figure 16). 
 
 
Figure 15. Severity of skin rash (CTCAE grade) in relation to (a) midazolam MR, and (b) erlotinib Css/dose. Red dots 
signify slow CYP3A4 metabolisers. The p-values are from ordinary one-way anova tests. 
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 Figure 16. Occurrence of skin rash with regard to erlotinib Css,dose. Values are mean ± SD. The p-value is from an 
unpaired t-test.  
 
Using the MR of paraxanthine to caffeine, the 25th and 75th percentile did not lead to 
any suggestions of likely skin rash development (data not shown). 
 
3.5. Plasma vs. DBS correlations 
Using Bland-Altman analysis we compared the data collected in plasma, DBS, and 
whole blood to assess the level of agreement of concentration measurements ob-
tained from the different sample matrices.  
The Bland-Altman blots of erlotinib (Figure 16a) show the bias between plasma and 
DBS to be around +11%, whereas the 95% limits of agreement (± 2SD range) 
ranged between -31% and 51% (1.11 [0.69 - 1.51]). Consequently, when comparing 
DBS and plasma extracted samples, 35% of respective samples showed a deviation 
outside of the ± 20% threshold, according to the EMEA guideline for cross-validation 
[33]. Therefore, on average, DBS and plasma values were within the acceptable 
threshold of ± 20% in less than 67% of cases, narrowly exceeding the requisite cut-
off imposed by the EMEA. No concentration dependent trend was observed between 
the ratios of the two biospecimens across the entire concentration range. For OSI-
420 (Figure 16b), the respective bias and ± 2SD range was (1.07 [0.53 - 1.61]). In 
the case of OSI-420, according to the EMEA-guideline for cross-validation, 42% of 
respective samples showed a deviation outside of the ± 20% threshold. Bland-
Altman blots of the comparison between plasma and whole blood, as well as DBS 
and whole blood, can be found in the supplementary material (Figures S1 and S2). 
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Figure 17. Bland-Altman plots of (a) erlotinib, and (b) OSI-420, were generated for DBS and plasma samples. Val-
ues were coloured grey if the concentration ratio of the two matrices was less than ±20%; otherwise, values were 
coloured white. The white plot area illustrates the 95% limits of agreement. The black dashed line represents the 
mean concentration ratio of DBS to plasma.  
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 4. Discussion 
Although the oral formulation of TKIs is considered to be very convenient for the pa-
tient, due to the bioavailability of a number of TKIs being dependent on gastrointesti-
nal absorption and first-pass hepatic metabolism, it does, however, introduce two 
processes that are prone to considerable variability among individuals [6, 22, 34-37].  
In this prospective, non-randomised, pharmacological cohort study in patients treated 
with erlotinib (Tarceva®) for non-small cell lung cancer (NSCLC), the correlation be-
tween CYP3A4 and CYP1A2 phenotype and erlotinib exposure was investigated with 
the aim of determining whether the degree of variability could be attributed to the 
metabolic activity of CYP450 enzymes.  Treatment-dependent adverse reactions in 
relation to the respective phenotypes were also evaluated. Furthermore, it was tested 
whether bioanalysis of erlotinib samples could be performed using dried blood spots.  
Orally administered midazolam, to assess CYP3A4 activity, has previously been 
used as a non-invasive phenotyping probe in relation to TKI exposure [38-41]. A sig-
nificant association was found that accounted for a considerable percentage of 
pharmacokinetic variability. Results of the present study could not mirror aforemen-
tioned study outcomes, as it was not possible to determine a marker of total erlotinib 
exposure for the following reasons. Firstly, limitations due the outpatient status of the 
study patients did not allow for the collection of blood samples at regular intervals up 
to 24h post dosing, which is necessary to get an adequate estimate of total drug ex-
posure. Hence the elimination constant, which would have permitted the calculation 
of the half-life could not be estimated due to an insufficient number of samples during 
the elimination phase. Nevertheless, our partial AUC0-6h values seem plausible when 
compared to the published AUC0-24h values of erlotinib, while measured Cmax was also 
in agreement [37]. Therefore, future studies should try to collect a sufficient number 
of blood samples, including during the elimination phase of the drug. Secondly, not 
all samples collected during the follow-up visits were taken at the end of the dosing 
interval (i.e. trough levels, Ctrough), as the timing of drug intake, as well as blood col-
lection, appear to differ considerably. Erlotinib is dosed once daily, as its half-life (t1/2) 
at steady state is 18h [37], and therefore a substantial decrease or increase in erlo-
tinib steady state concentration (Css) can be expected, if collected samples do not 
correspond to Ctrough values. Although patients were instructed on how to administer 
the anticancer drug, a number of other potential explanations remain for the large 
scattering of Css values. For instance, typical adherence issues commonly found in 
elderly patients that include skipped dosing, dose-self adjustment due to side effects, 
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 over-adherence, or inappropriate drug administration, could have played a role. This 
would corroborate reported adherence rates to therapy, with oral antineoplastic 
agents ranging from 20 to 100% [42]. Furthermore, it is not clear whether patients 
swallowed the tablet at least 1h before or 2h after intake of a meal, as food can lead 
to a substantial increase in erlotinib exposure [17, 36, 43]. Likewise, drugs or dietary 
components (e.g. grapefruit juice) that inhibit or induce CYP3A4 (and CYP1A2) that 
were not mentioned in the patient diary, might have been ingested. Additionally, the 
widespread intake (46% of study population) of proton-pump-inhibitors (PPIs) might 
have decreased the solubility of erlotinib, by raising the pH of the upper gastrointesti-
nal tract, and thereby reducing absorption [35, 44]. In summary, the lack of reliable 
estimates for total drug exposure (AUC0-24h), combined with the described uncertainty 
regarding the steady-state concentrations, require additional modelling efforts before 
correlations can be analysed. Currently, a population-PK model is being developed 
using nonlinear-mixed-effects modelling (NONMEM), which is expected to support 
meaningful analysis of the gathered data. As an example, the inclusion of exact time 
of dosing and sampling into the model will provide more precise estimates of steady-
state concentrations. In addition, a number of other factors associated with the varia-
bility of erlotinib exposure (apart from CYP phenotype), such as polymorphisms in 
breast cancer resistance protein (BCRP; ABCG2) [24, 25, 27], concentrations of α-1-
acid glycoprotein [45-47], and hepatic impairment [23, 24, 48], may have to be in-
cluded as covariates in the model. 
An association between the CYP-phenotype and treatment-related toxicity was in-
vestigated, as a large number of studies have reported correlations between erlotinib 
PK exposure parameters, the development of cutaneous toxicity [13, 23-25, 27, 46, 
49], and the grade of skin rash [23, 24, 50, 51]. In more detail, it has been reported 
that patients that went on to develop cutaneous toxicity were found to have higher 
AUC0-24h values after the intake of their first erlotinib dose, than patients without cuta-
neous toxicity [13]. Our data (Figure 14a) showed a similar trend, as patients with 
high metabolic ratios for midazolam (and of erlotinib), classified as ‘slow metabolis-
ers’ of CYP3A4, were more likely to develop cutaneous toxicity and were also more 
likely to develop grade 3 skin toxicity (Figure 15a), than patients with ‘extensive” 
CYP3A4 metabolism.   
After having previously characterised the Basel phenotyping cocktail in healthy, male 
subjects [30, 52], this study represents the first time two of its substrates were used 
together to gather phenotyping information in elderly, patients of both sexes who 
were being treated for non-small cell lung cancer (NSCLC). Previous studies have 
comprehensively shown that instead of full pharmacokinetic profiles, the metabolic 
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 ratios (MRs), i.e. the ratio of parent to metabolite concentrations, can be used to 
simplify sample collection in phenotyping considerably [31, 53, 54]. The average 
MRs and AUC0-6h ratios of caffeine and midazolam determined in this study com-
pared well to the corresponding concentration and AUC ratios found in healthy study 
subjects [52]. Using either the MR at 2h or the partial AUC0-6h ratio of erlotinib, we 
found a significant association with the midazolam MR and the AUC0-6h ratio. Howev-
er, the metabolic ratio of midazolam on day one of the study no longer correlated 
with erlotinib MR measured after 2, 4, 8, and 10 weeks. A limitation of phenotyping is 
that it represents a “snapshot in time”, meaning that it only describes the activity level 
of a CYP at the time it is performed. External factors such as diet, co-medication, 
smoking habits, as well as the deterioration of general health of the patients could 
have altered the phenotype [34-36, 55, 56]. Similar findings have been reported for 
imatinib, a related oral tyrosine kinase inhibitor, in which pre-treatment clearance of 
midazolam correlated with imatinib clearance on day 1, but ceased to correlate after 
a period of continuous treatment [57]. Importantly, we demonstrated that the single 
point metabolic concentration ratio between erlotinib and osi-420 decreased consid-
erably after two weeks of treatment (Figure 11), previously also reported in relation to 
the AUC ratio of erlotinib [27, 58]. This clear change in metabolic ratio is due to auto-
induction of CYP3A4 through erlotinib itself [27, 58]. In vitro experiments support this 
assumption, as erlotinib leads to an up regulation of the pregnane X receptor (PXR), 
a prominent nuclear receptor known to be involved in the induction of CYP3A4 [59, 
60].  
Tobacco smoke is a known inducer of CYP1A2 [61], which matches the finding that 
half of the patients classified as CYP1A2 rapid metabolisers were current smokers, 
while only one out of the six patients classified as slow CYP1A2 metabolisers, was 
known to be a smoker.  However, current smoking status was not significantly corre-
lated with erlotinib metabolism in this study, which does not correspond with previous 
findings [34]. This could be due to the somewhat unclear divide in subpopulations, 
the uneven size of subgroups, the lack of information concerning the extent of pa-
tients’ smoking behaviour, and absent adherence to not smoking.  
Recent studies advocate the implementation of therapeutic drug monitoring (TDM) in 
patients being treated with erlotinib, as a number of arguments show its potential 
usefulness [27, 37]. Posthoc TDM analysis revealed that average concentrations of 
erlotinib were around 4 to 6 times higher than the 500ng/mL threshold estimated to 
provide a level of EGFR inhibition leading to a sufficient degree of antiproliferative 
activity [13]. Systematic overdosing of patients increases the likelihood of adverse 
events, as shown by skin rash development [9, 13, 16, 24, 25, 49]. Therefore, our 
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 findings suggest TDM implementation could have been beneficial to patients forced 
to discontinue treatment (43% of the population), as it could have allowed erlotinib 
dose-reductions, thereby lessening dose-related cutaneous toxicity, and thus keep-
ing patients on treatment.  
Minimally invasive sampling procedures, such as dried blood spots (DBS) could fur-
ther increase the attractiveness and ease of performing TDM for TKIs. Suitably in-
structed patients would even be able to collect a sample at home: without the neces-
sity of travelling to the hospital or their GP’s office, they could simply send the DBS 
through regular mail to the analytical laboratory. Therefore, the feasibility of imple-
menting therapeutic drug monitoring through drug bioanalysis from patients’ DBS 
could be evaluated. Erlotinib and OSI-420 have not previously been measured using 
DBS. In our study, comparisons of erlotinib concentrations in DBS and plasma 
showed the bias of the respective biospecimens to be marginal, whereas a consider-
able degree of scattering was observed (bias ±2SD: 1.11 [0.69-1.51]). Visual inspec-
tion of DBS showed that inappropriate spot formation (e.g. size, volume, shape) led 
to spot inhomogeneity, which can have a significant impact on accuracy and preci-
sion of measurements [62]. Hence, improving ‘good blood spotting practice’ through 
more vigorous training of hospital staff is of great importance. Literature data also 
suggests that improvements to the analytical method, such as spraying the internal 
standard directly on to the blood spots, could lead to an increase in accuracy and 
precision of the DBS measurements [63-65]. The use of an automated DBS extrac-
tion system could also prove advantageous (see chapter 8). By incorporating these 
improvements, we deem it feasible for future studies to demonstrate the implementa-
tion of the bioanalysis of erlotinib in DBS, especially recently, four different TKIs, 
namely imatinib, dasatinib, nilotinib, and pazopanib have been shown to yield reliable 
and reproducible results when measured in either plasma or DBS samples [66, 67]. 
In conclusion, we were able to demonstrate that low dose, orally administered mid-
azolam and caffeine could successfully be utilised in a clinical setting to perform 
phenotyping of CYP3A4 and CYP1A2. However, a correlation between CYP3A4/ 
CYP1A2 phenotype and erlotinib exposure could not be determined due to a lack of 
reliable exposure markers (i.e. AUC0-24h or Ctrough). Interestingly, the assessment of 
treatment-dependent toxicity showed that patients with slow CYP3A4 metabolism 
were more likely to develop skin rashes than patients with higher CYP3A4 activity. 
Posthoc data analysis furthermore suggested that implementation of TDM guided 
dose adjustment could have helped to avoid toxicity-related treatment discontinua-
tion. After having performed bioanalysis of erlotinib using the current set of DBS 
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 samples, we are at present not able to recommend the interchangeability of DBS and 
conventional plasma measurement.  
Before final conclusions can be drawn, a population pharmacokinetic analysis 
(NONMEM), which is predominantly used in studies of this manner [23, 25, 27, 39, 
43], might be able to clarify some of the as yet unanswered questions.  
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 Supplementary material 
 
 
 
Figure S1. Bland-Altman plots generated for erlotinib concentrations in (a) whole blood and plasma samples, and in  
(b) DBS and whole blood samples. Values were coloured grey if the concentration ratio of the two matrices was less 
than ±20%; otherwise, values were coloured white. The white plot area illustrates the 95% limits of agreement. The 
black dashed line represents the mean concentration ratio of DBS to plasma. 
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Figure S2. Bland-Altman plots generated for OSI-420 concentrations in (a) whole blood and plasma samples, and in 
(b) DBS and whole blood samples. Values were coloured grey if the concentration ratio of the two matrices was less 
than ±20%; otherwise, values were coloured white. The white plot area illustrates the 95% limits of agreement. The 
black dashed line represents the mean concentration ratio of DBS to plasma. 
0
50
0
10
00
15
00
20
00
25
00
30
00
Mean plasma and whole blood concentration [ng/mL]
O
SI
-4
20
 c
on
ce
nt
ra
tio
n
w
ho
le
 b
lo
od
 : 
pl
as
m
a 
[%
]
+20%
0%
-20%
+33%
-50%
-8%
0
50
0
10
00
15
00
20
00
25
00
30
00
Mean whole blood and DBS concentration [ng/mL]
O
SI
-4
20
 c
on
ce
nt
ra
tio
n
D
B
S 
: w
ho
le
 b
lo
od
 [%
]
+20%
0%
-20%
+76%
-35%
+19%
a
b
121
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122
  
 
 
8. Therapeutic drug monitoring of antiretroviral drugs using a fully 
automated dried blood spot extraction method to measure  
samples from a clinical study in rural Tanzania 
 
 
Benjamin Berger1, Urs Duthaler1, Stefan Erb2, Manuel Battegay2, Stefan Gaugler3, 
Stephan Krähenbühl1,4, Manuel Haschke1 
 
 
 1Division of Clinical Pharmacology & Toxicology, University Hospital Basel and 
Department of Biomedicine, University Hospital Basel, Switzerland 
2 Division of Infectious Diseases and Hospital Epidemiology, Departments of 
Medicine and Clinical Research, University Hospital Basel, Switzerland 
3 CAMAG, Muttenz, Switzerland 
4Swiss Center for Applied Human Research (SCAHT) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123
Abstract 
For therapeutic drug monitoring (TDM) in remote settings, obtaining dried blood spots 
(DBS) is particularly advantageous, as blood is withdrawn after a simple finger prick 
and the ensuing DBS sample is generally stable at room temperature. However, 
factors such as variable haematocrit and the small sample volume pose a challenge 
for the development of reliable and sensitive bioanalytical methods. The aim of this 
study was to develop and validate an automated extraction method for the analysis of 
nevirapine, efavirenz, and lopinavir in DBS samples, thereby circumventing 
drawbacks of conventional DBS methodology. To test the feasibility of using DBS 
within the framework of a clinical adherence assessment study in HIV patients in 
rural Tanzania, concentrations of antiretrovirals found in DBS samples were 
compared with conventional plasma samples. 
From 299 patients, DBS and plasma samples for the analysis of nevirapine (n=192), 
efavirenz (n=482), and lopinavir (n=66) were collected. DBS samples were extracted 
with methanol:H2O (70:30 v/v), using a CAMAG DBS-MS-500 autosampler, which 
was coupled with an LC-MS/MS system. The analytes were detected through 
multiple reaction monitoring with electrospray ionisation in positive (nevirapine and 
lopinavir) or negative (efavirenz) mode.  Analytes were separated within a 3 minute 
run time on a pentafluorophenyl phase analytical column, using methanol and water, 
both of which were supplemented with 0.1% formic acid as mobile phases.  
The method was linear between 10-25’000ng/ml (R2>0.99) for all three analytes. 
Recoveries and matrix effects were consistent between different donors and were 
independent of concentration. A mean recovery of 70%, 63%, and 60% was 
determined for nevirapine, efavirenz, and lopinavir respectively. Higher haematocrit 
values reduced the extraction recovery by approximately 10-25%. This could be 
compensated by spraying the internal standard directly onto the DBS before analysis. 
Inter- and intra-assay accuracy and precision deviations were ≤15%. A correction 
factor was implemented for the relationship of blood spot area and haematocrit, 
which improved the overall reliability of the DBS analysis. Under accelerated storage 
conditions (4 weeks, 40°C, 75%rH), only lopinavir demonstrated a time-dependent 
degradation of approximately 20%. Manual and automated extractions showed good 
agreements with deviations of less than 9%. No bias between DBS and plasma 
concentrations was detected for nevirapine (bias ±2SD range: 1.05 [0.73-1.36]). By 
contrast, concentrations in DBS were approximately 50% lower, compared to 
plasma, for efavirenz (0.59 [0.43-0.74]) and lopinavir (0.48 [0.28-0.67]). In the case of 
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efavirenz, the bias could be removed by correcting the DBS concentrations with 
patient-specific haematocrit values and plasma protein binding  (0.91 [0.66-1.16]).  
Our study highlights that concentrations of nevirapine and efavirenz can be reliably 
determined by automated extraction in DBS samples, obtained in the challenging 
setting of rural Africa.  This facilitates high throughput DBS analysis of large sample 
numbers and confirms that DBS are a suitable alternative to conventional plasma 
samples for future studies conducted in remote settings without reliable cold chains.  
 
 
 
Keywords: Dried blood spots, automated extraction, nevirapine, efavirenz, lopinavir, 
haematocrit, therapeutic drug monitoring, LC-MS/MS 
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1. Introduction 
The dried blood spots (DBS) technique is a microsampling tool, whereby capillary 
blood is spotted onto a filter paper, leading to a more or less homogenously 
distributed blood spot. After complete drying, a fixed blood spot area can be punched 
out for drug analysis, thereby avoiding exact pipetting [1]. Contrasting against 
conventional plasma sampling, the DBS technique does not require a trained 
phlebotomist.  Only a few drops of blood are withdrawn after a simple and minimally 
invasive finger prick: a process that could be performed by patients who have been 
given adequate instruction [2]. Moreover, DBS samples minimise biohazardous risk 
during further sample handling and are generally stable at room temperature, making 
the maintenance of cold chains unnecessary [3]. Hence, the collection of DBS 
samples is especially attractive for field studies in remote or resource-constrained 
settings, where uninterrupted cold chains cannot be guaranteed [4].  
Worldwide, an estimated 37 million people are HIV-positive, of which the majority 
reside in Sub-Saharan Africa [5]. Adherence to antiretroviral therapy has been 
strongly correlated with viral suppression, increase in survival, and improved quality 
of life [6, 7]. Patients with suboptimal adherence are at risk of HIV progression and 
the development of drug resistance, which consequently narrows options for future 
treatment [6, 8, 9]. However, particularly in developing countries, adherence 
assessment by healthcare providers is performed infrequently [6, 8, 10]. The 
previously mentioned DBS qualities, therefore, make it an ideal tool for adherence 
assessments in such environments.  
However, the development of bioanalytical DBS methods is more complex than those 
used in conventional liquid matrices, as variable haematocrit values not only alter the 
analyte recovery, but also the extent of blood diffusion within the filter paper, thereby 
impacting the reliability of the DBS analysis [11]. On the other hand, the small 
amount of blood collected on a blood collection card complicates the development of 
highly sensitive bioanalytical methods [11]. Finally, concentrations found in DBS must 
be compared to conventional plasma samples to be able to correctly interpret results 
from DBS measurements [12-15].  
DBS and plasma samples of patients treated with combined antiretroviral therapy 
(cART) were collected in the framework of an adherence assessment study in 
Tanzania (Ifakara) [16]. Treatments with two non-nucleoside reverse transcriptase 
inhibitors, efavirenz and nevirapine, and a protease inhibitor, lopinavir, were 
monitored in this study. In contrast to previous studies, which used manual DBS 
extraction for the measurement and validation of the respective cART compounds 
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[17-21], we extracted DBS using a fully automated CAMAG DBS-MS-500 
autosampler [22]. A number of different approaches enabling the automated handling 
of DBS have been developed, thereby facilitating the laborious manual DBS work-up 
[23-26]. The DBS-MS-500 autosampler exhibits a TLC based extraction head, with a 
circular plunger that seals a vent of 4 mm inner diameter (ID) on the blood spot. The 
extraction solvent passes horizontally from the inlet capillary, through the blood spot 
to the outlet capillary, and into a sample loop (unilateral extraction). Thus, in contrast 
to other online DBS extraction systems, the extraction solvent is not forced vertically 
through the filter paper (flow-through extraction) [27]. The autosampler is connected 
to the LC-MS/MS system, features 500 DBS card slots, takes an image of the blood 
spot before and after the extraction process, and works with a low volume (~25 µL) of 
extraction solvent.  
The aim of the present study was to develop and validate a fully automated DBS 
extraction method for the analysis of nevirapine, efavirenz, and lopinavir, with 
sufficient robustness to handle a large number of samples from a field study in rural 
Tanzania (Ifakara). We demonstrate that methodological drawbacks of DBS analysis 
can be partially overcome with the applied automated extraction system. Feasibility 
of the automated procedure was demonstrated by comparing concentrations 
obtained after automated DBS extraction with concentrations after manual DBS 
extractions. Furthermore, the agreement of plasma and DBS concentrations was 
determined. 
 
 
2. Materials and Methods 
2.1. Chemicals, reagents and reference compounds 
Gradient grade water and methanol for liquid chromatography as well as formic acid 
(98-100%) were purchased from Merck (Darmstadt, Germany). Dimethyl sulfoxide 
(DMSO) was obtained from Sigma-Aldrich (St. Louis, USA). The reference 
compounds, nevirapine, efavirenz, and lopinavir and its deuterated internal standards 
(IS) – nevirapine-d3, efavirenz-d5, and lopinavir-d8 – were products of Toronto 
Research Chemicals (Toronto, Canada). Dried blood spot cards (grade 226 filter 
paper) were kindly provided by CAMAG (Muttenz, Switzerland). Fresh whole blood 
was obtained from the blood donation centre (Basel, Switzerland). 
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2.2. LC–MS/MS Instrumentation and settings 
Chromatography was performed on a modular HPLC system from Shimadzu (Kyoto, 
Japan); it contained a system controller (CBM-20A), four pumps (2x LC-20AD and 2x 
LC-20AD XR), a degasser (DGU-20A5), and a column oven (CTO-20A). A CTC HTS 
PAL autosampler (CTC analytics, Zwingen, Switzerland) was used to perform 
manual extraction of DBS samples.  Automated extractions were carried out with a 
DBS-MS 500 autosampler (CAMAG, Muttenz, Switzerland). Analytes were separated 
on a Kinetex 2.6µ F5 100 Å (50x2.1 mm) analytical column (Phenomenex, Torrance, 
USA). A filter frit (SS 0.5 µm 0.62x0.65, Ercatech AG, Bern, Switzerland) was 
connected upstream to the analytical column. Mobile phase A consisted of water plus 
0.1% formic acid, while methanol supplemented with 0.1% formic acid was used as 
mobile phase B. The following stepwise gradient was applied: 5% (0-0.25 min), 5%-
60% (0.25-0.4 min), 60%-80% (0.4-2.0 min), 80%-95% (2.0-2.2 min), 95% (2.2-3.0 
min), 5% (3.0-3.3 min). The flow rate was set at 0.5 mL/min at 45°C. HPLC liquid 
stream was connected to an API 4000 Q-trap tandem mass spectrometer (ABSciex, 
MA, USA) between minute 0.6 and 2.5 of each run to reduce system contamination. 
The analytical run was divided into three multiple reaction monitoring (MRM) periods, 
whereas electrospray ionisation was switched from positive to negative ionisation 
between minute 1.3 and 1.7 (period 2) of each run. The following mass transitions 
and compound specific settings were used: 267→226 m/z for nevirapine 
(declustering potential [DP]: 76 V, collision energy [CE]: 20 V, entrance potential 
[EP]: 10 V, collision cell exit potential [CXP]: 16 V), 270→229 m/z for nevirapine-d3 
(DP: 121 V, CE: 37 V, EP: 10 V, CXP: 16 V), 314→244 m/z for efavirenz (DP: -95 V, 
CE: -26 V, EP: -10 V, CXP: -13 V), 319→248 m/z for efavirenz-d5 (DP: -75 V, CE: -
28 V, EP: -1 V, CXP: -15 V), 629→155 m/z for lopinavir (DP: 111 V, CE: 35 V, EP: 10 
V, CXP: 10 V), and 637→163 m/z for lopinavir-d8 (DP: 66V, CE: 75 V, EP: 10 V, 
CXP: 10 V). The general settings of the mass spectrometer were as follows: Ion 
source gas-1 60 L/min (N2), Ion source gas-2 50 L/min (N2), curtain gas 10 L/min, 
collision gas 4 L/min, ion spray voltage 5500 V (positive mode) and -4200 V 
(negative mode), and a source temperature of 350°C. Analyst software 1.6.2 (AB 
Sciex, MA, USA) was used to operate the LC-MS/MS system. 
 
2.3. Preparation of standards and extraction solvents 
Nevirapine, efavirenz, and lopinavir stock solutions were prepared in DMSO (10 
mg/mL) and stored at -20°C. Stock solutions were pooled and serially diluted with 
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DMSO to cover a range from 2500 to 1 µg/mL. The dilution series for calibrators and 
QC samples originated from different weightings. Internal standard (IS) stock 
solutions were likewise prepared in DMSO at a final concentration of 1 mg/mL. The 
extraction solvent was a mixture of methanol and water (70:30 v/v). In the case of the 
automated extractions, the IS was dissolved in methanol at a concentration of 1 
µg/mL for nevirapine-d3 and at 2 µg/mL for efavirenz-d5 and lopinavir-d8. 
 
2.4. Preparation of calibration and quality control samples 
Fresh collected human blood was obtained from the local blood donation centre 
(Basel, Switzerland). EDTA was used as an anticoagulation agent (vacutainer tubes, 
BD, Allschwil, Switzerland). Calibrators and Quality control (QC) samples were 
prepared by spiking blank blood with the analyte dilution series in a ratio of 1:100 
(v/v). Calibration samples encompassed a range from 10-25’000 ng/mL. QC samples 
were prepared at the lower limit of quantification (LLOQ, 10 ng/mL), as well as at low 
(50 ng/mL), medium (500 ng/mL), and high (5000 ng/mL) concentration levels. In the 
case of manual extractions, the LLOQ was set to 50 ng/mL. Spiked blood samples 
were gently mixed and agitated on a roll-agitator (RM 5, CAT, Staufen, Switzerland), 
after which 15 µL aliquots were spotted onto CAMAG DBS cards (CAMAG, Muttenz, 
Switzerland). DBS cards were dried at room temperature for at least 2h and were 
subsequently stored at -20°C in sealed plastic bags containing desiccants. Each 
calibration set consisted of one blank sample (DBS sample processed without IS), 
one zero sample (DBS sample processed with IS), and eleven calibrators (nine 
calibrators in the case of manual extractions). Calibration lines were established by 
linear regression of the nominal analyte concentration against the analyte:IS peak 
area ratio using a weighting factor of 1/x2.  
 
2.5. Dried blood spots sample procession 
2.5.1. Automated extraction 
The DBS cards were photographed with the built-in camera of the CAMAG-DBS 500 
autosampler before and after each run to check for the presence of a blood spot and 
to adjust the extraction head to the centre of each spot. 10 µL of internal standard 
was sprayed in a homogenous layer onto each spot. After a 20 second drying time, 
the samples were extracted with a volume of 25 µL and a 40 µL/min flow rate. As a 
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20 µL loop was installed, the first 5 µL of the extract were discarded. To complete the 
automated DBS extraction cycle, the system was first rinsed for 20 seconds with a 
methanol:acetonitrile:isopropanol:water (1:1:1:1 v/v) mixture, after which it was 
cleaned for a further 20 seconds with water containing 0.1% formic acid.  
 
2.5.2. Manual extraction 
10 µL of internal standard was sprayed using the internal spraying device of the 
CAMAG autosampler onto each spot. The card was then removed, left to dry at room 
temperature, and then a disc, 3 mm in diameter, was manually punched out, using a 
manual hole puncher (Whatman, Sanford, ME, USA), from the centre of each spot 
and transferred to a 0.75 mL autosampler matrix tube (Thermo Scientific, Reinach, 
Switzerland). Then, 200 µL extraction solvent, methanol:water (70:30 v/v), was 
added to each blood disc. The samples were mixed for 3 minutes and afterwards, 
centrifuged (30min; 3220 g; 10°C, Eppendorf, Hamburg, Germany), and kept at 10°C 
in the autosampler. To perform the analysis, an aliquot of 20 µL supernatant was 
introduced into the LC-MS/MS system. Subsequently, the system was washed with 
methanol and a methanol:water mixture (1:1 v/v).  
 
2.6. Method validation 
The automated DBS extraction LC-MS/MS method was validated following the FDA 
guidance for bioanalytical method validation for industry. The method was validated 
in terms of selectivity, sensitivity, accuracy, precision, linearity, extraction recovery, 
matrix effect, and analyte stability.   
 
2.6.1. Selectivity and sensitivity 
Blank DBS samples from seven different subjects were examined for interfering 
endogenous matrix components. The signal at the designated LLOQ was set to be at 
least five times higher than the noise signal, with a bias in precision of less than 20%, 
and accuracy of 80-120%.  
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2.6.2. Intra- and inter-day accuracy and precision experiments 
The accuracy and precision of the method were determined by analysing QC 
samples from seven different subjects at four concentration levels (LLOQ, low, 
medium, and high level QC). Placing the QC samples between two calibration lines, 
one spot was analysed per condition (n=28 QC samples, n=22 calibrators). Precision 
and accuracy were evaluated within a single validation run (intra-day) as well as 
between three runs recorded at different days (inter-day). The precision was 
calculated as the percentage relative standard deviation (CV, %) for each QC 
concentration within an analytical run (intra-day precision) and over all three runs 
(inter-day precision). A precision of <15% (<20% at the LLOQ) was accepted in our 
study. The accuracy was assessed from the overall mean of each QC concentration 
divided by its nominal value (bias, %). A mean accuracy of 85-115% (LLOQ: 80–
120%) was acceptable; however, at least 67% of the QC samples of each 
concentration level had to be within the acceptance range.  
 
2.6.3. Linearity 
The coefficients of variation (R2) of the linear regression, between the analyte peak 
area, normalised by the internal standard peak area and the nominal concentration, 
had to be ≥0.99. At least 75% of the calibration samples had to be in within ±15% 
(LLOQ: ±20%) of the nominal value. 
 
2.6.4. Recovery and matrix effect 
The extraction recovery of the DBS-MS 500 autosampler was investigated for DBS 
samples of seven different subjects. Furthermore, the influence of varying 
haematocrit values on recovery was analysed over a range of 20 to 50% (same 
preparation as described in Section 2.6.5). DBS spots at 50, 500, 5000 ng/mL were 
prepared for the recovery experiments. Each spot was extracted six times for 
medium and high concentration samples (500 and 5000 ng/mL), while low 
concentration samples (50 ng/mL) were extracted three times. Between two 
extractions, a drying time of approximately 15 minutes was programmed. Spots were 
visually inspected to ascertain whether the extraction head always locked onto the 
same area of the blood spot. The recovery was finally estimated as the percentage 
ratio of the analyte peak area of the first extraction to the sum of the peak areas of all 
conducted extractions.  
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Blank DBS samples from seven different subjects were prepared to quantify the 
effect of the blood matrix itself on the analyte signal intensity. The extraction solvent 
was spiked with 10, 100, or 1000 ng/mL nevirapine, efavirenz, and lopinavir. Each 
blank DBS sample, and a corresponding card without a blood spot, were processed 
at each concentration level. The matrix effect was calculated as the ratio of the 
analyte peak areas measured, following extraction of filter cards containing a blank 
DBS, to the peak areas of filter cards without matrix. 
 
2.6.5. Impact of the haematocrit value and the applied blood volume 
Haematocrit levels in the study population ranged from 20 to 50%, with a mean 
haematocrit of 35%. Therefore, blood samples with haematocrit values of 20%, 25%, 
30%, 35%, 40%, 45%, and 50% were prepared by adding or removing plasma from 
blood with a known haematocrit [28]. Modified haematocrit values were verified for 
quality control reasons using a haematology analyser (Sysmex KX-21N, Kobe, 
Japan). The correlation between the haematocrit value and the resulting blood spot 
area was evaluated by measuring the area of 12 blood spots per haematocrit level. 
This experiment was carried out by pipetting three different volumes of blood (10, 15, 
and 20 µL). Blood spots were photographed using the built-in camera of the CAMAG 
autosampler, and the areas were digitally measured with GIMP software (GNU 
Image Manipulation Program 2.8.10). The relationship between the spot area, 
normalised to the applied volume of blood and the respective haematocrit value, was 
analysed by linear regression.  
DBS spots using 15 µL and 30 µL blood were prepared at LLOQ, low, medium, and 
high concentration levels. Additionally, the change in concentration of 15 µL to 30 µL 
spots was calculated. A deviation of ≤15% (LLOQ ≤20%) implied that the method 
does not depend on the applied volume of blood.    
 
2.6.6. Stability 
Stability tests of nevirapine, efavirenz, and lopinavir were performed under different 
conditions at a medium concentration level of 500 ng/mL. Stability was evaluated 
under accelerated storage conditions, aimed at mimicking weather conditions in 
Tanzania, at 40°C and 75% relative humidity after 1 day and, again, after 1, 2, 3, and 
4 weeks. Stability in the fridge (4°C) and the freezer (-20°C) was tested after 4 weeks 
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of storage. Five replicates were analysed per condition and compared to a set of QC 
samples, prepared on the day of analysis.  
 
2.7. Method application 
DBS and plasma samples (nevirapine n=192, efavirenz n=482, lopinavir n=66) were 
collected from within the framework of an adherence assessment study in Tanzania, 
which included 299 patients [16]. Ethical approval was obtained from the Institutional 
Review Board of the Ifakara Health Institute, Dar es Salaam, Tanzania (IRB 
reference no. IHI 28-2013). 
 
2.7.1. Comparison of automated/manual DBS extraction and plasma/ DBS 
samples 
Clinical application of the LC-MS/MS method was demonstrated by analysing 50 
randomly chosen DBS samples for each analyte, which were processed by 
automated and manual extraction. In both cases, the IS was sprayed onto the DBS. 
Bland-Altman plots were created with GraphPad Prism 6.04 (La Jolla, CA, USA) to 
compare the two extraction methods [29]. In so doing, a mean ratio plot was 
generated including the mean ratio bias and the 95% limits of agreement (±2 
standard deviations). 
Furthermore, 192 nevirapine, 482 efavirenz, and 66 lopinavir plasma, and their 
corresponding DBS samples, were analysed and compared using Bland-Altman 
plots. DBS samples were extracted using the CAMAG-500 autosampler. An aliquot of 
50 µL plasma was precipitated with 500 µL methanol, containing the IS (nevirapine-
d3: 50 ng/mL, efavirenz-d5: 100 ng/mL, and lopinavir-d8: 100 ng/mL). After 
centrifugation (3220 g, 30 min, 10° C), 5 µL supernatant was injected (CTC PAL 
autosampler, Zwingen, Switzerland) into the LC-MS/MS system. EMEA Criteria set 
for the cross-validation of two methods were applied in this study, meaning at least 
67% of the samples had to be within ±20% limits: “For study samples, the difference 
between the two values obtained should be within 20% of the mean for at least 67% 
of the repeats” [30].  
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3. Results and Discussion 
3.1. Method development 
Assessment of adherence to antiretroviral therapy is essential to assure sufficient 
viral suppression and thus improve survival and quality of life. While therapeutic drug 
monitoring (TDM) is part of the standard of care in industrialised nations, less is 
known about adherence to antiretroviral treatments in developing countries. Using 
DBS to perform TDM, instead of conventional plasma or serum sampling, does entail 
several method-specific drawbacks. When working with DBS, the preparation of 
calibrator and QC samples, alongside the extraction procedure, is more laborious. 
Moreover, the small amount of blood available in the DBS sample is a challenge for 
the development of particularly sensitive methods. Finally, technical difficulties, such 
as variations in haematocrit, can lead to variable blood spot areas, while the 
haematocrit can also be the reason for variable analyte recovery that can further 
complicate accurate quantification. Here we demonstrate that these challenges can 
be partially overcome by using the CAMAG DBS-MS 500 autosampler for the 
analysis of nevirapine, efavirenz, and lopinavir.   
In the first stage of method development, mass spectrometer voltages were adjusted 
to maximise the peak response of the parent mass and the product ions for each 
compound. The best results were obtained when using the transitions 267→226 m/z, 
314→244 m/z, and 629→155 m/z for nevirapine, efavirenz, and lopinavir, 
respectively. Similar transitions were used for the internal standards, with the addition 
of the respective amount of deuterium atoms (nevirapine-d3: 270→229 m/z, 
efavirenz-d5: 319→248 m/z, lopinavir-d8: 637→163 m/z). The same MS/MS 
transitions were also utilised in other published methods [17, 18, 21, 31].  
Nevirapine and lopinavir were optimised in positive ionisation mode, while efavirenz 
was optimised in negative ionisation mode. Therefore, efavirenz had to be 
chromatographically separated from nevirapine and lopinavir, as negative and 
positive ionisation modes cannot be run in parallel with the employed mass 
spectrometer. Figure 1 illustrates that baseline separation of all analytes was 
efficiently achieved within a 3 minute running time, using a core-shell 
pentafluorophenyl phase column. Peak symmetry was reasonable using methanol 
and water supplemented with formic acid (0.1%) as mobile phase.  
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Figure 1. Chromatogram of a high concentration QC sample of nevirapine, efavirenz, lopinavir, and their respective 
internal standards. Polarity was switched to negative ionisation mode between 1.3 and 1.7 minutes. 
	
The emphasis of method development focused on improving the automated 
extraction. The main adjustable instrument parameters for this process consisted of 
the amount of IS sprayed onto the DBS, the extraction-flow, -volume, and -solvent 
composition. Parameters giving the highest signal intensities, best precisions, and 
optimal peak shapes were selected (Figure 2), and extraction parameter optimisation 
was investigated at low and high QC levels (n=4).  
First, different methanol:water mixtures (50:50, 60:40, 70:30, 80:20, and 90:10 v/v) 
were tested. A high water amount increased the risk of clogging the extraction head, 
as presumably more biomolecules and cellular components are removed from the 
dried spot. Extraction robustness was thereby limited. Overall a mixture of 70:30 
methanol:water resulted in the highest signal intensities and showed good precisions. 
Peak symmetry was disturbed by methanol concentrations exceeding 80% in the 
extraction solvent. Replacing methanol with acetonitrile did not improve extraction 
yield and worsened peak shapes. The extraction volume was increased stepwise 
from 20 to 70 µL (20, 25, 30, 40, 50, 60 and 70 µL), while the last 20 µL of each 
extraction were trapped in the sample loop. Signal intensities decreased with larger 
extraction volumes to about 80-90% of the initial value. Almost 50% is extracted 
within the first 10 µL of the extraction fraction. An extraction volume of 25 µL was 
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selected because the precision was enhanced compared to 20 µL and the signal 
intensity was only marginally lower. As extraction flow did not seem to have a 
significant impact, the standard setting of 40 µL/min flow was used to perform 
automated extraction.  
 
	
Figure 2. Optimisation of the DBS-MS 500 method for the extraction of nevirapine, efavirenz, and lopinavir from DBS 
samples. High concentration QC samples (n=4) were extracted for every extraction condition. The effects of the 
methanol:water mixture, extraction volume, and extraction flow on the extraction yield were evaluated. Conditions 
with grey coloured box plots were selected for the extraction method. 
	
The wash cycle had to be optimised in order to reduce analyte carry-over. In the case 
of nevirapine and efavirenz, the signal in a blank sample after injection of the highest 
calibrator was ten times lower than the signal detected at LLOQ. However, the carry-
over of lopinavir led to signal intensities around three to four times lower than the 
signal at LLOQ. Nevertheless, through a sequential injection of another blank 
sample, the interference was removed, meaning that carry-over of lopinavir is 
manageable.  
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3.2. Method validation 
3.2.1. Selectivity and Sensitivity 
Selectivity of the method was tested for interfering matrix components in seven blank 
human DBS samples (Figure 3). Noise level baselines of the blank samples did not 
show co-eluting peaks at the retention time of nevirapine (1.1 min), efavirenz (1.5 
min), or lopinavir (1.9 min). Moreover, internal standards that were sprayed onto 
blank DBS spots did not cause interfering signals. Hence, the developed method is 
selective for the analysis of the investigated antiretrovirals. 
A sensitivity of 10 ng/mL was achieved for all analytes. Based on published data, we 
expect this quantification limit to be sufficient to perform therapeutic monitoring of 
nevirapine, efavirenz, and lopinavir [32]. Figure 3 illustrates that the signal intensity at 
LLOQ is at least five times higher than the background noise level.  
	
Figure 3. Chromatograms of blank DBS samples (n=7 donors) were placed next to a LLOQ sample. The method is 
selective for the quantification of nevirapine, efavirenz, and lopinavir in DBS samples. 
 
3.2.2. Linearity 
Linearity was attained over a calibration range of 10 to 25’000 ng/ml for all analytes. 
Taking all validation experiments into account, the coefficient of variation (R2) was 
always >0.99 for each respective analyte. The upper limit of quantification also 
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encompasses high therapeutic concentrations [33], which is especially important for 
the automated extraction of DBS, as dilution of the DBS samples cannot be easily 
performed. Thus, clinically occurring concentrations can be quantified by linear 
regression within the chosen calibration range.  
 
3.2.3. Accuracy and Precision 
Intra- and inter-day accuracy and precision data are summarised in Table 1. QC 
samples were derived from seven donors with haematocrit values varying between 
39-44%. An intra-day precision of less than 14.8%, 12.0%, and 13.9% was found for 
nevirapine, efavirenz, and lopinavir respectively. Inter-day precisions were ≤11.3%. 
Mean inter-day accuracies were between 88.9-106.8% for nevirapine, 91.3-104.6% 
for efavirenz, and 90.1-108.5% for lopinavir. On all occasions, not more than two out 
of the seven QC samples per concentration were outside the 85-115% (LLOQ: 80-
120%) limits. Overall, results were consistent with conditions specified by regulatory 
guidelines.  
 
Table 1. Intra- and inter-assay accuracy and precision of nevirapine, efavirenz, and lopinavir analysed in DBS 
samples. 
 
 
3.2.4. Recovery and Matrix effect 
The relative recovery and matrix effect were determined in four different donors at 
low, medium, and high concentrations. In addition, the recovery of the analytes was 
assessed in dried water spots. The highest mean recovery was achieved for 
nevirapine with 70%, followed by efavirenz (63%), and lopinavir (60%). A bias in 
recovery of less than 7.2% was determined between subjects, indicating high 
consistency in the sample extraction process (Figure 4). Recovery at low 
Nevirapine 10 9.3 93.2 ± 7.4 9.7 96.9 ± 7.4 10.7 106.8 ± 8.3 9.9 99 ± 9.5
50 44.4 88.9 ± 8.6 47.1 94.1 ± 14.8 47.9 95.9 ± 7.3 46.5 93 ± 10.7
500 469.8 94 ± 5.9 474.1 94.8 ± 5.4 482.1 96.4 ± 7 475.3 95.1 ± 5.9
5000 4753.9 95.1 ± 8.3 4772.5 95.4 ± 6 4941 98.8 ± 10.4 4822.5 96.4 ± 8.2
Efavirenz 10 9.1 91.3 ± 7.1 9.7 96.9 ± 11 10.5 104.6 ± 10.6 9.8 97.7 ± 11
50 46.7 93.4 ± 9.1 47.4 94.8 ± 12 50.1 100.1 ± 9.7 48.1 96.1 ± 10.3
500 480.4 96.1 ± 5.9 480.5 96.1 ± 5.5 495.5 99.1 ± 7 485.5 97.1 ± 6.1
5000 4779.6 95.6 ± 9.2 4655.2 93.1 ± 8.6 4934.1 98.7 ± 9.7 4789.7 95.8 ± 9.1
Lopinavir 10 9.7 96.5 ± 5.8 10.2 98.4 ± 12.8 10.9 108.5 ± 8.7 10.2 101.1 ± 10.5
50 45.9 91.8 ± 10.7 45.9 91.8 ± 13.9 47.2 94.4 ± 10.5 46.3 92.7 ± 11.3
500 482.4 96.5 ± 7.8 455.7 91.1 ± 7.2 464.2 92.8 ± 7.9 467.5 93.5 ± 7.7
5000 4723.2 94.5 ± 10.3 4506.4 90.1 ± 9.5 4618.2 92.4 ± 12.8 4615.9 92.3 ± 10.6
Analyte
Intra-assay Inter-assay
Day 1 Day 2 Day 3 Day 1-3
Conc. found 
at [ng/mL]
Accuracy ± 
CV [%]
Accuracy ± 
CV [%]
Conc. found 
at [ng/mL]
QC Level 
[ng/mL]
Conc. found 
at [ng/mL]
Accuracy ± 
CV [%]
Conc. found 
at [ng/mL]
Accuracy ± 
CV [%]
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concentration was overestimated by around 10% compared to medium and high 
concentration samples, as the limit of quantification was already reached after three 
instead of six consecutive extractions. The recovery of dried water spots was >97%, 
which implies that blood acts as an extraction barrier. For this reason, the influence 
of the haematocrit on extraction recovery was additionally investigated (see section 
3.2.5).  
The signal intensity of nevirapine and lopinavir was only suppressed by about 8% 
and 6% respectively, through the DBS matrix. However, a significant suppressive 
matrix effect was observed for efavirenz, where the signal was reduced to 
approximately 50% due to the biological matrix. Importantly, the matrix effect was 
independent of concentration, as its deviation was ≤10.4% at different 
concentrations, and did not vary between subjects (CV ≤11.0%).  
 
Table 2. Matrix effect (ME) of nevirapine, efavirenz, and lopinavir in DBS samples. 
 
 
Hence, the matrix of different donors did not alter the reliability of the method. Online 
solid phase purification of DBS extracts, via column switching or through more 
thorough separation of efavirenz and blood ingredients, may eliminate suppressive 
matrix effects [27, 34]. All in all, the automated extraction was eminently reproducible 
and delivered consistent matrix effects. 
ME ± CV [%] Mean ± CV [%] ME ± CV [%] Mean  ± CV [%] ME ± CV [%] Mean  ± CV [%]
10ng/mL 92.2 ± 1.0 92.0 ± 0.4 52.7 ± 4.9 54.8 ± 10.4 100.6 ± 2.0 94 ± 6.2
100ng/mL 91.5 ± 1.8 50.4 ± 5.4 91.5 ± 2.0
1000ng/mL 92.1 ± 3.4 61.2 ± 11.0 89.7 ± 2.0
Nevirapine LopinavirEfavirenz
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Figure 4. (a) Pictures of DBS before and after six consecutive extractions. The extraction head was always aimed 
onto the same coordinates on the blood spot. (b) Extraction recovery of nevirapine, efavirenz, and lopinavir 
determined at low, medium, and high concentrations of four different donors. Decrease in peak areas after six 
(medium and high QC) or three (low QC) repetitive extractions are shown. Recoveries were consistent between 
different subjects and over different concentrations.    
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3.2.5. Impact of the haematocrit value and the applied blood volume 
It is comprehensively described that the blood haematocrit can affect the reliability of 
DBS methods, as the diffusion behaviour is altered by its magnitude [11]. Blood spot 
area on the filter paper grade 226 decreased in a linear manner (R2 ≥0.93), with 
increasing haematocrit values, as shown in Supplementary Figure S1. A linear 
relationship between haematocrit and spot size has also been described for other 
brands of filter paper [12]. QC sample concentrations differed by less than 5.7% 
when 30 µL instead of 15 µL blood was spotted onto cards. Hence, the applied blood 
volume produced reproducible, volume-dependent spot areas and, therefore, 
importantly, did not affect accuracy and precision of the analysis (Table S1 and 
Figure S2). To counteract the haematocrit-area bias the following correction formula 
for the applied filter paper grade 226 was established, based on the observed linear 
regression between area and haematocrit (Figure S2b):  
DBS area = -1.157 x HCT + 261.8 
Accordingly, the haematocrit value of the calibrator and of the TDM sample must be 
known before the correction can be applied. A clear tendency, for DBS samples 
spotted with a haematocrit below or above that of the calibrators (HCT 35%), to 
under- or overestimate the actual concentration is shown in Figure 5. A significant 
linear correlation between haematocrit and the deviation from the calibration 
haematocrit was observed. Overall, 24% (nevirapine), 46% (efavirenz), and 22% 
(lopinavir) of the QC samples (n=54) exhibited a bias of >15%. After correction, this 
proportion was reduced to 2% for nevirapine, 20% for efavirenz, and 9% for lopinavir. 
Thus, only efavirenz demonstrated a significant haematocrit-driven bias. It is, 
therefore, conceivable, that the haematocrit might additionally influence the diffusion 
behaviour of efavirenz, leading to a haematocrit dependent concentration gradient 
across the spot (e.g. volcano effect) [35].  
Moreover, higher haematocrit values complicate analyte recovery and thereby 
diminish the area-haematocrit bias [36]. In the case of nevirapine, efavirenz, and 
lopinavir a change in haematocrit from 20 to 50% decreased the extraction recovery 
by 7.7 to 27.4% over the tested concentration range (QClow, QCmed, QChigh). 
Importantly, the recovery of the IS solution, which was sprayed on top of each spot, 
declined by roughly the same degree (Table S2). To spray the IS onto the DBS, 
instead of adding it to the extraction solvent, has been shown to reduce the recovery-
haematocrit bias, which is in line with our findings [36]. Crucially, if the haematocrit of 
the DBS sample were to be unknown, it could be estimated by measuring the 
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potassium concentration, which has been shown to correlate with the haematocrit 
and therefore enables haematocrit corrected DBS analysis [37]. 
 
	
Figure 5. Relationship between haematocrit and the deviation related to a haematocrit of 35% determined for 
nevirapine, efavirenz, and lopinavir. The DBS of the calibrators exhibited a haematocrit of 35%. Each Box-plot 
included low, medium, and high QC samples (n=3 each). White Box-plots are before correction and grey box-plots 
after correction with the area-haematocrit correction formula. The upper and lower limits of the boxes correspond to 
the interquartile range and the middle line is the median of the data set. The limits of the whiskers are the minimum 
and maximum values. Linear regression through the mean-value of the boxes was established. 
	
3.2.6. Stability 
Stability data are summarised in Table 3. The data implied that analytes were stable 
in DBS for four weeks at -20°C or 4°C, as the change in concentration compared to a 
freshly prepared DBS sample was less than 6.1%. Nevirapine and efavirenz were 
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also stable, if temperature and relative humidity were increased to 40°C and 75%rH, 
respectively. Previous studies demonstrated that efavirenz was stable for at least 7 
months [21], and nevirapine for 15 months at room temperature [31]. Under 
accelerated storage conditions (e.g. 40°C/75rH), we observed a time-dependent 
degradation from -5.7% to -24.3% for lopinavir over the course of four weeks. That 
lopinavir is stable for one week at 30°C, as determined by Heine et al., was in line 
with our data as it required an additional three weeks at 40°C/75rH to degrade >15% 
of lopinavir [18]. In summary, it is important that DBS samples containing lopinavir, 
especially if collected in tropical countries, should be kept in a fridge or freezer for 
prolonged storage. Moreover, and by contrast, our data shows that nevirapine and 
efavirenz are not likely to be degraded through storage outside of the cold chain.  
 
Table 3. Stability of nevirapine, efavirenz, and lopinavir evaluated under different conditions for DBS samples at a 
concentration of 500ng/mL. 
 
 
3.3. Method application 
TDM samples (n=740), which were collected in the framework of a drug adherence 
study in Ifakara (Tanzania), were analysed in Basel (Switzerland). 50 DBS samples 
of each analyte were extracted, manually as well as automatically, using the DBS-MS 
500 autosampler. Nevirapine concentrations in DBS were between 3360 and 19’000 
ng/mL, efavirenz concentrations  were between 262 and 15’000 ng/mL , and lopinavir 
concentrations between 41.8 and 16’100 ng/mL; thus the selected calibration range 
(10 to 25’000 ng/mL) was suitable for the quantification of all collected TDM samples 
of this study. Sample dilution was therefore not necessary, which is relevant because 
it cannot be easily performed through automated extraction.  
Overall, automated and manual extractions were in strong agreement (Figure 6). 
Mean bias of automated to manual extractions was -9% for nevirapine, -8% for 
RT, normal rH 519.5 103.9 ± 3.6 - 481.6 96.3 ± 6.1 - 532.7 106.5 ± 3.3 -
24 h,        
40°C, 75%rH 540.9 108.2 ± 3.9 4.1 486.4 97.3 ± 2.5 1 502.5 100.5 ± 6.9 -5.7
1 week,   
40°C, 75%rH 540.7 108.1 ± 8.2 4.1 486 97.2 ± 9 0.9 492.4 98.5 ± 6.5 -7.6
2 weeks, 
40°C, 75%rH 529.3 105.9 ± 5.2 1.9 489.7 97.9 ± 5.8 1.7 460.7 92.1 ± 6.2 -13.5
3 weeks, 
40°C, 75%rH 531.8 106.4 ± 4.4 2.4 507.6 101.5 ± 3.7 5.4 427.7 85.5 ± 4.2 -19.7
4 weeks, 
40°C, 75%rH 533 106.6 ± 6.9 2.6 495.2 99 ± 6.5 2.8 403.2 80.6 ± 4.3 -24.3
4 weeks,    
4°C 532.4 106.5 ± 7.3 2.5 511.1 102.2 ± 8.8 6.1 537.2 107.4 ± 8.2 0.8
4 weeks,          
-20°C 517.4 103.5 ± 7.2 -0.4 477.7 95.5 ± 8.2 -0.8 559.2 111.8 ± 6.7 5
Change in 
Conc. 
[ng/mL]
Conc. 
[ng/mL]
Accuracy ± 
CV [%]
Change in 
Conc. 
[ng/mL]
Nevirapine Efavirenz Lopinavir
Condition Conc. [ng/mL]
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CV [%]
Change in 
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efavirenz, and -1% for lopinavir. 95% limits of agreement were narrow with a range 
smaller than ±24% (nevirapine: -30 to +11%; efavirenz: -32% to +16%; lopinavir:       
-24% to +22%). Consequently, when comparing automated and manually extracted 
samples, not more than 16% of respective samples showed a deviation outside of 
the ±20% threshold, according to the EMEA guideline for cross-validation [30]. No 
concentration-dependent trend was observed between the ratios of the two extraction 
methods across the entire concentration range. Overall, automated extraction was 5 
times more sensitive than manual extraction, which is mainly due to DBS being 
extracted with less solvent through the automated sample workup (25 µL vs. 150 µL) 
resulting in more concentrated samples. Both extraction procedures achieved similar 
results and the data obtained were in agreement with aforementioned criteria [30]. 
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Figure 6. Bland-Altman plots of nevirapine, efavirenz, lopinavir were generated for automated and manual DBS 
extractions. Values were coloured grey if the concentration ratio of the two extraction methods was less than ±20%; 
otherwise values were coloured white. The white plot area illustrates the 95% limits of agreement. The black dashed 
line describes the mean ratio of automated to manual extraction. 
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A negligible mean bias of +5% between DBS and plasma concentrations was 
detected for nevirapine. The 95% limits of agreement reached from -27% to +36%, 
and only 11.9% of the nevirapine samples were outside ±20% limits (Figure 7). In 
contrast, DBS concentrations were about 50% lower, as in plasma samples for 
efavirenz (bias ±2SD range: 0.59 [0.43-0.74]) and lopinavir (bias ±2SD range: 0.48 
[0.28-0.67]. In the case of efavirenz the bias could be greatly reduced by correcting 
the DBS concentration with the corresponding haematocrit value and protein binding 
(bias ±2SD range: 0.91 [0.66-1.16]), as previously described by Kromdijk et al. and Li 
et al. [14, 21]. After correcting the efavirenz values through the formula – ([DBS(analyte) 
/ (1-haematocrit)] x fbpp) – the percentage of samples outside the ±20% limits was 
reduced from 99.2% to 18.7%. Furthermore, applying the same correction formula to 
lopinavir samples improved the agreement between DBS and plasma considerably 
(bias ±2SD range: 0.73 [0.44-1.03]). Nevertheless, 71.9% of the DBS samples still 
demonstrated a deviation of more than 20%. In conclusion, DBS analysis of 
nevirapine and efavirenz align with criteria set for cross-validation of two methods, 
whereas lopinavir concentrations determined in DBS samples are, on average, about 
25% lower than in plasma [30].  
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Figure 7. Bland-Altman plots of nevirapine, efavirenz, lopinavir were generated for DBS and plasma samples. Values 
were coloured grey if the concentration ratio of the two matrices was less than ±20%; otherwise values were coloured 
white. The white plot area illustrates the 95% limits of agreement. The black dashed line represents the mean 
concentration ratio of DBS to plasma. In the case of the plots depicted on the right side, DBS concentrations were 
corrected with haematocrit and with plasma protein binding (fppb). 
 
In summary, an innovative automated LC-MS/MS method was developed and 
validated for the quantification of nevirapine, efavirenz, and lopinavir DBS samples. It 
took approximately 3-4 minutes to extract and analyse one DBS sample. Automated 
DBS extraction resulted in extremely consistent inter-individual recoveries and matrix 
effects. Validation parameters were in accordance with specifications put in place by 
regulatory guidelines. Through the spraying of IS onto the DBS, the haematocrit-
recovery bias could be minimised. Furthermore, by making use of the installed 
camera in the autosampler, a correction function between the haematocrit and the 
blood spot area could be established, thereby reducing the haematocrit-area bias. 
The method was successfully applied to analyse TDM samples. Results obtained by 
automated and manual extraction were comparable. However, the sample 
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processing time and method sensitivity was improved by the DBS-500 autosampler. 
Automated DBS extraction was reliable and will facilitate analysis of large sample 
numbers. Our study confirms that TDM of nevirapine and efavirenz in DBS is a 
suitable alternative to conventional plasma analysis, especially when samples have 
to be collected in recourse-limited settings. 
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Supplementary files 
 
Table S1. Deviation between DBS samples using 15 µL or 30 µL blood spot volume. 
 
 
Table S2. Recovery determined for nevirapine, efavirenz, and lopinavir. 
 
 
 
Figure S1. (a) Linear relationship between spot areas, measured in pixels per spot, and the haematocrit was 
determined. 10, 15, and 20 µL were spotted onto the filter paper (R2>0.93). (b) For grade 226 filter paper, the 
following formula was established between DBS area, normalised to the spotted blood volume, and the haematocrit: 
DBS Area = -1.157 x HCT + 261.8.
QC Level Change [%] Change [%] Change [%]
15 µL 30 µL 15 µL 30 µL 15 µL 30 µL
QC LLOQ 9.3 9.4 1.1 9.1 9.7 5.7 9.1 9.7 5.7
QC Low 46.3 45.8 -1.1 48 46.3 -3.5 48 46.3 -3.5
QC Mid 470 482 2.5 480 481 0.2 480 481 0.2
QC High 4881 5011 2.7 4919 4824 -1.9 4919 4824 -1.9
Nevirapine
Concentration found at  
[ng/mL]       
Concentration found at  
[ng/mL]       
Lopinavir
Concentration found at  
[ng/mL]       
Efavirenz
HCT [%]
QcLow QcMid QcHigh IS QcLow QcMid QcHigh IS QcLow QcMid QcHigh IS
20 90.5 87 90.5 92.3 76.2 77.3 76.2 88.1 73.6 69.8 66.5 88.2
25 83.3 87 82.5 87.2 75.6 75.1 69.3 82.2 67 72.5 62.3 83.7
30 79.6 76.5 77.9 87.8 68.7 64.1 67.8 83.4 63.2 64.9 61.8 83.4
35 69.7 76.1 68.6 85 60.2 67.4 58.6 77.2 60.7 65.5 55.6 82
40 63.4 58.8 67 82.8 57.7 56.2 56.8 81.8 58.6 57.4 56.7 80.1
45 64.2 66.6 66.1 77.5 56.9 60.4 57.6 72.9 60.8 63.3 58.8 76.7
50 66.5 67.6 63.1 77.3 59.5 61.6 53.4 71.5 60.3 62.2 53.7 76.7
20-50 24 19.3 27.4 14.9 16.7 15.8 22.8 16.5 13.3 7.7 12.9 11.5
Nevirapine [%] Efavirenz [%] Lopinavir [%]
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9. General conclusions and outlook
The main goal of the presented projects in this thesis was to gain insight and 
contribute to procedures that are useful in personalised drug treatment. 
The first four studies furthered previous work that involved the development, 
validation, and implementation of a novel in vivo phenotyping cocktail. From the two 
published Basel cocktail studies [15, 16], a number of questions arose that required 
further evaluation. In a first step, the metabolism of the six CYP450 isoforms, 
characterised by the in vivo Basel cocktail, was further characterised in a variety of 
different in vitro liver cell models, using the same probe drugs as in the in vivo 
studies. We were able to demonstrate that the Basel cocktail substrates can be used 
not only in vivo [15, 16], but also that our in vitro results, obtained with these 
substrates, aligned with trials performed with classic in vitro substrates. An especially 
interesting model involved the co-culture of human cryopreserved hepatocytes with 
mouse embryo 3T3 fibroblasts, enabling the hepatocytes to reside in an in vivo-like 
3D environment. By comparing hepatocytes from an identical batch, cultured in a 2D 
and 3D milieu, we found a number of advantageous properties of 3D-culture. Among 
the four evaluated liver cell models, results obtained with the 3D co-culture model 
under induced conditions came closest to the in vivo situation [15]. This underscores 
that 3D-culture techniques open up new possibilities for in vitro metabolism and 
toxicological studies, as they have the capability of overcoming longstanding 
functional and temporal limitations of traditional 2D-hepatocyte culture.  
Having characterised the Basel phenotyping cocktail in both in vivo and in vitro 
settings makes it unique, as such data is usually unavailable. In two further studies, 
we were able to demonstrate in vitro that the α-hydroxylation pathway of metoprolol, 
which has been considered to be exclusively mediated by CYP2D6 [32, 33], is also 
mediated by CYP3A4, especially after pre-treatment with the CYP inducer rifampicin. 
Quantitatively, however, the amount of α-hydroxymetoprolol produced by CYP3A4 is 
irrelevant, both in vitro and in vivo [15], where no significant increase of α-
hydroxymetoprolol after induction was found. This could either be explained by a 
more pronounced clearance of α-hydroxymetoprolol in the urine or by a more 
pronounced degradation of metoprolol through CYP3A4 mediated demethylation- 
and dealkylation pathways. This hypothesis was confirmed in vitro, where we could 
show that the production of the O-desmethyl metabolite of metoprolol was indeed 
increased under induction treatment with rifampicin. Regardless, these findings do 
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not impede the utilisation of metoprolol as a phenotyping agent of CYP2D6, as the 
contribution of CYP3A4 is negligible, even after induction, when CYP2D6 activity is 
not evaluated, since CYP2D6 has previously been shown not to be inducible [37-42]. 
Previously, losartan was used as a CYP2C9 probe drug in the in vivo Basel cocktail 
[15]. In plasma, however, the losartan metabolic ratio did not reflect induction after 
pre-treatment with the inducer rifampicin, and therefore losartan needed to be 
replaced by another CYP2C9 probe drug. Instead of performing an expensive and 
time-consuming clinical study, the replacement of losartan with flurbiprofen was 
evaluated, together with the remaining probe drugs of the Basel cocktail, using the 
already characterised 3D co-culture in vitro model. The data showed that flurbiprofen 
did not cause a significant change in the enzyme activity of any of the other five 
CYP450 isoforms, thus enabling its inclusion into the cocktail. 
For phenotyping to become more widely accepted as a routine tool in clinical 
practice, simplified administration of the probe drugs is of great importance. Based 
on the in vitro results showing that flurbiprofen does not interfere with the other five 
Basel cocktail probe drugs, a previously developed combination-capsule (combi-
capsule) was adapted to contain the probe drugs of the modified Basel cocktail 
(including flurbiprofen instead of losartan), in the form of miniature tablets, and tested 
in a pilot study (n=2). The obtained PK profiles proved the feasibility of this concept 
and will serve as the basis for the design of a future clinical study comparing the new 
combi-capsule to the intake of the six probe drugs as individual commercially 
available formulations in healthy volunteers. 
  
In recent years, molecularly targeted drug therapy in oncology has become one of 
the main focus areas through which personalised medicine has been implemented 
by pharmaceutical and biotechnology companies. For instance, in the past two years 
(2014 - 2015) alone, 28 new antineoplastic drugs have been approved by the FDA, 
of which the vast majority are targeted drug therapies that can either be classified as 
monoclonal antibodies (mAbs) or small molecule protein kinase inhibitors [61-64]. 
TKIs are predominantly metabolised through CYP450 enzymes, resulting in high 
inter-individual variability. This, therefore, makes uniform drug intake – the current 
recommendation – an inadequate dosing strategy to safeguard against potentially 
avoidable side effects and under-treatment with diminished therapeutic activity.  
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In the study described in Chapter 7, the correlation between CYP3A4 and CYP1A2 
phenotype and pharmacokinetic parameters of erlotinib and sunitinib was evaluated. 
Single time-point metabolic ratios of midazolam (CYP3A4) and caffeine (CYP1A2) 
were successfully applied in order to phenotype elderly patients being treated for 
non-small cell lung cancer (n=37). Although with the present analysis, no clear 
correlation could be found relating individual metabolic status of CYP3A4 and 
CYP1A2 to erlotinib exposure, it is anticipated that, with the help of a population 
pharmacokinetic model (NONMEM) being developed by Parra-Guillen ZA et al. 
(Department of Clinical Pharmacy and Biochemistry, Freie Universität, Berlin), a 
more precise assessment of this correlation will be possible, as has previously been 
accomplished for a number of other TKIs [65-67]. The main goal will be to build an 
integrated covariate model on erlotinib pharmacokinetics and help define a dosing 
algorithm based on the individual CYP450-phenoype. 
Previously, therapeutic drug monitoring (TDM) has been routinely used in cancer 
therapy; for instance, to measure methotrexate concentrations [68]. Thus far, 
however, it has not been widely used to measure TKIs [69]. The apparent link 
between concentration, toxicity, and therapeutic response, its narrow therapeutic 
range, large PK variability, and the need of adhering to the treatment long-term, all 
point towards erlotinib being a promising candidate for TDM [70, 71]. According to de 
Wit et al., one of the general criteria for dose individualisation of TKIs includes “a 
validated dose-adaptation strategy” [46]. They argue that an impeding challenge of 
TDM remains the “patient unfriendly and time-consuming exposure-efficacy/ toxicity 
relations based on AUCs” and that to make TDM feasible in clinical practice, efforts 
should, therefore, be undertaken to determine surrogate PK markers – e.g. Ctrough or 
limited sampling – that show a good correlation with AUC. Preliminary 
recommendations on how to implement dosage adjustments have been postulated 
by Petit-Jean et al. [71]. In our clinical study, we found a good correlation between 
erlotinib single time-point concentration and partial AUC, which could in future be 
used for limited sampling.  
Dried blood spots (DBS) exemplify another approach to simplify sampling for TDM or 
PK studies. As erlotinib has not been previously evaluated in DBS, we compared 
erlotinib concentrations measured in DBS to plasma samples. However, using the 
current set of DBS samples, we were not able to find a sufficient correlation between 
plasma and DBS concentrations to be able to recommend using DBS instead of 
conventional plasma samples for TDM. This contrasts with recent work that 
demonstrated that samples collected in either plasma or DBS containing the TKIs 
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dasatanib, nilotinib, imatinib, and pazopanib can be interchangeably measured [72, 
73]. It is, therefore, possible that through a number of methodological modifications 
and implementation of good spotting practice [74] (both previously alluded to in 
Chapter 8), the replacement of conventional plasma sampling through DBS sample 
collection may also be achieved for erlotinib. 
The application of DBS sampling for TDM of antiretroviral drugs was evaluated within 
the framework of an HIV-adherence study conducted in Tanzania. For TDM in 
remote settings, obtaining dried blood spots (DBS) is particularly beneficial, as drug 
concentrations in DBS are generally stable at room temperature, making cold chains 
unnecessary. Performing TDM using DBS is a patient-friendly alternative to 
conventional plasma sampling, since it does not require a trained phlebotomist, and, 
simultaneously, the DBS sample does not yield a further biohazardous risk [75-78]. 
As a micro-sampling technique, DBS use considerably less blood than conventional 
blood sampling techniques [79], making DBS an interesting sampling method with 
which to perform clinical trials as well as the aforementioned TDM in resource-limited 
settings [53, 55, 59, 80]. Furthermore, in South Africa, which has the world’s largest 
HIV-positive population, as well as in other African countries, DBS have recently 
been used to screen for HIV-1 DNA by PCR in infants whose mothers are HIV-
positive [81]. Therefore, the use of DBS is already familiar to trained hospital 
personnel in several Sub-Saharan African countries and can, according to 
Johannesen et al., “serve as a model for further expansion of DBS monitoring in such 
settings” [78]. In Tanzania alone, HIV and AIDS is a serious health issue, as more 
than 2 million people are living with HIV/AIDS (prevalence 3.1%) [82]. Both the 
introduction of combined antiretroviral therapy (cART) and a massive global health 
campaign aiming for universal access to cART, has led to the dramatic decline in 
morbidity and mortality rates in HIV/ Aids patients [83]. A report highlighted that even 
in the short period between 2011 and 2014, the coverage of people having access to 
HIV antiretroviral treatment has more than doubled, from 18 to 43% [84]. It is, 
therefore, all the more important to make sure that patients, who now have access to 
drugs, are upholding compliance/adherence recommendations of health care 
professionals. We therefore successfully developed and validated an automated LC-
MS/MS method with which TDM DBS samples collected in rural Tanzania could be 
analysed. Compared to manual DBS extraction, sample processing time and method 
sensitivity could be improved using an automated DBS extraction method. 
Automated DBS extraction was reliable and facilitated analysis of the large numbers 
of samples for this study. Our data confirmed that the TDM of nevirapine and 
efavirenz in DBS is a suitable alternative to conventional plasma analysis.  
158
 10. General References 
1. Chainuvati, S., et al., Combined phenotypic assessment of cytochrome p450 
1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase 
activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther, 2003. 
74(5): p. 437-47. 
2. Ryu, J.Y., et al., Development of the "Inje cocktail" for high-throughput 
evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol 
Ther, 2007. 82(5): p. 531-40. 
3. Sharma, A., et al., A convenient five-drug cocktail for the assessment of 
major drug metabolizing enzymes: a pilot study. Br J Clin Pharmacol, 2004. 
58(3): p. 288-97. 
4. Christensen, M., et al., The Karolinska cocktail for phenotyping of five human 
cytochrome P450 enzymes. Clin Pharmacol Ther, 2003. 73(6): p. 517-28. 
5. Zgheib, N.K., et al., Validation of incorporating flurbiprofen into the Pittsburgh 
cocktail. Clin Pharmacol Ther, 2006. 80(3): p. 257-63. 
6. Turpeinen, M., et al., Multiple P450 substrates in a single run: rapid and 
comprehensive in vitro interaction assay. Eur J Pharm Sci, 2005. 24(1): p. 
123-32. 
7. Spaggiari, D., et al., A cocktail approach for assessing the in vitro activity of 
human cytochrome P450s: an overview of current methodologies. J Pharm 
Biomed Anal, 2014. 101: p. 221-37. 
8. Walsky, R.L. and R.S. Obach, Validated assays for human cytochrome P450 
activities. Drug Metab Dispos, 2004. 32(6): p. 647-60. 
9. Testino, S.A., Jr. and G. Patonay, High-throughput inhibition screening of 
major human cytochrome P450 enzymes using an in vitro cocktail and liquid 
chromatography-tandem mass spectrometry. J Pharm Biomed Anal, 2003. 
30(5): p. 1459-67. 
10. Dierks, E.A., et al., A method for the simultaneous evaluation of the activities 
of seven major human drug-metabolizing cytochrome P450s using an in vitro 
cocktail of probe substrates and fast gradient liquid chromatography tandem 
mass spectrometry. Drug Metab Dispos, 2001. 29(1): p. 23-9. 
11. Kim, M.J., et al., High-throughput screening of inhibitory potential of nine 
cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass 
spectrometry. Rapid Commun Mass Spectrom, 2005. 19(18): p. 2651-8. 
12. Lahoz, A., et al., A new in vitro approach for the simultaneous determination 
of phase I and phase II enzymatic activities of human hepatocyte 
preparations. Rapid Commun Mass Spectrom, 2008. 22(2): p. 240-4. 
13. Zientek, M., et al., Development of an in vitro drug-drug interaction assay to 
simultaneously monitor five cytochrome P450 isoforms and performance 
assessment using drug library compounds. J Pharmacol Toxicol Methods, 
2008. 58(3): p. 206-14. 
159
14. Gomez-Lechon, M.J., J.V. Castell, and M.T. Donato, An update on
metabolism studies using human hepatocytes in primary culture. Expert Opin
Drug Metab Toxicol, 2008. 4(7): p. 837-54.
15. Derungs, A., et al., Effects of Cytochrome P450 Inhibition and Induction on
the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover
Study. Clin Pharmacokinet, 2016. 55(1): p. 79-91.
16. Donzelli, M., et al., The basel cocktail for simultaneous phenotyping of human
cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin
Pharmacokinet, 2014. 53(3): p. 271-82.
17. Ohkura, T., et al., Evaluation of human hepatocytes cultured by three-
dimensional spheroid systems for drug metabolism. Drug Metab
Pharmacokinet, 2014. 29(5): p. 373-8.
18. Grammaticos, P.C. and A. Diamantis, Useful known and unknown views of
the father of modern medicine, Hippocrates and his teacher Democritus. Hell
J Nucl Med, 2008. 11(1): p. 2-4.
19. Michl, S., Inventing Traditions, Raising Expectations. Recent Debates on
“Personalized Medicine”. 2015. 7: p. 45-60.
20. Xie, H.-G. and F.W. Frueh, Pharmacogenomics steps toward personalized
medicine. Personalized Medicine, 2005. 2(4): p. 325-337.
21. Meyer, U.A., Pharmacogenetics - five decades of therapeutic lessons from
genetic diversity. Nat Rev Genet, 2004. 5(9): p. 669-76.
22. Issa, A.M., Personalized medicine and the practice of medicine in the 21st
century. Mcgill J Med, 2007. 10(1): p. 53-7.
23. Opdam, F.L., H. Gelderblom, and H.J. Guchelaar, Phenotyping drug
disposition in oncology. Cancer Treat Rev, 2012. 38(6): p. 715-25.
24. Fuhr, U., A. Jetter, and J. Kirchheiner, Appropriate phenotyping procedures
for drug metabolizing enzymes and transporters in humans and their
simultaneous use in the "cocktail" approach. Clin Pharmacol Ther, 2007.
81(2): p. 270-83.
25. Venter, J.C., et al., The sequence of the human genome. Science, 2001.
291(5507): p. 1304-51.
26. Lander, E.S., et al., Initial sequencing and analysis of the human genome.
Nature, 2001. 409(6822): p. 860-921.
27. Josephs, D.H., et al., Clinical pharmacokinetics of tyrosine kinase inhibitors:
implications for therapeutic drug monitoring. Ther Drug Monit, 2013. 35(5): p.
562-87.
28. Marshall, W.J. and S. Bangert, Clinical Chemistry. 2008, Edinburgh, London:
Mosby Elsevier.
160
29. Group, M.-H.S., Effect of metoprolol CR/XL in chronic heart failure: 
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure 
(MERIT-HF). Lancet, 1999. 353(9169): p. 2001-7. 
30. Chen, Z.M., et al., Early intravenous then oral metoprolol in 45,852 patients 
with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 
2005. 366(9497): p. 1622-32. 
31. Hansson, L., et al., Randomised trial of old and new antihypertensive drugs in 
elderly patients: cardiovascular mortality and morbidity the Swedish Trial in 
Old Patients with Hypertension-2 study. Lancet, 1999. 354(9192): p. 1751-6. 
32. McGourty, J.C., et al., Metoprolol metabolism and debrisoquine oxidation 
polymorphism--population and family studies. Br J Clin Pharmacol, 1985. 
20(6): p. 555-66. 
33. Otton, S.V., et al., Use of quinidine inhibition to define the role of the 
sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human 
liver microsomes. J Pharmacol Exp Ther, 1988. 247(1): p. 242-7. 
34. Frank, D., U. Jaehde, and U. Fuhr, Evaluation of probe drugs and 
pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol, 
2007. 63(4): p. 321-33. 
35. Tamminga, W.J., et al., An optimized methodology for combined phenotyping 
and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol, 2001. 
57(2): p. 143-6. 
36. Birkett, D.J., et al., In vitro approaches can predict human drug metabolism. 
Trends Pharmacol Sci, 1993. 14(8): p. 292-4. 
37. Eichelbaum, M., et al., The influence of enzyme induction on polymorphic 
sparteine oxidation. Br J Clin Pharmacol, 1986. 22(1): p. 49-53. 
38. Gerets, H.H., et al., Characterization of primary human hepatocytes, HepG2 
cells, and HepaRG cells at the mRNA level and CYP activity in response to 
inducers and their predictivity for the detection of human hepatotoxins. Cell 
Biol Toxicol, 2012. 28(2): p. 69-87. 
39. Glaeser, H., et al., Influence of rifampicin on the expression and function of 
human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol, 2005. 
59(2): p. 199-206. 
40. Madan, A., et al., Effects of prototypical microsomal enzyme inducers on 
cytochrome P450 expression in cultured human hepatocytes. Drug Metab 
Dispos, 2003. 31(4): p. 421-31. 
41. Rae, J.M., et al., Rifampin is a selective, pleiotropic inducer of drug 
metabolism genes in human hepatocytes: studies with cDNA and 
oligonucleotide expression arrays. J Pharmacol Exp Ther, 2001. 299(3): p. 
849-57. 
42. Wenk, M., L. Todesco, and S. Krahenbuhl, Effect of St John's wort on the 
activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine 
161
oxidase in healthy males and females. Br J Clin Pharmacol, 2004. 57(4): p. 
495-9. 
43. Keates, R.H. and K.A. McGowan, Clinical trial of flurbiprofen to maintain 
pupillary dilation during cataract surgery. Ann Ophthalmol, 1984. 16(10): p. 
919-21. 
44. Compendium. Froben® Fachinformation des Arzneimittel-Kompendium der 
Schweiz. 2015  [cited 2016 12.02.2016]; Available from: 
http://compendium.ch/mpro/mnr/9886/pdf/de - page1. 
45. Bosilkovska, M., et al., Geneva cocktail for cytochrome p450 and P-
glycoprotein activity assessment using dried blood spots. Clin Pharmacol 
Ther, 2014. 96(3): p. 349-59. 
46. de Wit, D., et al., Individualized dosing of tyrosine kinase inhibitors: are we 
there yet? Drug Discov Today, 2015. 20(1): p. 18-36. 
47. Bangsberg, D.R., Less than 95% adherence to nonnucleoside reverse-
transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis, 
2006. 43(7): p. 939-41. 
48. Burkhart, P.V. and E. Sabate, Adherence to long-term therapies: evidence for 
action. J Nurs Scholarsh, 2003. 35(3): p. 207. 
49. Schneider, J., et al., Better physician-patient relationships are associated with 
higher reported adherence to antiretroviral therapy in patients with HIV 
infection. J Gen Intern Med, 2004. 19(11): p. 1096-103. 
50. Meesters, R.J., et al., Incurred sample reanalysis comparison of dried blood 
spots and plasma samples on the measurement of lopinavir in clinical 
samples. Bioanalysis, 2012. 4(3): p. 237-40. 
51. Paterson, D.L., et al., Adherence to protease inhibitor therapy and outcomes 
in patients with HIV infection. Ann Intern Med, 2000. 133(1): p. 21-30. 
52. Erb S, L.E., Elzi L, Hatz C,Klimkait T, Manuel Haschke, Berger B, Duthaler U, 
Langewitz W, Tanner M, Battegay M, , Adherence assessment in HIV-
infected patients treated with combination antiretroviral therapy (cART) in 
rural Tanzania. (manuscript in preparation), 2016. 
53. Edelbroek, P.M., J. van der Heijden, and L.M. Stolk, Dried blood spot 
methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther 
Drug Monit, 2009. 31(3): p. 327-36. 
54. Smit, P.W., et al., An overview of the clinical use of filter paper in the 
diagnosis of tropical diseases. Am J Trop Med Hyg, 2014. 90(2): p. 195-210. 
55. Koal, T., et al., Quantification of antiretroviral drugs in dried blood spot 
samples by means of liquid chromatography/tandem mass spectrometry. 
Rapid Commun Mass Spectrom, 2005. 19(21): p. 2995-3001. 
56. ter Heine, R., et al., Quantification of protease inhibitors and non-nucleoside 
reverse transcriptase inhibitors in dried blood spots by liquid chromatography-
162
triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed 
Life Sci, 2008. 867(2): p. 205-12. 
57. Ter Heine, R., et al., Clinical evaluation of the determination of plasma
concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood
spot samples. Bioanalysis, 2011. 3(10): p. 1093-7.
58. Meesters, R.J., et al., Ultrafast and high-throughput mass spectrometric
assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1
infection applying dried blood spots. Anal Bioanal Chem, 2010. 398(1): p.
319-28.
59. Kromdijk, W., et al., Use of dried blood spots for the determination of plasma
concentrations of nevirapine and efavirenz. J Antimicrob Chemother, 2012.
67(5): p. 1211-6.
60. Abu-Rabie, P. and N. Spooner, Direct quantitative bioanalysis of drugs in
dried blood spot samples using a thin-layer chromatography mass
spectrometer interface. Anal Chem, 2009. 81(24): p. 10275-84.
61. Aggarwal, S., Targeted cancer therapies. Nat Rev Drug Discov, 2010. 9(6): p.
427-428.
62. The National Cancer Institute. Targeted Cancer Therapies Fact Sheet. 2014
25.04.2014 03.09.2016]; Available from: http://www.cancer.gov/about-
cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet.
63. Centerwatch. FDA Approved Drugs for Oncology. 2016; Available from:
https://http://www.centerwatch.com/drug-information/fda-approved-
drugs/therapeutic-area/12/oncology.
64. FDA. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2016
11.03.2016 Available from:
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.ht
m.
65. Swaisland, H.C., et al., Exploring the relationship between expression of
cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin
Pharmacokinet, 2006. 45(6): p. 633-44.
66. de Wit, D., et al., Midazolam as a phenotyping probe to predict sunitinib
exposure in patients with cancer. Cancer Chemother Pharmacol, 2014. 73(1):
p. 87-96.
67. Li, J., et al., CYP3A phenotyping approach to predict systemic exposure to
EGFR tyrosine kinase inhibitors. J Natl Cancer Inst, 2006. 98(23): p. 1714-23.
68. Galpin, A.J. and W.E. Evans, Therapeutic drug monitoring in cancer
management. Clin Chem, 1993. 39(11 Pt 2): p. 2419-30.
69. Klumpen, H.J., et al., Moving towards dose individualization of tyrosine kinase
inhibitors. Cancer Treat Rev, 2011. 37(4): p. 251-60.
70. Fukudo, M., et al., Population pharmacokinetics/pharmacodynamics of
erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid
163
drug concentrations in Japanese patients with non-small cell lung cancer. Clin 
Pharmacokinet, 2013. 52(7): p. 593-609. 
71. Petit-Jean, E., et al., Erlotinib: another candidate for the therapeutic drug 
monitoring of targeted therapy of cancer? A pharmacokinetic and 
pharmacodynamic systematic review of literature. Ther Drug Monit, 2015. 
37(1): p. 2-21. 
72. Kralj, E., et al., Simultaneous measurement of imatinib, nilotinib and dasatinib 
in dried blood spot by ultra high performance liquid chromatography tandem 
mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2012. 
903: p. 150-6. 
73. de Wit, D., et al., Dried blood spot analysis for therapeutic drug monitoring of 
pazopanib. J Clin Pharmacol, 2015. 55(12): p. 1344-50. 
74. Meesters, R., et al., Impact of internal standard addition on dried blood spot 
analysis in bioanalytical method development. Bioanalysis, 2011. 3(20): p. 
2357-64. 
75. Bond, W.W., et al., Survival of hepatitis B virus after drying and storage for 
one week. Lancet, 1981. 1(8219): p. 550-1. 
76. Evengard, B., et al., Effect of heat on extracted HIV viral infectivity and 
antibody activity using the filter paper technique of blood sampling. Aids, 
1989. 3(9): p. 591-5. 
77. Centers for Disease Control and Prevention. Shipping Guidelines for Dried-
Blood Spot Specimens. 1995 09.03.2015; Available from: 
http://www.cdc.gov/labstandards/pdf/nsqap/Bloodspot_Transportation_Guidel
ines.pdf. 
78. Johannessen, A., Dried blood spots in HIV monitoring: applications in 
resource-limited settings. Bioanalysis, 2010. 2(11): p. 1893-908. 
79. Li, W. and F.L. Tse, Dried blood spot sampling in combination with LC-
MS/MS for quantitative analysis of small molecules. Biomed Chromatogr, 
2010. 24(1): p. 49-65. 
80. Malm, M., et al., Determination of lamivudine, zidovudine, and nevirapine in 
capillary blood sampled on filter paper by LC. J Chromatogr Sci, 2009. 
47(10): p. 855-62. 
81. Sherman, G.G., et al., Dried blood spots improve access to HIV diagnosis 
and care for infants in low-resource settings. J Acquir Immune Defic Syndr, 
2005. 38(5): p. 615-7. 
82. WHO. United Republic of Tanzania: WHO statistical profile. 2015  
11.02.2016]; Available from: http://www.who.int/gho/countries/tza.pdf?ua=1. 
83. AIDSinfo. Panel on Antiretroviral Guidelines for Adults and Adolescents. 
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and 
adolescents. 2015; Available from: 
https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. 
164
84. World Bank. Antiretroviral therapy coverage (% of people living with HIV). 
2015  14.03.2016]; Available from: 
http://data.worldbank.org/indicator/SH.HIV.ARTC.ZS. 
165
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
166
